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ABSTRACT

The liver plays an important role in controlling glucose and lipid
homeostasis. Metabolic abnormalities such as obesity and type 2 diabetes are
often associated with profound changes in the expression of genes involved in
hepatic glucose and lipid metabolism. Dietary nutrients provide us with
macronutrients for energy and micronutrients for maintenance of general
health. However, the effects of individual micronutrients on the development
of metabolic diseases are unknown. Sterol regulatory element binding protein1c (SREBP-1c) is the master regulator of fatty acid synthesis, and glucokinase
(GK) is the key enzyme in glucose metabolism. Based on the preliminary
results from our laboratory and others, we hypothesized that the metabolism
of vitamin A (VA) regulate lipid and glucose metabolism by controlling the
expression of Srebp-1c and Gck in hepatocytes. We show that retinoids
synergize with insulin to induce the expression of Srebp-1c and Gck in
primary rat hepatocytes. Retinoid-induced expression of Srebp-1c, due to the
activation of RXR, results in increased expression of SREBP-1c target gene,
Fas. Results obtained from the reporter gene assays demonstrate that the
retinoic acid responsive elements (RAREs) in the Srebp-1c promoter overlap
previously identified liver X receptor elements that mediate insulin action. For
hepatic Gck, we first characterized its promoter and identified a RARE using
serial deletion reporter gene assays and linker-scan analyses. This RARE
overlaps a putative binding site for HNF4α [hepatic nuclear factor 4 alpha].
We then performed chromatin immunoprecipitation and electrophoretic
mobility shift assays to study the binding of this RARE to nuclear receptors
(NRs) potentially mediating retinoid actions: RARα [retinoic acid receptor
alpha], RXRα [retinoid X receptor alpha], HNF4α, and COUP-TFII. We show
that these NRs are capable of binding to the RARE and their binding activities
are modulated by retinoic acid. In addition, the effects of the recombinant
adenovirus-mediated over-expression of these NRs on the expression of
retinoids-

and

insulin-responsive

genes
iv

were

analyzed

in

primary

hepatocytes. We observed profound modulation of the gene expression by
these NRs. We conclude that VA can control hepatic glucose and lipid
metabolism via regulation of the expression of genes involved.

v
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CHAPTER I
INTRODUCTION
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The significant increase in the prevalence of obesity and diabetes is an
important health issue worldwide. According to the World Health Organization
(WHO) approximately 1.6 billion adults worldwide were overweight (body
mass index, BMI, between 25 and 30 kg/ m2) in 2005 and at least 400 million
adults were obese (BMI of 30 kg/ m2 or higher). The numbers will continue to
rise and WHOʼs projections estimate that by 2015, approximately 2.3 billion
adults will be overweight and more than 700 million will be obese [1]. In the
United States, the current prevalence of obesity among adults is about 33%,
compared to estimates four decades earlier showing a prevalence of about
13% [2]. Unfortunately, obesity is not exclusively a problem in adults. More
than one third of children and adolescents in the United States were
overweight or obese in 2008 [3]. In addition, the obesity epidemic is imposing
a significant economic burden on healthcare system globally. It is estimated
that obesity accounts for between 0.7% and 2.8% of a countryʼs total
healthcare expenditures. Moreover, obese individuals are found to have
medical costs that are approximately 30% greater than their normal weight
peers [4].
Obesity is associated with increased risk of many chronic diseases,
including type 2 diabetes (T2D), cardiovascular disease, and many forms of
cancer [5]. T2D affects approximately 6% of the worldʼs adult population and
this number will continue to soar with the increase of obese population. In
North America, about 90% of people with T2D are obese, overweight, or have
a medical history of being so [6]. Co-existence of obesity and T2D, which
poses a challenge to the treatment of both conditions, is attributed to both
genetics (i.e. genes that affect feeding behavior and metabolism) and
environment (i.e. excess calories, sedentary lifestyles, etc.). Although the
exact mechanism linking increased risk of T2D to obesity is not completely
understood, insulin resistance, a common feature of obesity and T2D, is
considered to play an important role. Genetic and environmental factors
confer susceptibility to excess adiposity, which in turn promote insulin
resistance. Insulin resistance is initially compensated for by increased insulin
2

secretion from pancreatic β cells. Hyperglycemia develops when insulin
secretion is unable to overcome the insulin resistance and continued
deterioration of pancreatic β cell function causes further impairment of
glucose homoeostasis into T2D [6].
The liver plays a critical role in mediating glucose and lipid homeostasis
in response to hormonal and nutritional stimuli. In the liver and hepatocytes,
insulin regulates the expression of a variety of genes responsible for
glycolysis, glycogenesis and lipogenesis, and inhibits gluconeogenesis. This
insulin-regulated hepatic gene expression, at least in part, is responsible for
glucose and lipid homeostasis [7]. For example, insulin increases the
expression of glucokinase gene (Gck), the enzyme responsible for the first
step of hepatic glucose utilization. It suppresses the expression of the
cytosolic form of phosphoenolpyruvate carboxykinase (Pck1) and glucose 6phosphatase

catalytic

subunit

(G6pc),

the

first

and

last

steps

of

gluconeogenesis, respectively. For hepatic lipid metabolism, insulin increases
the expression levels of sterol regulatory element binding protein 1c gene
(Srebp-1c), a master regulator of fatty acid synthesis [8]. In hepatic insulin
resistance, gluconeogenesis is not adequately suppressed by insulin,
whereas the lipogenic actions of insulin is not compromised, thus creating a
vicious cycle that aggravated insulin resistance and ultimately contributes to
the onset of overt diabetes [9].
Dietary nutrients provide us with macronutrients for energy and
micronutrients for maintenance of general health [7]. The link between obesity
development and over-nutrition seems to be obvious. However, the exact
roles of each micronutrient in the development of metabolic diseases have not
been clearly defined. Vitamin A (VA, retinol), a micronutrient, plays crucial
roles in many physiological processes, including embryonic growth,
development, tissue differentiation, and nutrient metabolism [10]. Previously,
our lab demonstrated a synergistic effect between retinoids and insulin to
induce Gck and Srebp-1c expression in primary rat hepatocytes [11, 12]. This
dissertation work was to investigate the underlying mechanism. Its results
3

may shed some lights on our understanding of the development of hepatic
insulin resistance.
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CHAPTER II
LITERATURE REVIEW
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2.1 Obesity
2.1.1 Obesity Overview
The survival of all organisms depends on continuous availability of energy
despite highly variable energy supplies in the environment [13]. Mammals
including human have acquired a robust physiological system to promote
efficient storage of unused energy in the form of triglycerides (TGs) in
specialized adipose cells, from which stored energy could be rapidly released
for use by other cells upon starvation [13]. It has been suggested that body
weight (BW) and energy balance (EB), the long-term balance between energy
intake (EI) and energy expenditure (EE) [14], are delicately regulated [15].
Obesity results from a chronic surplus of EI compared to energy expenditure
(EE), which leads to storage of excessive amounts of TGs in adipose tissue
[16]. EE is consisting of the energy consumed in the processes of physical
work, basal metabolism, and adaptive thermogenesis [14]. In a consequence
of social trends toward high EI and reduced EE [17], obesity has reached
epidemic proportions globally (see Chapter I). Obesity is associated with
increased risk of T2D, cardiovascular disease, and many types of cancer,
fatty liver disease, hormonal disturbances, hypertension, and increased
mortality [18]. In addition, obesity is associated with respiratory difficulties,
chronic musculoskeletal problems, lumbago, skin problem, and infertility. It is
noteworthy that most of the evidence proposing obesity-associated health
problems has been obtained from epidemiological analyses of human
subjects and the underlying mechanisms have yet to be revealed [5]. Despite
current intensive efforts to reduce obesity by diet, exercise, education,
surgery, and drug therapies, an effective, long-term solution to this epidemic is
yet to be established [18].

2.1.2 EB and BW
EB is reached when the EI is equal to EE. Although the role of genes in
body fat regulation is well established, it is unlikely that the increasing
prevalence of obesity is due to a recent genetic change of the Western world
6

[14]. In fact, the obesity epidemic is considered on a large scale to result from
changes of lifestyle, including increased fat intake and reduced physical
activity. It has been suggested that a physiological system in human body
functions to maintain homeostasis of energy stores in response to variable
access to nutrition and demands for EE [19]. Any perturbation of the
component of the EB system can lead to abnormal weight.
The regulation of EI has been considered a coordinate response of the
energy storage inside the body and environmental stimuli. The hypothalamus
is a major site for interpretation and integration of central and peripheral
signals that regulate energy homeostasis. Lesions in the ventromedial
hypothalamus cause hyperphagia and obesity, lesions in the lateral
hypothalamus cause aphagia and leanness and even death by starvation [20].
Within the hypothalamus, neurons residing in the ARC-PVN-PF/LH axis
communicate among each other and are subjected to the influence of several
peripheral factors, such as leptin and insulin [21]. Fig. 2.1 summarizes the
importance of hypothalamus in regulating energy homeostasis.

2.1.3 Genetics of Obesity
Although a large percentage of human obesity is attributed to adverse
lifestyle, it is well known that genetic variation among individuals influences
responses to environmental factors such as food intake and physical activity.
In the 1960s, Neel proposed the ʻthrifty geneʼ hypothesis, whereby genes that
predispose to obesity would have had a selective advantage in populations
that frequently experienced starvation. People who possess these genes in
the current obesogenic environment might be overweight or obese [22]. It is
estimated that heritability for BMI ranges between 50-70%, while heritability
for total body fat is as high as 80% [23]. These numbers, along with twin
studies that provide the most powerful test of heritability, demonstrate that
obesity is partially genetically regulated.
Obesity is commonly classified into subgroups depending on suspected
etiology: monogenic obesity, syndromic obesity, and polygenic or common
7

Figure 2.1 Hypothesized model of nine peptide systems in the
hypothalamus involved in energy homeostasis
Signals shown at the bottom, which control the expression and production of
these peptides, are indicated with arrows as a stimulatory effect (+) or
inhibitory effect (−). The behavioral and physiological actions of these
peptides are also shown. Hypothalamic areas represented are the
pariventricular nucleus (PVN), perifornical area + lateral hypothalamus
(PFLH), and arcuate nucleus (ARC). The nine peptides are: AgRP, agoutirelated protein; CART, cocaine- and amphetamine-regulated transcript; CRF,
corticotropin-releasing factor; GAL, galanin; GALP, galanin-like peptide; MCH,
melanin-concentrating hormone; NPY, neuropeptide Y; ORX, orexins; and
POMC, pro-opiomelanocortin. Adopted from Leibowitz et al., 2004 [24].
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obesity [18].

2.1.3.1 Monogenic Obesity
Monogenic obesity is characterized by extremely severe phenotypes in
the absence of developmental delays [18]. The first human single gene defect,
which leads to leptin deficiency and causes monogenic obesity, was
discovered in 1997 [25, 26]. Subsequently, variations in other genes in the
Leptin-Melanocortin pathway were identified as causative of obesity.
Additionally, mutations in three genes (SIM1, BDNF, and NTRK2) involved in
neural development have been shown to cause rare monogenic obesity [27].
Currently, there are at least 20 single gene disorders that result in an
autosomal form of human obesity [16]. All these genes control the central
sensing of EB and their mutations lead to obesity due to increased appetite
and reduced satiety.

2.1.3.2 Syndromic Obesity
There are about 30 different Mendelian disorders in which patients are
clinically obese and additionally distinguished by mental retardation,
dysmorphic features, and organ-specific developmental abnormalities. These
syndromes, syndromic obesity, arise from discrete genetic defects or
chromosomal abnormalities, and can be autosomal or X-linked. The most
common disorders known are Prader-Willi syndrome (PWS), Bardet-Biedl
syndrome (BBS), and Alström syndrome [28]. PWS, caused by a
chromosomal abnormality of an imprinted region on chromosome 15q11-q12,
is characterized by early-onset obesity resulting from hyperphagia caused by
CNS dysfunction [29]. BBS is characterized by early-onset obesity and rodcone dystrophy, morphological finger abnormalities, learning difficulties, and
renal disease, among other clinical traits. BBS has been associated with at
least 11 different chromosomal locations, including 11q13, 16q21, 3p13,
15q22.3, 2q31, 20p12, 4q27, 14q32.11, 7p14, 12q21.2, and 9q33.1 [28].

9

2.1.3.3 Polygenic or Common Obesity
Polygenic obesity arises when an individualʼs genetic makeup is
susceptible to an environment that promotes EI over EE. In contrast to
monogenic obesity, many genes and chromosomal regions contribute to
defining the common obese phenotype. These genes have been implicated in
a wide variety of biological functions, such as the regulation of food intake,
EE, lipid and glucose metabolism, and adipose tissue development [28].
Three main strategies have been adopted in genome-wide association studies
of genetic variants influencing BMI and obesity: a) genome-wide association
studies of population-based samples to examine the full range of BMI values;
b) case-control analysis of persons selected from the extremes of the BMI
distribution; and c) genome-wide analyses of pattern of fat distribution,
prompted by the particularly deleterious health effects of visceral fat
accumulation [17]. These strategies have led to the identification of a number
of common genetic variations (see review by McCarthy [17]).

2.2 T2D
2.2.1 Diabetes Overview
Diabetes is a condition defined by a state of chronic elevation of plasma
glucose levels. There are two main types of diabetes. Type 1 diabetes (T1D),
or insulin-dependent diabetes mellitus (IDDM), is mainly diagnosed during
childhood or adolescence and results from an autoimmune destruction of
insulin-producing pancreatic β cells by CD4+ and CD8+ cells and
macrophages infiltrating the islet. T2D, or non-insulin dependent diabetes
mellitus (NIDDM), constitutes over 90% of all diabetes cases. In humans, it
has mostly been diagnosed after age of forty, although recently much younger
cases are being reported. Unlike T1D in which insulin production nearly
vanishes, insulin in T2D is usually produced, but cannot be properly utilized
due to insulin-resistance in target cells [1].
T1D accounts for about 10% of all cases of diabetes. However, the
prevalence of T1D has been globally rising during the past decades by as
10

much as 5.3% annually in the United States. It is estimated that T1D is
responsible for $14.4 billion in medical costs and lost income each year in the
United States [30]. Although there are rare monogenic forms of T1D, the
common form is thought to be determined by the actions, and possible
interactions, of multiple genetic and environmental factors [31]. Like obesity,
genetic studies have identified a number of genes as important genetic
susceptibility factors. For instance, the major susceptibility locus has been
mapped to the HLA class II genes at 6p21 and accounts for up to 30-50% of
genetic T1D risk [32]. However, identification of environmental factors has
been difficult, mainly due to the wide gap between initiation and detection of
ongoing diabetogenic events [31]. Viral infection has been considered as a
popular candidate. It is proposed that decreased exposure to widespread
infection of developing immune system of the infants may contribute to the
increases in T1D incidence [33].

2.2.2 Insulin Resistance, β-cell Dysfunction, and T2D
Insulin resistance and β-cell dysfunction are two common processes
underlying the development of type 2 diabetes. It has been clear that most
insulin resistant individuals do not develop hyperglycemia. Under normal
conditions, the pancreatic islet β-cells increase insulin release sufficiently to
overcome the reduced efficiency of insulin action, thereby maintaining normal
glucose tolerance. For insulin resistance to be associated with T2D, β-cell
must be unable to compensate fully for decreased insulin sensitivity [34].

2.2.2.1 Insulin Signaling
Tight control of blood glucose in humans is dependent on the balance
between glucose absorption from the intestine, production by the liver, and
uptake by peripheral tissues. Insulin plays a critical role in regulating blood
glucose concentration by increasing glucose uptake in muscle and fat, and
inhibiting hepatic glucose production. In addition, insulin stimulates cell growth
and differentiation, and promotes the storage of substrates in fat, liver, and
11

muscle by stimulating lipogenesis, glycogenesis, and protein synthesis, and
inhibiting lipolysis, glycogenolysis, and protein breakdown. Insulin resistance
or deficiency results in profound dysregulation of these processes, and
produces elevations in fasting and postprandial glucose and lipid levels [35].
Insulin signaling is triggered by the binding of insulin to its receptor in the
plasma membrane of the cell (Fig. 2.2). The insulin receptor is a
heterotetrameric complex, consisting of 2 extracellular α subunits that bind
insulin and 2 transmembrane β subunits with tyrosine kinase activity. Insulin
binding to the α subunit induces the transphosphorylation of one β subunit by
another on specific tyrosine residues in an activation loop, resulting in the
increased catalytic activity of the kinase. The receptor also undergoes
autophosphorylation at other tyrosine residues in the juxtamembrane regions
and intracellular tail. The activated insulin receptor then phosphorylates
tyrosine residues on intracellular substrates that include the insulin receptor
substrate family (IRS1-4), IRS5/DOK4, IRS/DOK5, Gab-1, Cb1, APS and Shc
isoforms, and signal regulatory protein family members. Once phosphorylated,
these substrates act as docking molecules for proteins that contain Src
homology region 2 (SH2) domains, which in turn become activated or
associated with other downstream signaling molecules, setting off a
complicated cascade of events [36, 37]. Recently, structural analysis of the
insulin-insulin receptor complex revealed that the carboxy-terminal α-chain
segment is critical to the hormone-receptor recognition [38].
Activation of protein kinase B (Akt/PKB) is a critical step in insulin signal
transduction cascade. The effects of insulin on glucose metabolism are
mediated

by

phosphatidylinositol

(PI)

3-kinase.

Upon

tyrosine

phosphorylation, IRS proteins interact with the regulatory subunit of PI3kinase and activate the enzyme. Activated PI3-kinase in turn activates
Akt/PKB, which phosphorylates and deactivates glycogen synthase kinase 3,
leading to the activation of glycogen synthase and stimulation of glycogen
synthesis. Another target of Akt/PKB is forkhead box protein O1 (FOXO-1).
Phosphorylation of FOXO-1 by Akt/PKB leads to its exclusion from the
12

Figure 2.2 Structure of insulin receptor
See text for details. Adopted from Chang et al., 2004 [36].
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nucleus, preventing it from activating transcription of Pck1 and G6pc (see also
Chapter I). In addition, Akt/PKB is essential to glucose uptake and glucose
transporter 4 (Glut4) translocation as insulin-stimulated Glut4 translocation
was inhibited by expression of a dominant-interfering Akt/PKB mutant [37].
However, it was recently shown that Akt/PKB was dispensable for insulin- and
nutrient-mediated hepatic metabolic regulation in vivo [39].
It is considered that many of insulinʼs effects on lipogenesis are mediated
by SREBP-1c (see Section 2.6).

2.2.2.2 Insulin Resistance
Insulin resistance is a common characteristic of obesity, T2D, and
components of cardiometabolic syndrome, including hypertension and
dyslipidemia [40]. It was proposed that the cluster of insulin resistance,
impaired glucose tolerance, abnormalities of plasma lipids, and hypertension
were part of a single syndrome, Syndrome X (also called insulin resistance
syndrome, or metabolic syndrome) [41]. Insulin resistance is a decreased
ability of some of the insulin-regulated processes and tissues (liver, muscle,
and adipose tissue) to respond to insulin.
Liver plays a central role in glucose and lipid metabolism. In the liver,
insulin regulates fasting glucose concentrations by inhibiting hepatic glucose
production and stimulating glycogen synthesis. Hepatic glucose production
involves two different mechanisms: glycogenolysis and gluconeogenesis.
Glycogenolysis produces glucose during a relatively short-term fast of up to
several hours, and is suppressed by insulin within 1-2 h after food intake
under normal physiological conditions. During long periods of fasting (> 12-14
h), liver glycogen stores become depleted and there is an increase in the
percentage contribution made by gluconeogenesis to the total glucose supply.
The expression of two key enzymes for gluconeogenesis, PEPCK and
G6Pase, is suppressed by insulin (see also Chapter I). However, this action is
compromised in insulin resistance status.
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Insulin also promotes the synthesis and inhibits the oxidation of fatty
acids in the liver. When delivered to the liver in large quantities, glucose is first
converted to glycogen and stored. Once glycogen stores are replenished,
glucose enters the glycolysis pathway and thereby provides carbons for de
novo lipogenesis. Lipids are then stored as triglycerides or exported from the
liver as very-low-density lipoprotein (VLDL). The effects of insulin on hepatic
lipogenesis are mediated by SRBEP-1c. Insulin induces the expression of
Srebp-1c and key lipogenic genes, including fatty acid synthase (Fas),
stearoyl-coenzyme A desaturase 1 (Scd1), and acetyl-CoA carboxylase (Acc)
[42]. However, even in the presence of marked insulin resistance, hepatic
transcription of Srebp-1c and lipogenesis are still stimulated by insulin,
resulting in unaffected rates of de novo fatty acid synthesis [43]. The failure to
suppress gluconeogenesis coupled with decreased peripheral glucose uptake
accentuates the hyperglycemia and increases insulin secretion, further
stimulating lipogenesis, resulting in a vicious cycle.
Several molecular mechanisms of insulin resistance have been proposed
[37]. For examples, insulin resistance can be caused by impairments of insulin
signaling cascade, which can be acquired through increased degradation,
decreased expression, and/or decreased activity of major components of
insulin signaling cascade, or through the interaction of inhibitory proteins with
major components of insulin signaling cascade, such as the suppressors of
cytokine signaling (SOCS) proteins that are induced by inflammatory
cytokines. In addition, insulin resistance can be due to increased activity or
amount of the enzymes reversing insulin action, such as phosphatase and
tensin homolog and SH2 domain-containing inositol phosphatase [37].

2.2.2.3 β-cell Dysfunction
Although obesity often leads to insulin resistance, only a subset of obese,
insulin resistant individuals progress to T2D. In both animal models and
human, the triggering factor is β-cell failure, which involves a decrease in β-
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cell mass and deterioration of key β-cell functions such as glucose-stimulated
insulin secretion (GSIS).
At the very beginning of the progression towards T2D, increased plasma
glucose due to insulin resistance is balanced by increased insulin secretion,
which is mainly resulted from increased β-cell number, despite that β-cell
hypertrophy may also contribute. As β-cells are no longer able to be
compensating and normal glucose levels can no longer be maintained, loss of
acute GSIS occurs (glucose toxicity). The loss of acute GSIS is accompanied
by marked changes in β-cell phenotype demonstrated by changes in gene
and protein expression (i.e. the highly expressed genes in β-cells are downregulated while those that are normally suppressed are up-regulated in their
expression). The glucose toxicity (glucotoxic effect), together with elevated
plasma non-esterified fatty acid concentrations (lipotoxic effect), act
synergistically to produce further deleterious effects on insulin, leading to
continued β-cell loss and less efficient insulin secretion in T2D [34]. It has
been shown that people with T2D have ~50% less of β-cell mass compared
with control subjects. The reduction of the capacity of β-cell secretion is even
more considerable [44].
A number of different hypotheses have been advanced as explanations
for the development of β-cell dysfunction in T2D. One of the hypotheses is
shown in Fig. 2.3.

2.3 GK in the Regulation of Glucose Homeostasis
2.3.1 Introduction of Glucose Metabolism
Glucose is of central metabolic importance in virtually all organisms, from
microbes to humans. Glycolytic metabolism of glucose is a major pathway for
the generation of energy (ATP), and glycolytic intermediates also serve as
precursors for biosynthesis of other cellular constituents. Metabolism of
glucose through the pentose phosphate pathway generates NADPH and
precursors required for a variety of anabolic pathways. Alternatively, glucose
may be converted to its polymeric forms (glycogen, starch), which are the
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Figure 2.3 Mechanisms of β-cell failure in T2D
The model includes metabolic overload (mitochondria), endoplasmic reticulum
(ER) stress and deposition of harmful amyloid fibrils. Overnutrition and
increased lipid supply induce enzymes of β-oxidation, such as carnitine
palmitoyltransferase-1 (CPT1), resulting in increased acetyl CoA levels,
allosteric activation of pyruvate carboxylase (PC) and constitutive upregulation
of pyruvate cycling. This leads to basal insulin hypersecretion and loss of the
glucose-stimulated increment in pyruvate cycling flux, thereby blunting GSIS.
The increased demand for insulin biosynthesis increases workload in the ER,
gradually leading to ER stress and increased protein misfolding. ER stress
initially relieved by the unfolded protein response (UPR), mediated by the
transcription factor XBP1, but over time, the UPR becomes less effective and
the deleterious effects of ER stress lead to cell death, mediated by IRE1.
Finally, insulin hypersecretion is accompanied by amylin secretion, which in
humans can from amyloid fibrils that accumulate at the surface of the β-cell to
induce dysfunction and apoptotic death. elF2a, eukaryotic translation initiation
factor-2a; IRE1, inositol-requiring kinase-1; LC-CoA, long-chain acyl CoA;
PERK, protein kinase RNA (PKR)-like ER-associated kinase. Adopted from
Muoio and Newgard, 2008 [45].
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storage forms of this carbohydrate in many organisms [46].
For the cells to utilize glucose, it has to be first phosphorylated into
glucose 6-phosphate (G6P). This reaction is catalyzed by a family of enzymes
called hexokinases (ATP: D-hexose 6-phosphotransferase, EC 2.7.1.1).
Hexokinase is one of the key enzymes of the Embden-Meyerhof glycolytic
pathway, which phosphorylates glucose to G6P by using ATP [47], the initial
step in metabolism of glucose through most common pathways. In two
preliminary studies conducted about 50 years ago, four hexokinases were
identified in rat liver as A, B, C and D in the order of elution from DEAEcellulose columns [48], or I, II, III, IV by the anodal mobility on starch gel
electrophoresis [49]. The hexokinase D (IV) is commonly called “GK”. In
addition, it was demonstrated that the occurrence of multiple hexokinases in
the rat is a general phenomenon not restricted to any single tissue. The
proportions of the hexokinase types constituting the total activity of any one
tissue are variable, depending on the tissue, age of animal, and nutritional
factors [50]. The hexokinase isoenzymes can catalyze the phosphorylation of
both α- and β-D-glucose, although with different kinetic constants. Generally,
there is a higher limiting rate for phosphorylation of the β-anomers of glucose
and mannose, but much higher affinities for the α-anomers [51]. Each
hexokinase differs from the others with respect to Michaelis constant for
glucose, substrate specificity, immunological reaction, tissue distribution,
developmental and adaptive behavior [52]. It is noteworthy that more than four
electrophoretically different hexokinases were found in the liver of some
mammals [53].
Hexokinases A, B and C are 100 kDa molecules (two 50 kDa domains)
thought to have evolved by duplication and fusion of a gene encoding an
ancestral 50 kDa hexokinase. Therefore, these isoenzymes display internal
sequence repetition, and the N- and C-terminal halves have extensive
sequence similarity, both to each other and to other members of the
hexokinase family, which includes the 50 kDa mammalian GK and 50 kDa
hexokinases found in other organisms [46]. Hexokinases A, B and C share
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several properties: (a) low Km values for glucose (Km < 1mM); the reactions
catalyzed by them are barely affected by changes in the blood-glucose
concentration, because they are all largely saturated throughout the
physiological range; (b) low Ki values for G6P, i.e. they are strongly and
allosterically inhibited by G6P [54]; (c) ability to phosphorylate hexoses like
fructose or mannose in addition to glucose; (d) broad tissue distribution.
Hexokinase A is ubiquitously expressed, consistent with the importance
of glycolysis in all mammalian tissues. Moreover, it is expressed at particularly
high levels in brain, a tissue well known for its virtually total reliance on
glycolytic metabolism of glucose to sustain a high rate of energy metabolism.
Only the C-terminal domain of hexokinase A is catalytically active, but G6P
binds to both domains [55]. On the other hand, hexokinase B is much more
limited in its expression, primarily being found in insulin-sensitive tissues such
as skeletal muscle and adipose tissue. Unlike hexokinase A, both domains in
hexokinase B are catalytically active and sensitive to G6P, and glucose
binding to the N-terminal domain decreases the concentration of G6P required
to regulate the activity of the C-terminal domain, suggesting that the two
halves functionally interact [56, 57]. Hexokinase C expression is relatively low
in most tissues, with the highest levels detected in lung, kidney, and liver [58].
Hexokinases A and B contain a conserved 21-amino acid sequence in the Nterminal domain that is predicted to form a hydrophobic α-helix and enables
these proteins to bind to mitochondria [59]. In contrast, hexokinase C lacks
the hydrophobic N-terminal sequence critical for targeting to mitochondria. It
was reported that this isoenzyme was found in the “soluble” fraction of tissue
homogenates, indicating a cytoplasmic location [46]. Analysis of promoter
governing the transcription of hexokinase A, B and C indicated that they
respond to quite different transcription factors, offering the flexibility of
hexokinase isoenzymes in expression, in different tissues or in different
physiological states [60].
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2.3.2 Introduction of GK
In 1958, Cahill et al. [61] reported that the rat liver slices incubated in
media of increasing glucose concentrations show increased levels of glucose
uptake from the medium This observation suggested the existence of a
hexokinase with a much higher Michaelis constant in the liver, and led to the
discovery of rat liver GK (ATP: D-glucose 6-phosphotransferase, EC 2.7.1.2)
[62]. GK differs significantly from other hexokinases. It is half-saturated in the
physiological range of glucose concentrations (Km ≈ 10 mM). In fact, GK has
an affinity for glucose more than 20 times lower than that of hexokinase B, the
next ranking hexokinase. Another unique enzyme kinetics of GK is that the
steady-state velocity of the GK-catalyzed reaction displays a sigmoid rather
than hyperbolic dependence upon increasing glucose concentrations [63], a
hallmark of allosteric regulation. This enzyme has cooperative kinetics with its
substrates glucose and mannose as manifest by a Hill coefficient of 1.7.
Functionally, this positive cooperativity allows the enzyme to have increased
sensitivity to fluctuations in blood glucose levels. Further, it is inhibited only
weakly and non-allosterically by G6P under physiological conditions, as
substantial inhibition requires concentrations above 50 mM [64], consistent
with the fact that the liver is able to phosphorylate glucose in the presence of
high concentrations of G6P. These kinetic properties enable GK to be highly
responsive to glucose levels and to ensure that the glucose metabolic flux is
closely tied to the glucose concentration.
It was pointed out that the name “GK” for hexokinase D may be a useful
guide to its physiological role; however, it was unsatisfactory as the enzyme is
not wholly specific for glucose. In fact, the four hexokinases isoenzymes are
similar in sugar specificity, and the difference is that GK is less effective at
discriminating between glucose and fructose than some of the other
isoenzymes [65]. Mammalian GK accepts a variety of hexose substrates. The
specificity of this enzyme demonstrates the following preference of substrates:
glucose = mannose > deoxyglucose > fructose = glucosamine [66]. Since its
discovery, the enzyme has been considered as a separate entity meriting the
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name “GK” and an EC number, which have been considered misleading as
they are not specific for glucose [67]. Therefore, some have argued that the
name “GK” should be reserved for enzymes that are genuinely specific for
glucose, such as those expressed in moulds, bacteria and invertebrate
animals [51].
GK is predominantly produced in the liver and the pancreatic β-cells [68,
69], although lower levels have been detected in the hypothalamus,
enteroendocrine cells, gonadotropes, and the pituitary gland [70-73].

2.3.3 Metabolic Role of GK
The phosphorylation of glucose by GK is the first rate-limiting step of
glucose metabolism in the liver and pancreas. In 1992, two studies using the
candidate gene approach reported a genetic linkage between maturity onset
diabetes of the young (MODY2) and Gck [74, 75], suggesting a key role of GK
in glucose metabolism.
All mammalian cells can use glucose as an energy source. In addition,
the liver functions as the predominant organ of glucose production, with small
contributions by the kidney and the gut, whereas peripheral tissues (skeletal
muscle and fat) and the central nervous system remove glucose from the
plasma. In the liver, glucose moves freely across the plasma membrane in
either direction. At blood glucose levels of approximately 8.33 mM the liver
does not take up or supply glucose to the circulation. This level is therefore
termed the “steady state” or the “glucostatic level” at which the mechanisms of
normal supply and removal of glucose are operating at equal rates. At glucose
levels above 8.33 mM glucose removal is greater than supply whereas at
levels below 8.33 mM glucose supply is greater than removal, and the fasting
blood glucose level in most mammals is about 5 mM [76]. Due to the
fluctuations in food consumption and activity level throughout the course of a
day, most mammals maintain stable blood glucose levels by continuously
adjusting its metabolism in different tissues and organs. To achieve this, the
body initiated an intricate system of neural, hormonal and direct nutrient
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responses when exposed to stress (exercise or hypoglycemia) or a meal. One
of the key factors to this homeostatic control is GK.
GK activity in pancreatic β-cells is responsible for maintaining glucose
homeostasis throughout the body. This is achieved through a cascade of
cellular events that links the rate of glycolysis to the release of insulin into the
bloodstream. This process begins when glucose enters the β-cells via the
GLUT family of transporters, where it is phosphorylated by GK. Continuation
of the glycolytic pathway produces an increase in the ATP/ADP ratio, which
stimulates closure of the ATP-responsive K+ channels in the β-cell plasma
membrane. Upon channel closure, the plasma membrane becomes
depolarized allowing an influx of Ca2+ into the cell. Combined with intracellular
Ca2+ pools, these ions promote fusion of insulin-containing secretory granules
with the plasma membrane, and in turn, the rise of plasma insulin levels in
response to glucose stimulation. The elevated release of insulin causes the
translocation of the glucose transporter GLUT4 from intracellular storage
vesicles to the plasma membrane and the elevation of glucose uptake and
metabolism in the muscle and adipose tissues. Together, these processes act
to decrease blood glucose concentrations [77].

2.3.4 Cooperativity of GK with Glucose
Human GK consists of one chain of 448 amino acids forming a
monomeric molecule consisting of 13 α helices and 5 β sheets. The chain is
folded into two distinct regions, a small and large domain [78]. GK monomer
with a single glucose-binding site is active; therefore its cooperative behavior
cannot be explained by the classical multisubunit allosteric protein
mechanism. A mnemonic model mechanism of positive cooperativity has
been proposed for GK in which GK would alternate between low and high
affinity conformations involving a slow inter-conversion between the
conformational states of glucose-free low affinity GK rapidly evolving to a high
affinity state upon binding to glucose. Glucose and an activator modify the
space between the large and small globular GK domains, generating a narrow
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deep cleft containing the glucose-binding pocket. This ʻclosedʼ conformation
corresponds to the GK high-affinity-active form while in the absence of
ligands, GK displays a ʻsuper-openʼ low glucose affinity-catalytically-inactive
form [79].

2.3.5 Regulation of Gck Expression
2.3.5.1 Alternative Promoters of Gck
A defining feature of the Gck in mammals is the presence of two
alternative promoters. Bedoya et al. [80] originally discovered that Gck
expression control varied greatly from tissue to tissue. The compared GK
enzyme activities of liver and pancreatic islets in hyperinsulinemic and
hypoglycemic insulinoma-bearing rats and found that hepatic GK was greatly
increased and islet GK was drastically reduced when insulin was very high
and glucose very low, whereas the opposite was true when insulin was low
and glucose high, suggesting organ-specific differential expression control of
GK. This idea was substantiated a few years later by the cloning of a single
Gck and the discovery of two distinct promoters in this gene (an upstream
neuroendocrine and a downstream hepatic promoter) [81, 82].
The structure of Gck has been characterized in rats, human, and mouse
[83-85]. Human Gck on chromosome 7p15.3-p15.1 consists of 12 exons that
span ~45,169 bp and encode a 448-amino-acid protein, and three tissuespecific isoforms are known [86]. The mouse Gck is located on chromosome
11. Two promoters are expressed in a tissue-specific pattern. In 1989,
Magnuson and co-workers identified nine exons from rat liver and insulinomaderived cDNAs. The sequences were essentially identical [81, 83]. The
upstream, neuroendocrine promoter, and the adjacent leader exon, termed
exon 1β in reference to the β-cells of the islets of Langerhans, drive Gck
mRNA synthesis in non-hepatic tissues, including pancreatic β cells, central
nervous system, lung, thyroid, and gut cells; the downstream hepatic promoter
and its associated leader exon, termed exon 1L in reference to the liver, are
involved in gene transcription in hepatocytes [63, 87]. The islet-type exon 1β
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is located 25-30 kb upstream of the liver-specific exon 1L [88], and the
intervening sequence between the two leader exons has yet to be mapped
accurately [87].
For the activation of the 1β promoter, glucose seems to be a positive
regulator. This may serve the purpose of controlling the insulin secretion. The
sequences necessary for expression of the Gck in β-cells has been
characterized, with 294 bases of 5ʼ flanking sequence required for tissuespecific expression in transgenic mice [70, 89]. Elements in the proximal
promoter region have been identified that contribute to transcription in both
insulinoma cells and AtT-20 cells. Distal elements may also be involved,
although none have been reported [90]. In addition, Gck transcription in the
islet appears to be largely constitutive.
Although the fragments of the hepatic Gck promoter have been mapped
and characterized in hepatocytes and hepatoma cells, the identity of all
transcription factors regulating Gck promoter activity has not been fully
elucidated [63]. Insulin and glucagon increases and decreases hepatic Gck
transcription, respectively [91]. The cis-regulatory elements that determine
hepatocyte-specific expression and regulation of the hepatic Gck isoform are
largely undefined as a DNA fragment able to confer both hepatocyte-specific
and hormone-regulated expression to a reporter gene has not yet been
identified [90]. Transgenic studies have indicated that the sequences
necessary for position-independent expression of hepatic Gck are located
outside a fragment containing sequences from ~ -7.5 kb to + 18 bp (relative to
the transcription start site in liver) [85]. Another transgenic study suggested
that a DNA fragment of the mouse Gck, which spans from - 55 to + 28 kb
relative to the liver transcription start site, is expressed and regulated both in
the liver and in the islet [90]. In addition, it was reported that a 1 kb fragment
of the rat downstream promoter, which contains all hepatocyte-specific DNase
I hypersensitive sites that can be detected in a region spanning 35 kb of DNA,
is transcriptionally active in primary hepatocytes. However, it failed to respond
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to hormones, possibly due to disturbed hormone action in transiently
transfected hepatocytes [92].

2.3.5.2 Short-term (Post-translational) Regulation of Hepatic Gck
The activity of hepatic GK is controlled post-transcriptionally in the short
term by the concentration of its substrate glucose and by a regulatory protein
(GKRP), which acts as a competitive inhibitor with respect to glucose. In
mammalian species, the effect of this protein is modulated by fructose-6phosphate (F-6-P), which reinforces the inhibition, and by fructose-1phosphate (F-1-P), which antagonizes it and releases the GK-GKRP
interaction [93]. GK does not have a nuclear localization-signal (NLS) and
GKRP, which is mainly located in the hepatocyte nucleus, complexes with GK
and sequesters the enzyme in the nucleus in an inactive pool [79, 94]. At low
glucose concentration, GKRP is associated with GK in the nucleus. Acute
challenge of glucose, fructose, and other precursors of F-1-P induce
dissociation of the GK-GKRP complex, and then GK is translocated into
cytoplasm, resulting in increased GK activity [95, 96]. The long-term role of
GKRP is thought to be a GK stabilizer because GKRP knockout mice showed
decreased GK activity and GK protein level [97, 98].
In addition, long-chain acyl-CoAs (C-12 to C-20), such as palmitoyl-CoA,
have been shown to inhibit hepatic GK competitively with respect to glucose.
Their effect is instantaneous and can be reversed by dilution or upon addition
of albumin. Furthermore, they act at concentrations lower than those at which
they form micelles and their effect is not mimicked by fatty acids. These data
indicate that they do not act as detergents but by binding to an allosteric site
on GK [96, 99].

2.3.5.3 Transcriptional Regulation of Hepatic Gck
GK activity is largely regulated by the expression of its gene. Many
transcriptional factors have been shown to regulate Gck promoter activity.
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SREBP-1c
SREBP-1c belongs to a family of transcription factors involved in
cholesterol and fatty acid metabolism [100]. It was demonstrated that SREBP1c is a major factor of insulin action on Gck expression in cultured rat
hepatocytes [101]. In addition, recent work by Kim et al. [102] has identified
two functional SREBP-1c response elements (SREs) in rat hepatic Gck
promoter. SREPB-1c can bind to these SREs and activate hepatic Gck
promoter. However, these notions contrast with the observation that
overexpression of SREBP-1c does not affect the level of mRNA for Gck in
livers of transgenic mice [103], as well as the fact that insulin induces Gck
transcription at least 4 hours ahead of accumulation of mature SREBP-1c in
the nucleus, and knockdown of Srebp-1 does not affect Gck mRNA levels in
primary rat hepatocytes [104]. In addition, Hansmannel et al. [105] reported
that Gck mRNA is unresponsive to the liver X receptor (LXR) ligand T0901317
in primary hepatocytes and SREBP-1c does not bind to the hepatic Gck
promoter. Although the reason for this discrepancy is not readily evident,
further studies of the role of SREBP-1c in determining hepatic Gck expression
may help us to understand how the downstream Gck promoter is regulated by
insulin and other hormones [106] (see also Section 2.4.6).

FOXO1
FOXO1, a member of the FOXO family of forkhead transcription factors,
is phosphorylated by PKB/Akt in the presence of insulin signal and then
excluded from the nucleus, resulting in inhibition of the expression of target
genes [107]. On the other hand, unphosphorylated form of FOXO1 localizes to
the nucleus and interacts with insulin response sequences present within the
promoter regions of multiple target genes and activates their transcription.
Transfection assays in HepG2 cells suggest that FOXO1 represses the
hepatic nuclear factor 4α (HNF4α)-potentiated expression of Gck [108].
Transgenic mice expressing constitutively active form of FOXO1 in the liver
display reduced expression Gck and Srebp-1c [109]. A recent study showed
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that disruption of Foxo1 in the liver of mice lacking hepatic Irs1 and Irs2 (i.e.
disrupted insulin signaling) leads to decreased Gck expression [110]. In
addition, it was suggested that resveratrol represses Gck expression by
promoting the recruitment of FOXO1 to the Gck promoter and that resveratrolpromoted interaction between FOXO1 and HNF4α contributes to the effects of
resveratrol [111]. However, liver-specific deletion of Foxo1 does not affect
hepatic Gck expression in mice [112].

Upstream Stimulatory Factor-1 and -2 (USF-1 and -2)
USF is a ubiquitous nuclear protein that was first identified as a factor that
bound to an upstream element in, and stimulated transcription from, the
adenovirus major late promoter [113]. The USF proteins belong to the class of
basic helix-loop-helix zip (bHLHz) factors and act as sequence-specific transactivators in the form of homodimers or heterodimers, binding DNA in a
sequence-specific manner at E-box recognition elements [114]. In the liver,
USF1/USF2a heterodimers seem to be the favored DNA-binding species
[115]. Proteins of the bHLH gene family bind to sequences of the general type
CANNTG, where the central two nucleotides provide for discrimination in
binding between different family members [113]. In 1998, Iynedjian [114]
identified two protected sequence elements, designated P1 and P2, from in
vitro DNAse I protection assay using the proximal promoter region and rat
liver nuclear protein extract. The sequence of the P2 element contains the
core motif CACGTG, which serves as a binding site for a substantial number
of transcriptional activators including USF [113]. Co-transfection of an
expression plasmid coding for USF1 activated hepatic Gck promoter activity,
whereas expression of a truncated form of USF1 lacking the transcription
activation domain and the basic region decreased reporter activity by a
dominant-negative effect [114]. Consistently, a recent study showed that
hypoxia inducible factor 1 alpha (HIF-1α) and USF2a are able to bind to the
same site and activate hepatic Gck promoter in response to venous pO2. In
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addition, HIF-1α, but not USF1, can synergize with HNF4 to activate the
hepatic Gck promoter [116].

Hypoxia-Inducible Factor-1α (HIF-1α)
HIF-1α is ubiquitously expressed in human and mouse tissues and has a
general role in multiple physiological responses to hypoxia, such as
erythropoiesis and glycolysis [117]. Transient transfection in primary rat
hepatocytes has revealed that HIF-1α can affect promoter activity of hepatic
Gck by binding to the -87/-80 bp region of Gck promoter [116]. Both insulin
and hypoxia up-regulate hepatic Gck expression by increasing HIF-1α level
and its binding activity [118]. It was also reported that HNF4α and coactivator
p300 could enhance the HIF-1α-activated hepatic Gck transcription [119].

Peroxisome Proliferation-Activated Receptor γ (PPARγ)
PPARγ belongs to the superfamily of nuclear receptors and acts as a
transcriptional factor that dominates the regulation of adipose differentiation,
lipid storage, and of genes involved in energy storage and utilization. Upon
ligand binding, PPARγ heterodimerizes with RXRα, binds to the PPAR
response element (PPRE), and activates target gene transcription. It was
suggested that a PPRE is located in the -116/ -114 bp region of the rat hepatic
Gck promoter and that thiazolidinedionse (TZDs), synthetic ligands of PPARγ,
can induce Gck expresson in primary hepatocytes [120]. A recent study
reported that liver X receptor α (LXRα)-dependent activation of hepatic Gck in
Alexander cells is partly through activation of this PPRE [121]. In addition,
over-expression of PPARγ1 in PPARα-/- mouse liver notably increased Gck
expression [122].

HNF4α
HNF4α is a member of the nuclear receptor superfamily of transcription
factors and binds as a homodimer to a relatively degenerate consensus DNA
sequence consisting of two direct repeats separated by one or two
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nucleotides [123]. It was first identified by its interaction with a cis-regulatory
sequence of liver specific gene promoters [124]. Three different genes coding
for three different isoforms have been identified, HNF4α and HNF4γ in
mammals, drosophila, and xenopus, and HNF4β in xenopus. The expression
of HNF4α is restricted to liver, kidney, small intestine, colon, pancreas and
testis. HNF4γ is expressed in the same tissues, except for liver [124, 125].
HNF4α is a central regulator of gene expression in cell types that play a
critical role in metabolic homeostasis, including hepatocytes, enterocytes, and
pancreatic β cells [126]. Mutations in human Hnf4α are associated with
MODY1, an autosomal dominant genetic disorder that is characterized by
early

onset

T2D

[127].

MODY1

patients

are

hyperglycemic

and

hypoinsulinemic, have reduced levels of circulating lipids, and display defects
in the expression of genes involved in glucose and lipid metabolism [128,
129]. It was showed that Gck expression was activated by HNF4α via the
sequence -52/-39 of the Gck promoter. In addition, HNF4α might act as a
regulatory factor mediating the perivenous zonated Gck expression [130] (see
also Section 2.5.3).

2.4 SREBPs in the Regulation of Lipid Homeostasis
2.4.1. Introduction
SREBPs belong to the basic helix-loop-helix-leucine zipper (bHLH-Zip)
family of transcription factors and coordinate the synthesis of fatty acids and
cholesterol. SREBPs are synthesized as inactive precursors anchored in the
endoplasmic reticulum (ER) and nuclear membrane [100, 131]. Each SREBP
precursor is consisting of three domains: an NH2-terminal domain of about
480 amino acids that contains the bHLH-Zip region for binding DNA; two
hydrophobic transmembrane-spanning segments interrupted by a short loop
of about 30 amino acids that projects into the lumen of the ER; and a COOHterminal domain of about 590 amino acids that performs the essential
regulatory functions [131]. In order to enter the nucleus and influence
transcription, the NH2-terminal domain of SREBPs must be released from the
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membrane, which is accomplished by the coordination of four proteins:
SREBP cleavage-activating protein (SCAP), insulin-induced genes (Insigs),
Site-1 protease (S1P), and Site-2 protease (S2P). Under high cholesterol
conditions, binding of cholesterol to the sterol-sensing domain induces a
conformational change that results in SCAP binding to ER retention protein
Insigs, preventing vesicular trafficking of SREBPs from the ER to the Golgi
apparatus. In cholesterol-depleted cells, however, SCAP escorts SREBPs
from the ER to the Golgi apparatus, where the two-step proteolytic cascade
takes place [132, 133]. S1P, a membrane-bound serine protease, cleaves the
SREBP in the lumen loop between the two membrane-spanning segments
and the NH2-terminal bHLH-Zip domain is released from the membrane upon
a second cleavage mediated by the membrane-bound zinc metalloproteinase
S2P [131].
The mammalian genome encodes three SREBP isoforms: SREBP-1a,
SREBP-1c, and SREBP-2. The first two isoforms are derived from a single
gene on human chromosome 17p11.2 through the use of alternative splicing,
whereas SREBP-2 is encoded by a gene on human chromosome 22q13.
While SREBP-1a is a potent activator of all SREBP-responsive genes,
SREBP-1c preferentially enhances transcription of genes involved in fatty acid
synthesis, but not cholesterol synthesis. SREBP-2 preferentially activates
cholesterol synthesis [131]. It has been shown that SREBP-1a and SREBP-2
are preferentially expressed in most culture cell lines, whereas SREBP-1c and
SREBP-2 predominate in the liver and most other intact tissues [134].

2.4.2 SREBP-1c in Liver
Transgenic mice expressing the NH2-terminal fragment of SREBP-1c
display increased hepatic expression of genes encoding proteins involved in
fatty acid synthesis (acetyl CoA carboxylase, fatty acid synthase, and
stearoyl-CoA desaturase-1), but not in cholesterol uptake (LDL receptor) and
synthesis (HMG CoA synthase, HMG CoA reductase, and squalene synthase)
[135]. Similarly, the liver express a mutant version of SCAP that is resistant to
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feedback suppression by sterols, the amounts of nSREBP-1 and -2 rise and
there is a concomitant overproduction of cholesterol and fatty acids, leading to
marked engorgement of the liver with cholesteryl esters and triglycerides
[136]. In contrast, deficiency of SCAP [137] and S1P [138] in mouse liver
result in reduced rates of cholesterol and fatty acid synthesis due to declined
nuclear SREBPs.
Germline knockout of SREBP-1 [139] or SREBP-1c [140] in mouse lead
to a compensatory increase in hepatic expression of SREBP-2 and therefore
increased mRNA levels for cholesterol biosynthetic enzymes. Germline
disruption of SREBP-2 [139] or S1P [138, 141] causes embryonic lethality in
mice.

2.4.3 SREBP-1c in β Cells
SREBP-1c plays an important role in β-cell lipotoxicity. In pancreatic
MIN6 β-cells, SREBP-1c is required for glucose-stimulated expression of
acetyl-CoA carboxylase expression, a key lipogenic enzyme. On the other
hand, over-expression of SREBP-1c decreases glucose-stimulated insulin
release, indicating a critical role of SREBP-1c in promoting β-cell dysfunction
[142]. Similarly, in another insulin secreting cell line INS-1, over-expression of
nuclear active form of SREBP-1c using tet-on inducible system or adenovirus
induces massive accumulation of lipid droplets and blunted nutrient-stimulated
insulin secretion [143, 144]. In addition, adenovirus-mediated over-expression
of SREBP-1c in rat islets induces genes involved in cholesterol, fatty acid, and
eicosanoid synthesis [145].

2.4.4 SREBP-1c in Adipose Tissue
In addition to liver, adipose tissue is another organ that produces an
abundance of SREBP-1c relative to -1a. It has been shown that the mRNA
level of Srebp-1c exceeds that of Srebp-1a by 3-fold [134].
The implication of SREBP-1c in adipose differentiation was first
demonstrated by Spiegelman and coworkers [146], who identified SREBP-1c
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as an activator of fatty acid synthesis and differentiation of mouse 3T3-L1 preadipocytes into mature adipocyte in tissue culture. SREBP-1c therefore was
originally named adipocyte determination- and differentiation-dependent factor
1 (ADD1). On the other hand, ectopic expression of a dominant-negative
SREBP-1c in 3T3-L1 preadipocyte cell line strongly inhibits the adipocyte
differentiation and suppresses the expression of adipocyte-specific genes
[147].
Stimulation of the Srebp-1c with LXR agonist has negligible effects on the
expression of lipogenic enzymes in adipocytes, despite a concomitant
increase in nuclear active SREBP-1c, indicating that regulation of lipogenic
genes is independent of SREBP-1c in mouse adipocytes [148]. Disruption of
Srebp-1 has little effect on the dynamic changes (i.e. fasting-refeeding) of
lipogenic gene expression in adipose tissue [149]. In transgenic mice, overexpression of nSrebp-1c in adipose tissue under the control of the adipocytespecific aP2 enhancer/promoter resulted in disruption of the differentiation
processes of adipocytes, insulin resistance, hyperglycemia, fatty liver from
birth and elevated plasma triglyceride levels later in life [150].
It has been shown that the mRNA expression of Srebp-1c in adipose
tissue is reduced dramatically upon fasting and elevated upon refeeding [151].
Similar observations were obtained from healthy individuals and insulin
resistant non-diabetic patients, in which Srebp-1c mRNA levels were induced
by insulin [152]. These observations suggest that insulin regulates the mRNA
expression of Srebp-1c both in mice and human.

2.4.5 SREBP-1c in Muscle
It has been suggested that skeletal muscle Srebp-1c expression is
regulated by nutritional status in a fashion similar to that observed in liver and
adipose tissue [153]. Insulin induces the expression of Srebp-1c in cultures of
adult rat skeletal muscle cells [154] and in human [152]. Leptin suppresses
refeeding effects on Srebp-1c mRNA levels in rats [153].

32

2.4.6 Insulin-stimulated Expression of SREBP-1c in the Liver
The hepatic SREBP-1c expression is reduced during fasting but
increases markedly when animals are refed a high carbohydrate diet. In
contrast, such manipulations induce only minor effects on the expression of
the other SREBP isoforms [155]. In addition, rats treated with STZ display
dramatically reduced mRNA level of Srebp-1c, and insulin treatment restores
both mRNA and protein levels of SREBP-1c. However, these treatments have
little effect on the mRNA expression of Srebp-1a and Srebp-2, indicating the
in vivo role of insulin in regulating Srebp-1c transcription [156]. In primary
hepatocytes that transcription of SREBP-1c is induced by insulin and
suppressed by glucagon via induction of cellular cyclic AMP level [157].
Studies using primary rat hepatocytes revealed that insulin activates the
transcription of Srebp-1c and the synthesis of the precursor form of SREBP1c, through the PI3K/Akt pathway [158, 159]. PKCλ, which acts downstream
of PI3K, also plays a critical role in mediating insulin-induced SREBP-1c
expression in liver [160, 161].
SREBP-1c has been suggested to regulate the expression of genes
involved in glucose metabolism. A dominant active form of SREBP-1c in
primary hepatocytes induces Gck expression to similar extent as insulin
treatment [101]. This led to the conclusion that SREBP-1c is the mediator of
insulin-stimulated Gck expression in the liver and hepatocytes. However, this
view has been challenged by the several studies using different models. In the
study using liver-specific Srebp-1c knockout mice, the hepatic Gck expression
responded normally to the cycle of fasting and refeeding [140]. The
knockdown of Srebp-1c by small interfering RNA in primary hepatocytes did
not result in any change in insulin-induced Gck expression [104]. In our time
course study, insulin-induced Gck expression peaked at three hours after the
stimulation, a time point before significant induction of SREBP-1c protein. The
insulin-induced Srebp-1c mRNA expression peaked at 9 h, which is not
enough to mediate the insulin-induced Gck expression [12].
The insulin-induced Srebp-1c expression in primary hepatocytes has also
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been considered to mediate insulin-suppressed Pck1 expression. In that
study, overexpression of constitutive active SREBP-1c in hepatocytes caused
reduction of Pck1, which is an insulin-suppressed gene. However, our time
course study excluded the possibility of this mechanism to mediate short-term
regulation of Pck1 expression by insulin [12].

2.4.7 Role of LXR in the Regulation of Srebp-1c Expression
LXRα and β are members of the nuclear receptor superfamily that
heterodimerize with RXR [162]. LXRα is highly expressed in liver, intestine,
kidney, and adipose, whereas LXRβ is expressed more ubiquitously with
particularly high levels in the developing brain [163, 164]. Oxysterol, oxidized
derivatives of cholesterol, are endogenous ligands for LXRs [165]. Activated
LXRs have been shown to regulate expression of genes important in
cholesterol metabolism as well as fatty acid synthesis [166].
LXRs play an important role in the regulation of SREBP-1c expression. It
was demonstrated dietary cholesterol and synthetic agonists for LXRs and
RXR induced SREBP-1c expression through the LXR element (LXRE), without
affecting expression of SREBP-1a and -2. Hepatic SREBP-1c expression is
significantly reduced in mice deficient in both LXRα and LXRβ; however,
deficiency of only LXRα slightly reduces SREBP-1c mRNA while there is no
effect when only LXRβ in lacking [167]. LXR also plays a central role in
mediating the effect of insulin on Srepb-1c transcription. Chen et al. [168]
used reporter constructs to show that mutation of the LXREs in Srebp-1c
promoter significantly reduced insulin-mediated activation of Srebp-1c
transcription. In addition, high-fat feeding stimulates lipogenesis, with an
increase in SREBP-1c expression, possibly through LXR [169].
The primary role of LXR is thought to be in the control and protection of
cells from cholesterol overload [170]. Thus the reason why LXR would trigger
a parallel increase in fatty acid synthesis via transcriptional regulation of
Srebp-1c remains unclear. One hypothesis is that the blood transport and cell
storage of excess cholesterol requires the formation of cholesteryl ester. This
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increases the demand for oleate production, which is indeed stimulated upon
over-expression of Srebp-1c [170].
SREBP-1c also positively regulates its own production in a feed-forward
loop that ensures higher SREBP-1c production when the levels of the mature
nuclear form are elevated [171].
It was reported that high levels of polyunsaturated fatty acids (PUFA)
repress SREBP-1c expression through several possible mechanisms. First,
PUFA suppresses SREBP-1c expression by inhibiting the LXR binding to the
promoter [172, 173]. Second, PUFA may suppress SREBP-1c expression by
accelerating the decay of Srebp-1c transcripts as demonstrated in rat
hepatocytes [174].

2.5 Nuclear Receptors (NRs) in the Regulation of Glucose and Lipid
Metabolism
2.5.1 Introduction of NRs
NRs represent a family of transcription factors that mediate a complex
array of extracellular signals into transcriptional responses in a liganddependent manner [175]. This family includes receptors for endocrine
steroids, fat-soluble vitamins A and D, thyroid hormone, and a large number of
“orphan” NRs, whose ligands, target genes, and physiological functions were
initially unknown [162, 175-177]. Like other transcriptional regulators, NRs
exhibit a modular structure including six regions, A, B, C, D, E and F, with
different degrees of evolutionary conservation. The variable N-terminal A/B
region contains an autonomous transcriptional activation function 1 (AF-1).
The highly conserved region C that corresponds to the core of the DNAbinding domain (DBD) is responsible for specific binding to cognate response
elements. Region E contains the ligand-binding domain (LBD), a liganddependent transcriptional activation function 2 (AF-2) and a dimerization
interface. A variable region D functions as a flexible hinge between the DBD
and LBD and contains the nuclear localization signal. Some but not all NRs
contain a variable C-terminal region F of unknown function [162, 178-180].
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Upon ligands binding, NRs undergo a conformational change that coordinately
dissociates co-repressors and facilitates recruitment of coactivators to enable
transcriptional activation. NRs control the expression of a network of genes
with key roles in glucose and lipid metabolism [162, 181].
There are 48 known NRs in the human genome [162, 182], four of which
are focused in this dissertation: retinoic acid receptor α (RARα), RXRα,
HNF4α, and chicken ovalbumin upstream promoter-transcription factors II
(COUP-TFII).

2.5.2 RARα and RXRα
RA, the biologically active metabolite of VA, exerts its action through two
families of NRs, the RARs (α, β, γ) and the RXRs (α, β, γ), which bind as
RAR/RXR heterodimers to response elements (RARE) located in the
promoters of RA-target genes. The binding of RA to RAR/RXR induces a
conformational change that is followed by the replacement of co-repressor
with co-activator complexes (see also Section 2.8.6). Most of the RAREs are
composed of two hexameric motifs, 5ʼ-(A/G)G(G/T)TCA-3ʼ, arranged as
palindromes, direct repeats (DRs), or inverted repeats (IRs). The most
frequent DRs with 1, 2, or 5 nucleotide spacing are termed DR1, DR2, and
DR5 elements, respectively. DR1 elements exhibit different polarity of binding
of the liganded RAR subunit compared to the DR2 and DR5 elements. For
DR1 elements, an upstream half site is recognized by a RAR and this type of
RARE-bound complex acts as a transcriptional repressor. RXRs can also bind
as homodimers to DR1 elements and respond to 9-cis RA. In contrast, for
DR2/DR5 elements, a RAR occupies the downstream halves of these RAREs
and the NR complex functions as transcriptional activator. Additional
arrangement of two or three hexameric motifs with variable spacing have also
been identified [183].
Unlike the steroid receptors that function as homodimers, a lot of NRs,
other than RARs, require RXRs for high affinity binding to their cognate
responsive elements. These include thyroid hormone receptors (TRs), vitamin
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Figure 2.4 Schematic structure of a typical NR
See text for details.
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D3 receptors (VDRs), and peroxisome proliferation activated receptors
(PPARs) [178, 184]. In fact, RXRs are common partners in at least 11 distinct
signaling pathways. However, the activation state of RXR varies among these
heterodimers and seems to depend on the nature of its partner [185]. For
example, in the case of RAR/RXR heterodimer, it is believed that both
partners of the heterodimer can be transcriptionally active. However, the
liganded RXR is not active unless its RAR partner is itself liganded [186]. In a
PPAR/RXR heterodimer, both PPAR and RXR can bind their cognate ligands
and activate transcription, with the binding of both ligands resulting in
synergistic activation. Heterodimers in this case are referred to as permissive.
Similarly, LXR/RXR heterodimer retains 9-cis RA responsiveness, further
supporting that the view that RXR can be an active partner [176]. In contrast,
the TR/RXR and VDR/RXR heterodimers are thought to be nonpermissive, as
they are activated by the TR ligand triiodothyronine (T3) and VDR ligand 1,25dihydroxy-VD3 (calcitriol), respectively, but not by RXR-specific ligands. It is
generally believed that in a nonpermissive heterodimer, RXR is incapable of
ligand binding and thus is often referred to as a silent partner. However,
recent data indicated that RXR was able to bind ligand and lead to
dissociation of corepressors from TR, thus modulating heterodimer activity
[187].
Genetic studies have established RXRα/RAR heterodimers as the main
functional units transducing RA signals during development, and specific
heterodimers (RXRα/RARα, RXRα/RARβ, and RXRα/RARγ) are involved in
given developmental processes [188].

2.5.3 HNF4α
HNF4α (NR2A1) is a highly conserved member of the NR superfamily of
transcriptional factors. Expression of HNF4α gene (Hnf4a) is driven by two
distinct promoters, the P1 promoter that drives expression of splice variants
HNF4α1-6 in the liver, kidney, and intestine/colon and the P2 promoter that
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drives expression of splice variants HNF4α7-9 in the intestine/colon, stomach,
and β-cells of the pancreas [189].
HNF4α binds DNA as a homodimer and generally acts as a positive
transcriptional regulator of many hepatocyte genes. It was found in 1996 that
mutations in human HNF4α gene caused MODY1, an autosomal dominant
genetic disorder that is characterized by early onset T2D [190], indicating a
critical role of HNF4α in metabolic homeostasis. Liver-specific knockout of
Hnf4a in mouse resulted in accumulated lipid in the liver, reduced serum
cholesterol and TG levels, and increased serum bile acid concentrations
[191]. In addition, pancreatic β-cell-specific Hnf4a knockout mice have
impaired glucose-stimulated insulin secretion [192]. It was reported recently
that drosophila HNF4 (dHNF4), the single ancestral ortholog of HNF4α,
regulates lipid mobilization and β-oxidation [193]. dHnf4 null mutant larvae
were unable to efficiency mobilize stored fat for energy under starvation,
consistent with reduced expression of genes that control lipid catabolism and
β-oxidation. In addition, in vitro studies have established that HNF4α is
important in controlling many of the functional properties of developed and
mature pancreatic β-cells. For example, HNF4α activates the insulin gene
expression through indirect and direct mechanisms [194]. HNF4α also
regulates the expression of other pancreatic β-cell genes implicated in
glucose metabolism and nutrient-induced insulin secretion, including glucose
transporter-2 and L-pyruvate kinase [195]. Moreover, it has been shown that
HNF4α can activate hepatic Gck expression by binding to its promoter [108,
111, 130].
HNF4α, although initially believed to be an orphan receptor, its activity
can be modulated by fatty acyl-coenzyme A (CoA) thioesters, and also by
protein kinase A-mediated phosphorylation. This suggests that HNF4α may
be responsive to dietary signals and important in the control of metabolic
status [191]. Consistently, fatty acids released from triglycerides can activate
HNF4 in fasted drosophila, which in turn drives fatty acid oxidation for energy
production [193].
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A relationship between retinoids and HNF4 has been indicated in
controlling the hepatocyte phenotype. It was found that RA-mediated downregulation of α-Fetoprotein gene was dependent on the inhibition of HNF1 and
HNF4 in Hep3B cells [196]. Since there is no RARE at the HNF4 gene
promoter, the mechanism for RA-mediated inhibition of HNF4 remains to be
investigated. On the other hand, HNF4α regulates retinoid metabolism by
activating the transcription of CRBPII gene [197]. Furthermore, it is suggested
that HNF4α and RXRα compete for occupancy of the same site in cytokine
erythropoietin gene promoter and sequentially regulating its expression during
embryogenesis [198].

2.5.4 COUP-TFII
COUP-TFs are among the most studied orphan NRs with no
physiological ligand. In humans, COUP-TFs consist of at least three
members, COUP-TFI (also called NR2F1 or ErbA-related protein-3 [EAR3]),
COUP-TFII (also called NR2F2 or apolipoprotein-AI regulatory protein-1
[ARP1]), and the more distant COUP-TFIII (also called NR2F6 or EAR2 [199].
COUP-TFs are the most evolutionarily conserved NRs among all species, with
the LBDs of COUP-TFI or II being identical in vertebrates [200], suggesting
their functional importance. In fact, deletion of either COUP-TFI or COUP-TFII
in the mouse is lethal [201]. However, COUP-TFII is required earlier in
development than COUP-TFI [202].
COUP-TFII is implicated in a variety of biological processes, including
development, cellular differentiation, growth, and metabolic homeostasis
[203]. In vitro studies have shown that COUP-TFII regulates insulin gene
expression in pancreatic β-cells and several genes involved in glucose and
lipid metabolism [204, 205]. Gain-of-function and loss-of-function studies have
established COUP-TFII as a potent repressor of adipogenesis by suppressing
the expression of a number of pro-adipogenic factors, including SREBP-1c,
PPARγ1, PPARγ2, and C/EBPα [206]. Since global COUP-TFII deficiency is
lethal to embryos, conditional knockout mice had been generated to study the
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physiological roles of COUP-TFII in nutrient metabolism. It has been shown
that heterozygous mutant mice with COUP-TFII deleted from pancreatic β
cells have impaired glucose sensitivity and abnormal insulin secretion [207].
In addition, COUP-TFII plays an important role in regulating white adipose
tissue development and energy metabolism, as shown in COUP-TFII
heterozygous knockout mice that have improved glucose homeostasis and
increased EE [208].
Despite that COUP-TFII can activate transcription in certain cell types
and promoter contexts, it act primarily as repressors of ligand-mediated NR
signaling pathways via both protein-protein and protein-DNA interactions. For
example, COUP-TFII binds promiscuously to hormone response elements
(HREs) recognized by other NRs, thereby competing with them for their target
sites. It has been shown that COUP-TFII can bind DNA by a Zn finger DNA
binding domain on a variety of HREs that contain direct or inverted imperfect
AGGTCA repeats with various spacings [209]. COUP-TFII can also titrate the
common heterodimerization partner, RXR, which is required for high affinity
DNA binding of most members of the thyroid hormone/RAR subfamily. In
addition to these indirect mechanisms of repression, COUP-TFII can also
actively silence basal and activated transcription, likely through direct
interaction with TFIIB or other general transcription factors. COUP-TFII
therefore antagonizes cellular responses to multiple hormone signaling
pathways and can have profound effects on metabolic homeostasis [210].
It has long been clear that COUP-TFs are involved in the modulation of
RAR- and RXR-mediated responses to retinoids during embryogenesis [199].
Recently, COUP-TFII was identified as low-affinity RA receptor. High
concentration of RA is able to activate COUP-TFII and release it from the
autorepressed conformation [200]. These observations suggest a linkage
between RA and COUP-TFII signaling pathways.
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2.6 Vitamin A
2.6.1 Brief History of Vitamin A
The importance of a substance present in certain foods for the treatment
of night blindness was already known in ancient Egypt. The Greek physician
Hippocrates (460- 327 B.C.) recommended the intake of “raw beef liver,
soaked in honey, once or twice by mouth” for the treatment of “nyctalopia”, or
the total inability to see in darkness [211]. In 1881, N. Lunin in Russia reported
that mice could not survive on a purified diet of fats, carbohydrates, proteins,
and salts alone, but survival was more likely when whole milk was added
[212]. Thirty years later, F. G. Hopkins [213] found that animals fed a purified
diet of casein, starch, sugar, lard and salts failed to grow, whereas the
addition of a small supplement of whole milk equivalent to 2-4% of total
calories restored normal growth, consistent with Luninʼs observations.
Hopkins postulated the existence of unknown substances in the milk that were
necessary for life and growth. He called these substances “accessory food
factors”. In 1913, McCollum ultimately showed that there was a fat-soluble
growth factor in butter fat that could be transferred from one fat to another and
this factor was essential for growth and survival of rats. It was named “fatsoluble factor A” as opposed to other accessory dietary factors, called “watersoluble B” [211]. The factor was finally named vitamin A (VA) in 1920 [214]. In
1931, Karrer and co-workers determined the structure of retinol, and soon
thereafter the structure of β-carotene. In 1937, retinol was first crystallized
from fish liver oil, from which the first crystalline esters were also isolated five
years later. In 1946, Van Dorp and Arens synthesized retinoic acid and in
1947 the Isler group reported a commercially feasible synthesis of retinol. In
1950, Karrer and Eugster synthesized β-carotene. Synthetic retinol serves as
the precursor for the retinyl esters (REs) used widely in VA supplements and
in fortified food. These early developments have been summarized by Wolf
[211].
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2.6.2 Nomenclature
Retinoids are a class of compounds derived from four isoprenoid units
joined in a head-to-tail manner to produce a monocyclic parent compound
containing five carbon-carbon double bonds and a functional group at the
acyclic terminus, with or without biological activity. The term “VA” groups any
retinoid with the biologic activity of all-trans retinol (hereinafter referred to as
retinol), the parent retinoid compound [215]. It includes both preformed VA,
that is, biologically active derivatives of retinol, and provitamin A carotenoids
[216].
VA exists both in plants and animals. More than 600 carotenoids have
been identified from plants. However, only 50 serve as precursors of VA in
humans, which includes β-carotene, the best-known carotenoid [216]. Animal
products contain VA predominantly in the form of REs, an esterified product of
retinol and a fatty acid, but also as retinol and, in small amounts, as
provitamin A carotenoids originating from plants consumed by the animals. In
most animal tissues, the predominant retinoid is retinyl palmitate, but other
fatty acid esters, such as retinyl oleate and retinyl stearate, are also found.
Retinol moiety in most of these metabolites is in the all-trans configuration.
The 11-cis aldehyde form, 11-cis retinal, is the chromophore in the retina of
the eye, and several acid forms such as the all-trans, 3, 4-didehydro- and 9cis retinoic acid, are active metabolites of retinol found in most if not all tissues
[217].

2.6.3 Metabolism of VA
2.6.3.1 Absorption of Retinol
The uptake of VA by the absorptive cells of the small intestine is the
necessary first step in its utilization by the organism. Dietary VA is available
mainly in the form of provitamin A precursor compounds from plants and of
preformed VA, REs from animal tissues. All these compounds are lipid soluble
and therefore require normal fat digestion and absorption for their absorption.
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Figure 2.5 Chemical structure of all-trans retinol and some carotenoids
[218].
Carotenoids are organic hydrocarbon-based pigments naturally occurring in
plants, some bacteria, and algae. There are two types of carotenoids:
xanthophylls (oxygen containing) and carotenes (without oxygen). The
carotenes are vitamin A-related substances produced by plants but cannot be
synthesized by animals. There are several forms of the carotenes but only 4
forms (α, β, γ, and β-cryptoxanthin) have VA activity in humans. The α and β
forms are the 2 primary forms found in plants [219].
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2.6.3.2 Absorption of Carotenoids
It is considered that 5- 50% of carotenoids, dependent on the quantity of
dietary fat, can be absorbed by passive diffusion. Absorption efficiency is
reduced with increased carotenoid intake. Carotenoids may be converted to
VA by central cleavage to yield one or two molecules of retinal, which is
catalyzed by a 15, 15ʼ-dioxygenase enzyme that is found in the intestine
mucosa, liver and other tissues. Retinal is then reduced to retinol by a
aldehyde reductase in intestinal cells [220]. Eccentric cleavage of carotenoids,
which is catalyzed by β, β-carotene-9ʼ 10ʼ-dioxygenase, yields β-apocarotenals with different chain lengths, which then may be shortened by βoxidation to retinol. In addition, there is evidence showing that retinoic acid
may be formed directly from such carotenoids as β-carotene by a still
undefined pathway [221]. However, the exact mechanism of conversion of
carotenoids to retinol is still controversial.

2.6.3.3 Absorption of REs
In contrast to carotenoids, REs from the diet are hydrolyzed into retinol
and fatty acid in the intestinal lumen, which can be catalyzed by several
enzymes, including pancreatic lipase, pancreatic carboxyl ester lipase, and
one or more RE hydrolases associated with the brush border membranes
[222]. Free retinol is incorporated into lipid micelles in the gut lumen (i.e.
emulsification) and taken up by absorptive epithelial cells of the intestine. It
has been shown that retinol is absorbed by facilitated diffusion at
physiological concentrations (up to 150 nM) and by passive diffusion at
pharmacological levels (450-2,700 nM) [223]. A specific transporter for retinol
may also play a role in the absorption of free retinol [224].

2.6.3.4 Re-esterification of Retinol
Nearly all of the newly absorbed retinol, independent of its source, is
transported from enterocytes via the lymphatic route to the general circulation
in the form of REs associated with chylomicrons. It has been considered that
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more than 80% of the retinol that leaves the intestine in chylomicrons is
esterified, in both rats and humans [225]. Therefore, the intestinal
esterification of retinol is a key step in VA metabolism [226].
Within the intestinal mucosa, all retinol is re-esterified with long-chain
fatty acids (primarily palmitic, with smaller amounts of stearic, oleic and
linoleic acids) through the action of two enzymes: lecithin: retinol
acyltransferase (LRAT) that interacts directly with the retinol-CRBPII complex
and acyl CoA: retinol acyltransferase (ARAT) that interacts with free retinol
[226-232]. LRAT utilizes the fatty acid in the sn-1 position of membraneassociated phosphatidyl choline as the source of fatty acid for esterification
[228, 233], whereas the activity of ARAT requires fatty acyl-CoA [234]. The Km
of the LRAT reaction for retinol is lower than that of the ARAT reaction,
whereas the capacity (Vmax) of the ARAT reaction is substantially greater than
that of the LRAT reaction [235]. Although the Vmax of LRAT is low, it is
considered to be sufficient to esterify retinol in the range of standard
concentrations of retinol [236]. It has been suggested that LRAT is the major
contribution to RE synthesis under normal physiological conditions when cell
CRBP-II content exceeds the retinol, and ARAT esterifies excess retinol when
large doses are absorbed and CRBP-II are saturated [225]. However, in
tissues that do not synthesize CRBP, such as mammary gland, ARAT is the
only physiologically active enzyme that esterifies retinol [235].

2.6.3.5 Metabolism of REs in Chylomicrons
Although most of the absorbed VA is secreted into lymph as chylomicron
REs, a significant amount is also secreted into portal circulation as
unesterified retinol [237]. The portal absorption is likely to be important for
pathological conditions that affect secretion of chylomicrons, such as
abetalipoproteinemia [238] .
Chylomicrons are exclusively synthesized in the intestine to transport
dietary fat and fat-soluble vitamins into the blood. Chylomicrons consist of a
hydrophobic core that contains TG, cholesteryl esters, REs, other fat-soluble
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vitamins, and about 30% of the free cholesterol, whereas the surface
membrane consists of a monolayer of phospholipid, apoproteins, free
cholesterol, and some TG [239, 240]. In the general circulation, chylomicron
remnants are formed after the lipoprotein lipase (LPL)-mediated hydrolysis of
triglyceride and the transfer of apolipoproteins, phospholipids, and free
cholesterol to other lipoproteins. The formed chylomicron remnant, comprising
only 4% of the original chylomicron mass, is depleted in TG and more
enriched in cholesteryl esters, phospholipids, and proteins [240]. However,
essentially all chylomicron REs are associated with the particle during the
conversion to chylomicron remnants, which are transported either to
extrahepatic tissues or to the liver.

2.6.4 Uptake of VA
2.6.4.1 Extrahepatic Clearance of REs in Chylomicron Remnants (CRs)
Goodman et al. injected chylomicrons containing newly absorbed labeled
VA intravenously into normal intact rats and observed the tissue distribution of
radioactivity for several days. In so doing, they found that in rats
approximately 25% of postprandial REs could be taken up by kidney, spleen,
heart, adipose tissue, lung, skeletal muscle, and adrenals [241]. Other
important extrahepatic sites for uptake of REs include bone marrow [242],
myeloid leukemic cells [243] and leukocytes [244]. It has been shown that the
level of LPL expression in skeletal muscle, adipose tissue and heart directly
correlated with the amount of chylomicron VA taken up by the tissues,
indicating a critical role of LPL in facilitating uptake of postprandial VA by
these tissues. However, rabbit bone marrow is able to take up chylomicron
REs in the absence of LPL activity [245].

2.6.4.2 Uptake of REs in CRs by Liver Hepatocytes
The liver is the major organ in the body for the storage and metabolism of
VA. In fact, more than 90% of the bodyʼs VA is found in the liver. Two types of
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liver cells are involved in hepatic VA metabolism: hepatocytes (parenchymal
cells) and stellate cells.
Hepatocytes are thought to contain at least two plasma membrane
receptors that can bind CRs with high affinity: B/E receptor that binds
lipoproteins containing either apolipoprotein (apo) B or apoE, and apoE
receptor that specifically binds apoE containing lipoproteins. It was reported
that CRs were preferentially cleared by receptors that have high affinity for the
apoE moiety [246]. ApoE deficient mice display very high circulating levels of
total cholesteryl and REs even in the fasting state, indicating the critical role of
apoE receptor in the uptake of CRs [247]. Several distinct cell surface
receptors that are able to bind apoE-containing lipoproteins may be involved
in the uptake of CRs by hepatocytes. Other than low-density lipoprotein
receptor (LDLR, or B/E receptor), the LDLR-related protein (LRP), lipolysisstimulated receptor (LSR), lipoprotein lipase and hepatic lipase may also play
a role [248, 249].

2.6.4.3 Fate of REs in CRs in Hepatocytes
Lipoproteins are taken up into the hepatocytes via receptor-mediated
endocytosis. The receptors are normally associated with defined locations on
the cell surface. For example, LDLRs are normally present in clathrin-coated
pits on the cell surface, which when bound to CRs via adaptin, are pinched off
to form clathrin-coated vesicles inside the cell [250]. Soon after the
internalization of the CRs-receptor complex, the newly endocytosed retinyl
esters are hydrolyzed to retinol by bile salt-independent hydrolase at the
plasma membrane and by acid hydrolase in the early endosomes [251]. This
process is rapid so that the REs will not be delivery to lysosomes that other
ligands are transferred to. The receptors are then either destroyed or they can
be recycled via the endocytic cycle back to the surface of the cell where the
neutral pH will cause the receptors to revert to its native conformation [250]. In
contrast, newly formed retinol is bound to CRBP-I and the complex is
delivered to endoplasmic reticulum, where retinol binding protein (RBP) is
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found in high concentration [252]. Binding of retinol-CRBP-I to RBP initiates a
translocation of the holo-RBP to Golgi, followed by secretion from the cells
[253].

2.6.4.4 Transfer of Retinol from Hepatocytes to Stellate Cells
It was reported that when chylomicrons labeled with [3H]retinyl palmitate
or with retinyl [3H]palmitate were injected intravenously into rats, both retinol
and palmitate moiety were detected in hepatocytes. However, only the retinol
moiety was detected in stellate cells, indicating that the REs are hydrolyzed
before retinol is transferred to stellate cells. In addition, antibodies against
RBP completely block the transfer of retinol from hepatocytes to stellate cells,
suggesting that RBP is critical to the transfer [254, 255]. Under normal
conditions, most of retinol is found in stellate cells, the major cellular site of VA
storage in the body. It has been estimated that approximately 5-30% of the
total retinol in the livers of rats is present in hepatocytes, with the reminder in
stellate cells [256]. However, as hepatic VA store decline, the proportion of VA
in hepatocytes increases relative to hepatic stellate cells. It has been shown
that in VA deficient (VAD) rats, little chylomicron remnant-derived retinol was
found in stellate cells, possibly due to the little transfer from hepatocytes or to
the rapid release from stellate, indicating that the transfer of retinol to stellate
cell is influenced by VA status [257]. A minor fraction of the newly absorbed
retinol that is rapidly secreted from hepatocytes escapes the uptake
mechanism of stellate cells and reaches the blood [225].

2.6.4.5 Metabolism of VA in Stellate Cells
After entering into the stellate cells, retinol is re-esterified into REs. As in
the intestine, both LRAT and ARAT may be involved in retinol esterification in
stellate cells, which are highly enriched in CRBP-I and LRAT. When retinol is
present in normal amounts, it is bound to CRBP-I and esterified by LRAT.
When retinol is present at high levels and CRBP-I becomes saturated, ARAT
may esterify the excess [217].
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In the vitamin A-sufficient (VAS) adult rats, 70-95% of hepatic VA is
stored as REs in lipid droplets of stellate cells. Approximately 99% of the VA
present in stellate cells is present as REs. It was reported that the lipid of
droplets isolated from VAS rats consisted of approximately 42% RE, 28% TG,
13% total cholesterol (free and ester) and 4% phospholipid. The REs in the
droplets consisted of approximately 70% retinyl palmitate, 15% retinyl
stearate, 8% retinyl oleate, 4% retinyl linoleate and smaller percentages of
other long-chain REs [258].

2.6.4.6 Retinol Mobilization
It has been shown that RBP is required for mobilization and storage of
retinol. RBP, mainly found in the liver, belongs to the lipocalin protein family
and is able to bind to and protect retinol from being metabolized, due to a
special hydrophobic pocket [259]. It has been shown that RBP recycles
extensively between the liver, plasma, and extrahepatic tissues [238]. The
retinol levels in the blood of mice null for RBP (rbp-/-) are much lower than
those of wild-type littermates, and in the liver there is increased storage of
retinyl esters. In addition, by 5 month of age, rbp-/- mice accumulate much
higher stores of retinol than their wild-type littermates, and their hepatic stores
do not change after a short-term exposure to a VAD diet [260].
The concentration of the RBP-retinol complex in blood is regulated within
the physiological range (~ 1.4 μM) by stellate cells through the controlled
uptake and release of retinol [261]. REs need to be hydrolyzed before the
mobilization of retinol from stellate cells to ensure constant supply of
peripheral tissues with retinol. This is accomplished by RE hydrolyses.
However, little is known about the enzymes and mechanisms how REs are
mobilized and how these processes are regulated [262]. Early work
demonstrated that retinyl palmitate hydrolase played a partial role [263, 264].
The mechanisms for retinol mobilization from stellate cells have been
controversial. First, retinol is bound to endogenously synthesized or
internalized RBP, then secreted associated with this carrier protein in blood
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circulation, without direct involvement of the hepatocytes [265]. Second,
retinol is transferred from stellate cells to hepatocytes before secretion of
retinol-RBP from the hepatocytes [266]. In the third hypothesis, retinol
mobilization from stellate cells does not involve RBP synthesis and secretion
[267].

2.6.4.7 Transport of Retinol in Plasma
Retinol in plasma is bound to a specific plasma transport protein, RBP,
for the transport to peripheral tissues [268]. The retinol-RBP complex is bound
to another plasma protein, transthyretin (TTR). It is believed that formation of
retinol-RBP-TTR complex reduces the glomerular filtration of retinol and renal
catabolism of RBP. In addition, retinoic acid circulates in plasma bound to
albumin, and low levels of RE can be found in the plasma fractions of
lipoproteins, including VLDL, LDL, and HDL.

2.6.4.8 Cellular Uptake of Retinol
The circulating retinol-RBP is taken up by peripheral tissues via a
receptor that recognizes RBP. The existence of a specific receptor for RBP on
the retinal pigment epithelium was suggested more than 35 years ago [269].
During the past 3 decades, evidence has accumulated for the existence of the
RBP receptor on other tissue or cell types, including the placenta, choroid
plexus, testis, and macrophages [270]. However, the molecular mechanism by
which retinol is taken up by cells from the retinol-RBP complex was not
understood until STRA6 was identified in bovine retinal pigment epithelium
cells in 2007 [270]. STRA6 is a member of a large group of “stimulated by
retinoic acid” genes that encode transmembrane proteins and other proteins
whose functions are largely unknown [271]. They provided evidence that
STRA6 acts as a high-affinity cell-surface receptor for RBP and proposed that
STRA6 is a major physiological mediator of retinol uptake by cells [272].
STRA6 is widely expressed in the murine embryo and in the adult.
Particularly strong expression of STRA6 occurred in cells that compose
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human blood-organ barriers (e.g., the brain, eye, testis, kidney, spleen, and
female reproductive tract) [273]. Mutations in human STRA6 are associated
with severe pathological phenotypes in many organs such as the eye, brain,
heart, and lung [274]. More importantly, the phenotypes observed for STRA6
absence are more severe than those for RBP [275, 276], suggesting that
STRA6 may play other roles beyond mediating retinoid signaling. In fact, it
has been shown recently that association of RBP-retinol with STRA6 triggered
tyrosine phosphorylation and resulted in recruitment and activation of JAK2
and the transcription factor STAT5, leading to induced expression of STAT
target genes, including suppressor of cytokine signaling 3 (SOCS3) that
inhibits insulin signaling and PPARγ that enhances lipid accumulation both in
vitro and in vivo [277].

2.6.5 Cellular Metabolism of Retinoids
2.6.5.1 Retinol Processing
The major source of the synthesis of active retinoid metabolites in cells of
vertebrates is all-trans retinol taken up from plasma. However, retinol derived
from the circulating lipoproteins containing REs, carotenoids, and REs locally
stored in lipid droplets in the target cells themselves or neighboring cells is
also thought to contribute to the synthesis of active retinoid metabolites. In
addition, all-trans retinoic acid or its metabolites can also be taken from
plasma [238].
In the target cells, free retinol and CRBP-I-bound retinol is oxidized to
retinal (retinaldehyde) by cytosolic medium-chain alcohol dehydrogenases
(ADHs)

and

membrane-bound

short-chain

dehydrogenases

(SDRs),

respectively [278]. There are three ADHs: ADH1, ADH3, and ADH4. ADH3 is
ubiquitously expressed, whereas the expression of ADH1 and ADH4 is tissuerestricted. It has been shown that ADH3 functions as a ubiquitous
dehydrogenase, whereas ADH1 and ADH4 are necessary only in extreme
conditions such as VA excess or deficiency [279]. Mice lack for ADH3 (Adh3-/) have reduced viability and growth when maintained on a standard VAS diet,
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but this phenotype was rescued by placement on a retinol-supplemented diet,
indicating that other retinol-oxidizing enzymes can compensate for the ADH3
function if retinol is present at high enough levels [280]. Adh1-/- and Adh4-/mice do not exhibit defects in growth or survival when maintained on a VAS
diet [281, 282].
There are two major groups of human SDR proteins based on their
cofactor preference. One group of SDR comprises the enzymes with high
affinities for NAD+/NADH, including 11-cis-retinol dehydrogenase (RDH),
RDH4, RDH-like 3α-hydroxysteroid dehydrogenase, and RDH-like SDR. The
other group of SDR proteins have high affinities for NADP+/NADPH, including
RDH11, RDH12, RDH14, retinal SDR1, photoreceptor RDH, and RDH10
[279].

2.6.5.2 Retinal Processing
Retinal can be reversibly reduced to produce retinol or it can be
irreversibly oxidized to produce RA, the latter is accomplished by retinal
dehydrogenases (RALDHs) [283]. Vertebrates generally have four RALDHs:
RALDH1-4. An additional enzyme called ALDH1A4 and ALDH1A7 is present
in rat and in mouse, respectively [284].
RALDH1, also called ALDH1A1, is highly expressed in the dorsal retina of
embryos and in several adult epithelial tissues [285]. The dorsal retina of
Raldh1-/- embryos display only minor effects, suggesting that RALDH1 is not
essential for RA synthesis in most tissues but may instead be involved in the
catabolism of excess retinol [238, 279, 286]. Recently, it has been shown that
RALDH1 and its substrate retinal are determinants of the adipocyte plasticity
and adaptive thermogenesis in mice. White adipose tissue (WAT)-selective
Raldh1 knockdown can induce a brown adipose tissue-like transcriptional
program

in

WAT

that

drives

uncoupled

respiration

and

adaptive

thermogenesis, therefore limiting weight gain and improving glucose
homeostasis, suggesting that disruption of Raldh1 expression or function in
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visceral fat could be a previously unrecognized target for treating obesityrelated complications [287].
RALDH2, also called ALDH1A2, is expressed in multiple embryonic and
adult tissues. Raldh2-/- mice die at mid-gestation, around day E8.75, due to
defects in heart development. However, the Raldh2-/- embryos can be rescued
to a considerable extent with external administration of RA [288], suggesting a
critical role of RALDH2 in RA synthesis during embryonic development.
RALDH3, also called ALDH1A3, is expressed in mouse and chicken
retina, lens and olfactory pit, as well as ureteric buds and surface ectoderm
over the developing forebrain [279]. It has been shown that RALDH3 alone
may supply sufficient RA to control eye development in Raldh1-/- mice, and
contribute to the rescue of Raldh2-/- mice embryos [279].
RALDH4 is expressed in mouse liver and kidney and displays a
preference for 9-cis retinal over all-trans retinal [289]. Thus, it was suggested
that RALDH4 is involved in the synthesis of 9-cis RA [238].
Although both ALDH1A4 and ALDH1A7 have high sequence similarity
with that of RALDH1, neither of them functions in RA synthesis [290, 291].
Newly synthesized RA is bound to cellular RA binding proteins types I
and II (CRABP-I and CRABP-II) and can then either enter the nucleus to
activate transcription or be transported to a nearby target cell [286]. In the
mouse embryo, both isoforms of CRABP are widely expressed; in the adult,
CRABP-I is expressed almost ubiquitously, whereas CRABP-II is only
expressed in skin, uterus, ovary, and in the choroid plexus [292]. It was
suggested that CRABPs serve to solubilize and protect RA in the cytosol, and
deliver it to the nucleus [293]. However, mice deficient in CRABP-I, in CRABPII, or in both CRABP-I and CRABP-II are essentially normal [294, 295],
suggesting a possible compensatory effect by other cellular proteins that can
bind to RA.
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2.6.5.3 RA Metabolism
Due to the potent activity of RA in the expression of genes involved in a
variety of physiological processes, its level should be delicately regulated. It is
believed that the catabolism of RA is critical to the maintenance of RA in cells
and tissues. In vertebrates, three cytochrome P450 enzymes (CYP26s),
designated CYP26A1, CYP26B1, and CYP26C1, are able to metabolize RA to
polar metabolites, such as retinoyl β-glucuronide, 5,6-epoxyretinoic acid, 4hydroxyretinoic acid, 4-oxoretinoic acid, and 3,4-didehydroretinoic acid [296].
CYP26A1 is highly expressed in the liver, duodenum, colon, and placenta
and in some regions of the brain [238]. The Cyp26a1 null mice die during midto late-gestation and display a number of morphogenetic defects, which
resemble those observed in RA teratogenicity [297]. It has been shown that
Cyp26al is a RA responsive gene and that VAD rats exhibit significantly lower
mRNA expression of Cyp26al compared to pair-fed VAS rats [298].
CYP26B1 has a different tissue expression pattern than CYP26A1, even
though the two enzymes have similar catalytic activity [299]. The Cyp26b1 null
mice display severe limb malformations [300].
CYP26C1 metabolizes all-trans RA to polar metabolites similar to those
generated by CYP26A1 and CYP26B1. In the developing mouse embryo,
CYP26C1 functions to protect the hindbrain, first branchial arch, developing
ear, and tooth buds from RA exposure [300]. However, CYP26C1 can
catabolize 9-cis RA much better than CYP26A1 and CYP26B1 [238].
The expression patterns of the three CYP26s are non-overlapping,
suggesting individual roles for each of the enzymes in the catabolism of RA in
different tissues [301]. In addition, the mRNA expression of Cyp26a1 and
Cyp26c1 can be induced in the presence of RA, indicating a mechanism
through which the CYP26s sense the concentration of RA and regulate the
catabolism of RA accordingly [238].
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2.6.6 Retinoids Signaling
It is generally accepted that most of the activities of VA are mediated by
its metabolites all-trans and 9-cis RA via the regulation of gene expression.
This is achieved by the binding of RA to two classes of the superfamily of
NRs, RARs and RXRs. NRs represent a family of transcription factors that
mediate a complex array of extracellular signals into transcriptional responses
in a ligand-dependent manner. Other than VA, this family includes receptors
for endocrine steroids, vitamin D, thyroid hormone, and a large number of
“orphan” receptors, whose ligands, target genes, and physiological functions
were initially unknown [162, 175-177]. Upon ligands binding, nuclear receptors
undergo a conformational change that coordinately dissociates co-repressors
and facilitates recruitment of co-activators to enable transcriptional activation
[162]. Three types of RARs (RARα, β, and γ) bind and respond to all-trans
and 9-cis RA, and RXRs (RXRα, β, γ) can only bind and respond to 9-cis RA.
RAR/RXR

heterodimers

and

RXR/RXR

homodimers

modulate

gene

expression by binding to RA responsive elements (RAREs) located in the
regulatory regions of target genes [302]. Most of the naturally occurring
RAREs consist of the direct repeats of two core motif (A/G)G(G/T)TCA
separated by 5 (DR5), 2(DR2) or 1 bp (DR1) [178]. When bound to DR2 and
DR5 elements, the 5ʼ half-site is occupied by RXR and the 3ʼ half-site by RAR.
In contrast, when bound to DR1 elements, the polarity of the heterodimer is
inverted and the complex is unresponsive to RA stimulation, probably due to
the inability of RAR ligands to induce the dissociation of co-repressors [286]. It
is believed that the most important ligand for the RAR/RXR heterodimer is alltrans RA binding to the RAR heterodimer partner, since the physiological role
of 9-cis RA has been questioned [238] (see also Sections 2.5.1 and 2.5.2).
It is noteworthy that retinoid signaling can be mediated by receptors other
than the RAR/RXR heterodimer. It was recently demonstrated that RA is a
potent endogenous ligand for PPARβ/δ, which functions similarly to RAR and
RXR to regulate gene expression in response to retinoid [303]. In addition,
analyses of the crystal structure of RA receptor-related orphan receptors
56

(RORβ) and chicken ovalbumin upstream promoter-transcription factor II
(COUP-TFII) indicate that RA could be a potential ligand [200, 304] (see also
Section 2.5.4)

2.6.7 VA in Nutrient Metabolism
Except for being crucial to vision, growth, embryological development,
cell differentiation, reproduction, maintenance of mucous secretion and
apoptosis, VA also plays essential role in nutrient metabolism. The status and
metabolism of VA exert profound influence on the metabolism of liver,
adipocytes, pancreatic β-cells, and skeletal muscle (for a review, see [10]).

2.6.8 RBP and Insulin Resistance
Liver, skeletal muscle and adipose tissue are the three major targets for
the metabolic actions of insulin. Insulin regulates glucose homeostasis by
reducing hepatic glucose output and by increasing the rate of glucose uptake
by skeletal muscle and adipose tissue. Stimulation of glucose uptake into
muscle cells and adipocytes by insulin depends largely on translocation of the
glucose transporter GLUT4 from an intracellular compartment to the cell
surface [305]. Recently, Yang et al. identified RBP4, a plasma transport
protein for retinol, as a new adipokine that links glucose uptake in adipocytes
with systemic insulin sensitivity [306]. Using DNA array analyses on
epididymal adipose tissue RNA from two lines of mice in which GLUT4 is
increased or decreased only in adipocytes, they identified Rbp4 as one of the
genes that were reciprocally regulated by the genetic manipulations and that
encoded secreted proteins. They found that expression of RBP4 was
increased in adipose tissue of mice with adipocyte-specific deletion of GLUT4.
They also showed that circulating RBP4 levels were markedly increased not
only in several mouse models of obesity and insulin resistance, but also in
humans with these conditions. In addition, an insulin-sensitizing drug reduced
the elevated levels of RBP4 in both adipose tissue and serum of mice. Overexpression of RBP4 or injection of recombinant RBP4 in normal mice induced
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insulin resistance, whereas mice heterozygous or homozygous for knockout of
the gene encoding RBP4 showed increased insulin sensitivity compared with
wild-type mice. Moreover, the synthetic retinoid fenretinide, which reduced the
serum levels of RBP4 through urinary excretion, ameliorated insulin
resistance in mice fed a high-fat diet. These results suggest RBP4 as an
adipocyte-derived signal the may contribute to the pathogenesis of T2D.
Furthermore, serum RBP4 levels correlated with the magnitude of insulin
resistance in subjects with obesity, impaired glucose tolerance, or T2D and in
non-obese, non-diabetic subjects with a strong family history of T2D. A
therapeutic intervention that improves insulin sensitivity is associated with a
reduction in serum RBP4 levels [305]. Regarding the mechanism, RBP4
affected insulin action by decreasing the activity of PI3K and the
phosphorylation of IRS1. Moreover, Berry et al. have shown that association
of RBP-retinol with STRA6 can trigger tyrosine phosphorylation, resulting in
recruitment and activation of JAK2 and the transcription factor STAT5, which
in turn leads to inhibition of insulin signaling [277]. Although it has been
proposed that the correlation between RBP4 and the magnitude of insulin
resistance should be assessed in more diverse groups [307], all
abovementioned findings suggest the possibility that alterations of retinol
metabolism might influence the action of insulin and the risk of T2D. However,
there are no compelling data to suggest that dietary VA contributes to the
elevation in serum RBP4 levels observed in insulin-resistant states or to
insulin resistance [305]. Moreover, a recent study showed that lowering serum
RBP levels by a non-retinoid ligand for RBP did not improve insulin sensitivity
in mice, and that mice null for RBP displayed normal insulin sensitivity and
were not protected from high fat diet-induced insulin resistance [308].
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CHAPTER III
EFFECTS OF RETINOIDS ON THE EXPRESSION OF HEPATIC
SREBP-1C
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Disclosure: The work described in this chapter in its entirety has been
published in the following reference with minor modifications in the numbering
of figures: Li R, Chen W, Li Y, Zhang Y, Chen G: Retinoids synergized with
insulin to induce Srebp-1c expression and activated its promoter via the two
liver X receptor binding sites that mediate insulin action. Biochem Biophys
Res Commun 2011, 406:268-272.

3.1 Introduction
Elevation of hepatic vitamin A (VA, retinol) content in patients with
diabetes was observed more than 70 years ago (1937) [309]. Subsequently,
depletion of hepatic glycogen content in VA deficient (VAD) rats was reported
in 1957 [310]. When isotretinoin, 13-cis retinoic acid, was used to treat
patients

with

acne,

some

of

them

developed

isotretinoin-induced

hypertriglyceridemia [311]. All these early observations suggested that VA
status affected glucose and lipid homeostasis, a topic remained to be
investigated.
As an essential micronutrient, VA plays crucial roles in the general health
of an individual. Therefore, retinol homeostasis must be delicately maintained
to meet optimal physiological functions. This is achieved by a network of
enzymes and proteins involved in the transport, production, and catabolism of
retinoids [312]. The regulation of this system can be attributed to the control of
the expression levels of some of these enzymes by the active metabolite of
retinol, retinoic acid (RA) [313]. RA exists in multiple isomeric forms, such as
all-trans RA and 9-cis RA, and RA regulates gene expression through
activation of two families of nuclear receptors, retinoic acid receptors (RARα,
β, and γ) activated by all-trans RA, and retinoid X receptors (RXRα, β, and γ)
activated only by 9-cis RA [261].
Insulin resistance, diabetes and other metabolic abnormalities are
associated with profound changes of hepatic lipid and glucose metabolism.
These can be attributed to the altered expression of genes involved in glucose
and lipid metabolism [314]. Insulin responsive elements in the Srebp-1c
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promoter have been identified as two liver X receptor (LXR) binding sites and
one sterol regulatory element [168, 315]. This implies that insulin regulates the
expression of its responsive genes after it stimulates the synthesis of
endogenous agonists for nuclear receptor activation. When we analyzed the
effects of the lipophilic extract (LE) from rat livers on insulin-regulated gene
expression, we found that the LE synergized with insulin to induce
glucokinase gene (Gck) and Srebp-1c expression in primary rat hepatocytes
with different induction patterns [11]. The existence of retinol and retinal in LE
was confirmed later, and their effects on Gck, but not Srebp-1c, were
examined in that study [11]. It has been reported that SREBP-1c mediated the
retinoid-dependent increase in fatty acid synthase (Fas) promoter activity in
HepG2 [316]. Therefore, we hypothesized that retinoids may regulate the
expression of Srebp-1c in primary hepatocytes.
In this study, we report that retinoids transiently synergized with insulin to
induce the expression of Srebp-1c in primary rat hepatocytes via the
activation of RXR, but not RAR. The retinoic acid responsive elements
(RAREs) in its promoter are the previously identified two LXR responsive
elements that mediated insulin-induced Srebp-1c transcription.

3.2 Materials and Methods
Reagents
The reagents for primary hepatocytes isolation and culture have been
published [317]. Reagents for cDNA synthesis and real time PCR were
obtained from Applied Biosystems (Foster City, CA). Source of LG268 was
reported previously [11]. All other compounds or enzymes were purchased
from Sigma (St. Louis, MO) unless described otherwise.

Animals and Diets
Sprague-Dawley rats (for hepatocytes) were purchased from Harlan
Breeders (Indianapolis, IN). Rats were housed in colony cages, and fed a
standard rodent diet before isolation of primary hepatocytes. All procedures
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were approved by the Institutional Animal Care and Use Committee at the
University of Tennessee at Knoxville.

Primary Hepatocytes, RNA Extraction and Quantitative Real-time PCR
Methods for preparation of primary hepatocytes and analysis of RNA
were described previously [11]. The real time PCR primer sets for detecting
Fas (from Dr. Bruce Spigelmanʼs group in Harvard Medical School), Gck,
Cyp26a1 [298], Srebp-1c [11] have been published. The primers for Rarb
(forward

5ʼ-GGCCTCTGGGACAAATTCAG-3ʼ,

and

reverse

5ʼ-

GCAGACGCTTGGCGAACT-3) were designed using Primer Express software
(Applied Biosystems). The gene expression level was normalized to that of
36B4 unless described otherwise. Data were presented as the fold induction
calculated from the ΔΔCt values [317] using 36B4 as the invariable control
gene [11].

INS-1 Cell Culture, Reporter Gene Constructs and Assay
INS-1 cells (833/15) were maintained as described previously [318].
Standard protocols (Molecular Cloning) were followed in all recombinant DNA
engineering procedures. The reporter gene constructs reported previously
[168] were transfected into INS-1 cells using Fugene 6 transfection reagent
(Roche, Indianapolis, IN) according to the manufacturerʼs manual. The
activation of reporter gene constructs were measured using dual luciferase
assay as described previously [168] and reported as fold induction.

Statistics
Data were presented as means ± SD. The number of experiments
represented the independent experiments using hepatocytes isolated from
different animals on different days. Leveneʼs test was used to determine
homogeneity of variance among groups using SPSS 17.0 statistical software
and where necessary natural log transformation was performed before
analysis. Multiple comparisons were analyzed by one-way ANOVA. The
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independent sample t-test was used to compare two conditions. Differences
were considered statistically significant at P < 0.05.

3.3 Results
Retinal and RA Synergized with Insulin to Induce Srebp-1c Expression
Since we have observed that rat liver LE that contained retinol (ROL) and
retinal (RAL) synergized with insulin to induce Gck and Srebp-1c expression
with different induction patterns, we only reported the effects of ROL, RAL,
and RA on Gck expression in the previous publication [11]. We decided to
check the direct effects of retinoids on the expression level of Srebp-1c, a key
transcription factor controlling the hepatic fatty acid biosynthesis [131].
Primary rat hepatocytes were treated with increasing concentrations of ROL,
RAL, and RA in the absence or presence of insulin. As shown in Fig. 3.1,
retinol up to 20 μM did not induce Srebp-1c expression without or with insulin.
In the absence of insulin, RAL up to 20 μM did not affect Srebp-1c expression.
RAL synergized with insulin to induce Srebp-1c expression when its
concentration reached 20 μM. Without insulin, RA at 20 μM induced Srebp-1c
expression. RA at 2 and 20 μM synergized with insulin to induce Srebp-1c
expression. All these results demonstrated that RAL and RA had the ability to
synergize with insulin to induce Srebp-1c expression in primary rat
hepatocytes.

RA Transiently Synergized with Insulin to Induce the Expression of Gck and
Srebp-1c Differently, and Resulted in Elevation of SREBP-1c Target Gene,
Fas
Since RA induced the expression of both Gck and Srebp-1c, it is
important to determine whether their induction patterns are similar or not. The
expression levels of Gck, Srebp-1c, and Fas, a target gene of SREBP-1c,
were examined by real time PCR at 0, 3, 9, 12, and 24 h after treatment of 5
μM RA in the absence or presence of 1 nM insulin. As shown in Fig. 3.2A, RA
robustly synergized with insulin to induce Gck expression as early as three
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Figure 3.1 Retinal and RA synergized with insulin to induce Srebp-1c
mRNA expression in rat primary hepatocytes
Hepatocytes were treated with indicated ligands (μM) without or with 1 nM
insulin for 6 h. Total RNA was isolated and subjected to real-time PCR
analysis. Srebp-1c mRNA level in vehicle control group was assigned a value
of 1 (mean ± SD, n = 3, * for comparing indicated groups with control in the
presence of insulin; ** for comparing RA group with control group in the
absence of insulin; all P < 0.05).
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Figure 3.2 Comparison of the effects of RA (5 μM) and insulin (1 nM) on
the expression levels of Gck (A), Srebp-1c (B), and Fas (C) mRNA over
time
Hepatocytes were treated with or without RA in the absence or presence of
insulin. The expression level of indicated transcripts at time 0 was assigned a
value of 1 (mean ± SD, n = 3, * for comparing RA + insulin with insulin
treatment of indicated gene at the indicated time points; ** for comparing RA
with control group of Srebp-1c at the indicated time points; all P < 0.05).
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hours. The fold induction started to decline at 6 h after the stimulation, and the
synergy lasted for at least 12 h. Fig. 3.2B showed that hepatocytes treated
with 5 μM RA had significantly higher levels of Srebp-1c mRNA than control
cells did at 3 (2.1 ± 0.5- vs 0.71 ± 0.07-fold) and 6 (0.53 ± 0.09- vs 0.26 ±
0.02-fold) hours after treatment. RA also robustly synergized with insulin to
induce Srebp-1c expression at 3 h and the fold induction began to drop at 6 h,
similar to the pattern of Gck expression. However, at 9 h after the stimulation,
the synergistic induction of RA and insulin to Srebp-1c expression no longer
existed. As shown in Fig.3.2C, RA + insulin significantly induced Fas
expression to a higher level than insulin alone did at 6, 9 and 12 h, suggesting
that the rapid and robust increase of Srebp-1c downstream gene. All these
results demonstrated that RA, the active metabolite of VA, synergized with
insulin to induce glycolytic and lipogenic genes differentially, probably with
different induction mechanisms.

Activation of RXR, but not RAR, Synergized with Insulin to Induce Srebp-1c
Expression in Primary Hepatocytes
RA regulates gene expression through activation of RARs and RXRs
[261]. To determine whether one or both of these nuclear receptors mediate
the synergistic effect of RA and insulin on Srebp-1c expression, primary
hepatocytes were treated with TTNPB (1 μM), a specific agonist of RARs, LG
268 (1 μM), an RXR specific agonist, or the combination of both. Fig. 3.3A
showed that TTNPB induced the expression of Cyp26a1, a RA responsive
gene [298], by 6500 ± 1300- and 6200 ± 1600-fold in the absence and
presence of insulin (1 nM), respectively. Activation of RXR by LG268 only
induced Cyp26a1 moderately in the absence (15 ± 5.3-fold) and presence (12
± 4.2-fold) of insulin. In comparison to TTNPB alone, the combination of
TTNPB and LG268 further induced the Cyp26a1 expression in the absence
(27,000 ± 12,000-fold) and presence (28,000 ± 8700-fold) of insulin. The
enormous induction of Cyp26a1 expression by TTNPB showed the extreme
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Figure 3.3 The expression levels of Cyp16a1 (A) and Srebp-1c (B) in
primary hepatocytes treated with RAR and RXR agonists, and Srebp-1c
(C) and Rarb (D) in INS-1 cells treated with RA
(A and B) Primary hepatocytes were treated with vehicle, TTNPB (1 μM),
LG268 (1 μM), and TTNPB + LG268 in the absence and presence of insulin
(1 nM) for 6 h. The expression level of the vehicle control group was arbitrarily
assigned a value of 1 (mean ± SD, n = 3, * P < 0.05 for comparing TTNPB
group with TTNPB ±LG268 group of Cyp26a1 in the absence or presence of
insulin; **P < 0.03 for comparing TTNPB with LG268 or LG268 + TTNPB
group of Srebp-1c in the absence of insulin; ***P < 0.04 for comparing control
with TTNPB or LG268 with LG268 + TTNPB in the presence of insulin). (C
and D) 833/15 INS-1 cells were treated with increasing concentrations of RA
or RAL for 6 h. The expression level of the vehicle control group was
arbitrarily assigned a value of 1 (mean ± SD, n = 3, #P < 0.05 for comparing
RA and RAL groups at indicated concentrations).
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sensitivity of this gene to the activation of RAR and the efficacy of this
compound.
Fig.3.3B showed that LG 268 (3.2 ± 0.3-fold) and LG268 + TTNPB (2.5 ±
0.5-fold), but not TTNPB, induced Srebp-1c expression in the absence of
insulin (10.5 ± 1.5- to 5.7 ± 0.3-fold). However, LG268 synergized with insulin
to induce Srebp-1c expression. The synergy was attenuated in the presence
of TTNPB (from 64 ± 4.9- to 42 ± 3.1-fold). These results demonstrated that
activation of RXR potentiated insulin-mediated induction of Srebp-1c
expression. It suggests that RA synergizes with insulin to induce Srebp-1c
expression through activation of RXR in primary rat hepatocytes.

RA, but not RAL, Induced Srebp-1c, but not Rarb, in a Dose Dependent
Manner in 833/15 INS-1 Cells
To test the effects of retinoids on Srebp-1c expression in other cells, we
treated 833/15 INS-1 cells with increasing concentrations of RAL and RA.
Fig.3.3C showed that RA started to significantly induce Srebp-1c expression
in INS-1 cells at 0.1 μM, the lowest concentration tested. On the other hand,
RAL did not change Srebp-1c expression level at any concentration tested.
Due to the extremely low expression level of Cyp26a1 in 833/15 INS-1 cells,
we examined the effects of RAL and RA on the expression of retinoid acid
receptor beta isoform gene, Rarb, a RA responsive gene [319]. Fig.3.3D
showed that RAL or RA could not change the expression of Rarb at any
concentration tested, suggesting the activation of RXR, but not RAR by RA in
INS-1 cells. These results demonstrated that INS-1 cells can be used as a tool
for investigating RA-induced Srebp-1c expression.

RA Activated Srebp-1c Transcription via the LXREs in its Promoter
Given the fact that retinoids synergized with insulin to induce its
expression in primary hepatocytes, it is critical to determine the RAREs in its
promoter. We have examined primary rat hepatocytes, hepatoma cells and
INS-1 insulinoma cells for their potential use in the determination of the RA68

induced activation of the Srebp-1c promoter reporter constructs in them.
Subsequently, we found that RA robustly induced the activation of Srebp-1c
promoter reporter constructs in INS-1 cells, and decided to use these cells for
identification of RAREs in its promoter. As shown in the left panel of Fig. 3.4, a
series of Srebp-1c promoter reporter gene constructs [168], plasmid D (wild
type), m9 (LXRE1 mutant), m13 (LXRE2 mutant), m24 (SRE mutant), m31
(LXRE1/LXRE2 mutant), and m34 (LXRE1/LXRE2/SRE mutant) were made
previously for identification of insulin responsive elements in it. The RAinduced activation of these constructs in INS-1 cells was measured. Fig. 3.4
showed that both RA and T1317 (a positive control for LXR activation)
induced the activation of plasmid D, which contained wild type sequence of
Srebp-1c promoter fragment, by 2.6- and 2.2-fold, respectively. The disruption
of SRE as in plasmid m24 significantly improved the fold induction mediated
by either RA or T1317. This improvement was due to the reduced activation of
this promoter construct in basal condition as shown previously [168]. The
disruption of LXRE1 (m9) did not significantly affect RA response of this
construct, but significantly reduced its response to T1317. The disruption of
LXRE2 (m13) significantly reduced the response of this promoter construct of
RA and T1317. The disruption of LXRE1/2 (m31) or LXREs plus SRE (m34)
completely abolished the response to both RA and T1317, indicating the
critical role of these two previously identified LXREs in mediating RA-induced
activation of Srebp-1c promoter.

3.4 Discussion
We initiated our investigation based on the following reasons. First, we
previously reported that the rat liver LE synergized with insulin to induce Gck
and Srebp-1c expression in primary hepatocytes [11]. However, the induction
patterns of these two genes by LE were different, suggesting two distinct
mechanisms for the induction. After identification of retinol and retinal in the
LE, only the effects of retinoids of Gck, but not Srebp-1c, were investigated
and reported in that paper [11]. Given the different induction patterns of these
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Figure 3.4 The effects of RA and T1317 on activation of Srebp-1c
promoter reporter gene constructs containing indicated wild type or
mutant sequences of its promoter in INS-1 cells
The indicated reporter gene constructs were transfected into INS-1 cells, and
dual luciferase assay was performed to determine their activations by RA (5
μM) and T1317 (1 μM). The relative luciferase activity of each constructs
treated with ethanol vehicle control was arbitrarily assigned a value of 1
(mean ± SD, n = 3, a > b > d > e, a > c > e, aʼ > bʼ > cʼ > dʼ, all P < 0.05).
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two genes mediated by LE treatments and importance of SREBP-1c in
lipogenesis, it was reasonable to further investigate the effects of ROL, RAL,
and RA on Srebp-1c expression in primary hepatocytes without or with insulin.
Second, since identification of LXREs in its promoter [167, 320], recognition of
endogenous ligands for LXR activation [321], and the roles of LXRE in
mediating insulin-induced its expression [168, 315], Srebp-1c has been
considered as a downstream target gene of LXR activation. On the other
hands, these sites are also responsible for the effects of dietary signals, such
as polyunsaturated fatty acids, on Srebp-1c expression in hepatocytes [168,
322]. Since RXR is heterodimer partner of LXR and can be activated by
retinoids [298], it is reasonable to investigate the response of Srebp-1c
expression to retinoids that mediate nutritional signals from vitamin A.
Therefore, we reported the synergistic effects of retinoids with insulin to
induce Srebp-1c expression, and the identification of RAREs in its promoter.
In addition, we also discussed the differential induction patterns of Gck and
Srebp-1c by RA in the current manuscript.
We observed that RAL and RA, but not ROL, had the capability to
synergize with insulin to induce Srebp-1c expression (Fig. 3.1). It differed from
the induction of Gck, which was induced by ROL, RAL, and RA in the same
experimental settings [11], suggesting different induction mechanisms.
Additionally, it seems that RA was more effective than RAL to induce Srebp1c, implying involvement of retinoid metabolism. In INS-1 cells (Fig.3.3C), RA
induced Srebp-1c expression at 0.1 μM, much lower than that in hepatocytes.
However, RAL had no effects on Srebp-1c expression in them. This suggests
that INS-1 cells lack the retinoid metabolism. Whether RA production plays
any role in this phenomenon is under investigation.
RA-induced Srebp-1c expression only lasted less than 9 h in primary
hepatocytes without or with insulin (Fig.3.2B). This differed from that of Gck
expression, which lasted for more than 12 h (Fig. 3.2A). The activation of RAR
and RXR may play a role here. For Gck, activation of both RAR and RXR was
responsible for the induction [11]. For Srebp-1c, only activation of RXR was
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responsible (Fig. 3.3B). It has been shown that mouse hepatic Srebp-1c
expression was regulated by activation of LXR and RXR [167], which may be
responsible for the regulation of hepatic Srebp-1c expression by dietary
components, such as cholesterol [167] and polyunsaturated fatty acids [323].
Liver specific knock out of RXRα altered hepatic lipid metabolism in mice
[324]. Their hepatic expression levels of RARβ and RARγ were elevated,
suggesting changes of retinoid signaling as RARβ expression can be induced
by RA [319]. All these imply that retinoids differentially regulate gene
expression, probably through activation of different sets of nuclear receptors
on their promoters. It also demonstrates that rapid and dynamic changes of
transcription machinery may have happened at the Srebp-1c promoter similar
to the spatial and temporal recruitment of co-activators of nuclear receptors as
reported [325]. It seems that synergy between insulin signaling and RXR
activation is shorter than that of RXR when comparing expression patterns of
Gck and Srebp-1c in the same conditions. Since RXRs are the heterodimeric
partners for many other nuclear receptors [326], the mechanism of this
transient synergy between retinoids and insulin at Srebp-1c promoter
deserves to be investigated.
Another interesting observation was that TTNPB treatment significantly
attenuated insulin-induced Srebp-1c expression in the absence or presence of
LG268 (Fig. 3.3B). In the absence of insulin, this attenuation did not exist.
However, TTNPB synergized with insulin to increase the expression of Gck in
the absence and presence of LG268 [11]. Since TTNPB and LG268
respectively activate RARs and RXRs, it seems that RAR activation in primary
hepatocytes attenuates or potentiates insulin-regulated gene expression
depends on the promoter context of the gene. This may be another reason
that RA synergized with insulin for less than 12 h to induce Srebp-1c
expression (Fig. 3.2B), but for more than 12 h to induce Gck expression (Fig.
3.2A). The mechanism of this attenuation deserves further investigation.
It has been shown that VAD rats had lower plasma triglyceride (TG) level,
and hepatic lipogenic activity than VAS rats did [327]. These may be caused
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by reduction of hepatic lipogenic gene expression in VAD rats as SREBP-1c is
critical for fatty acid biosynthesis [131]. Here, we identified two RAREs in
Srebp-1c promoter (Fig. 3.4), which are also two previously identified LXREs
[320] that are also part of the insulin responsive elements [168, 315]. The role
of these two LXREs may be not only for mediating insulin response, but also
for sensing VA status. How nutritional (retinoids) and hormonal (insulin)
signals converge at the same sites in Srebp-1c promoter and determine the
hepatic lipogenesis is worth to be investigated. This regulation is particularly
important for a heterogenous population as the nutritional status probably
plays an important role in the development of metabolic diseases, such as
obesity and diabetes. Understanding the regulatory mechanisms in detail will
provide us with more tools for the intervention of metabolic diseases.
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CHAPTER IV
REGULATION OF HEPATIC GCK EXPRESSION BY RETINOIC
ACID AND NUCLEAR RECEPTORS
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4.1 Introduction
Glucose must first be phosphorylated before being utilized by cells. This
reaction is catalyzed by a family of enzymes called hexokinases, which are
found in different organisms ranging from bacteria to humans [328].
Mammalian hexokinase IV (D), also known as glucokinase (GK) (ATP: Dhexose 6-phosphotransferase; EC 2.7.1.1), plays a key role in maintaining
glucose homoeostasis [94]. GK mutations have been associated with maturity
onset diabetes of the young [329]. Whole-body or tissue-specific deletion of
Gck in rodents demonstrated that either pancreatic β-cell or hepatic GK
activity is essential for glucose homeostasis [330, 331].
As an essential micronutrient, VA (vitamin A; retinol) plays crucial roles in
the general health of an individual. Therefore retinol homeostasis must be
delicately

maintained

to

meet

optimal

physiological

functions.

This

homeostasis is achieved by a network of enzymes and proteins involved in
the transport, production, and catabolism of retinoids [312]. The regulation of
this system can be attributed to the control of the expression of some of these
enzymes by the active metabolite of retinol, RA (retinoic acid) [313]. RA exists
in multiple isomeric forms, such as all-trans RA and 9-cis RA, and RA
regulates gene expression through activation of two families of nuclear
receptors, RARs (RA receptors; RARα, β, and γ) activated by all-trans RA
and RXRs (retinoid X receptors; RXRα, β, and γ) activated only by 9-cis RA
[261].
Long-term regulation of hepatic GK activity is controlled by its mRNA
level. Transcription of Gck is regulated differentially by an upstream promoter
in pancreatic β-cells and a downstream promoter in hepatocytes [81, 91].
Activation of either one of them leads to the generation of a Gck mRNA with
distinct 5ʼ sequences derived from the tissue-specific first exon. In rat liver,
Gck mRNA is induced by insulin and suppressed by glucagon, a counter
regulatory hormone to the actions of insulin [332, 333]. Previously, we have
reported that retinoids can synthesize with insulin to induce Gck expression in
rat hepatocytes [11]. However, the underlying mechanism has not been
75

defined. Here, we identified a RA responsive element (RARE) in the promoter
of Gck and investigated the regulation of Gck transcription by nuclear
receptors (NRs) RARα, RXRα, HNF4α, and COUP-TFII.

4.2 Materials and Methods
Reagents
All compounds or enzymes were purchased from Sigma (St. Louis, MO)
unless described otherwise. Liver perfusion medium (#17701038) and liver
digestive buffer (#17703034) were purchased from Life Technologies
(Carlsbad, CA). Dulbeccoʼs Modification of Eagle Medium (DMEM) and
RPMI1640 were purchased from Cellgro (Manassas, VA). All primary and
secondary antibodies used in Western blotting were purchase from Cell
Signaling (Danvers, MA). For chromatin immunoprecipitation (ChIP) and
electrophoretic mobility shift assay (EMSA), antibodies against RAR (sc773X), RXR (sc-774X), and HNF4α (sc-8987X), and IgG control (sc-2027)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody
against COUP-TFII (PP-H7147-00) was obtained from Perseus Proteomics
(Tokyo, Japan).

Animals
Male Zucker lean (ZL) rats were bred in the Department of Nutrition at the
University of Tennessee at Knoxville (UTK, breeding protocol number 1256).
Male Sprague-Dawley (SD) rats were purchased from Harlan Breeders
(Indianapolis, IN) or bred at UTK (breeding protocol number 2123). Animal
facility was temperature controlled and kept on 12 h light/dark cycles (light
from 7 a.m. to 7 p.m.). Rats was fed a standard chow (Rodent diet # 8640,
Harlan Teklad, Madison, WI) and allowed to have free access to water.
Prior to preparation of hepatocytes, rats (200-260 grams) were
euthanized with carbon dioxide. All procedures were approved by the
Institutional Animal Care and Use Committee at UTK (Protocol numbers: 1642
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and 1582). The animals were cared for in accordance with Guide to the Care
and Use of Experimental Animals.

Plasmid Constructs
Standard molecular cloning procedures were followed during the process
of making all the plasmid constructs. All constructs were verified by the
restriction endonuclease digestion analysis and DNA sequencing.
The -944/-4, -843/-4, 641/-4, -455/-4, and -237/-4 (relative to the
translation initiation site +1) regions of the rat liver Gck promoter
(downstream) were amplified by PCR from ZL genomic DNA using the same
reverse primer oGC-738 and different forward primer oGC-739, oGC-740,
oGC-742, oGC-744, and oGC-746, respectively. The generated fragments
were each gel purified using the Qiaex II Gel Extraction Kit (Qiagen, Hilden,
Germany), digested overnight at 37°C with BglII and PciI, and inserted into
pGL3 basic (Promega, Madison, WI) cut with BglII and NcoI to generate
pGL3-Gck-1K (A), pGL3-Gck-0.8K (B), pGL3-Gck-0.6K (C), pGL3-Gck-0.4K
(D), and pGL3-Gck-0.2K (E), respectively. Plasmid m1 was constructed by
PCR, using plasmid E as a template and the primer pair oGC-816/oGC-817.
The generated 251-bp fragment was gel purified, digested with BglII and NcoI,
and inserted into the same sites of plasmid E to yield m1. Analogously,
plasmid m2 was constructed by PCR using primer pair oGC-818/oGC-817.
Scramble mutations in plasmids m3 to m12, m6/7-1 to m6/7-5, and m6/7-4-1
to m6/7-4-5 were generated with the QuickChange site-directed mutagenesis
kit (Stratagene, La Jolla, CA). Mutagenic oligonucleotides were synthesized
so that the sequences to be scrambled were located in the center of the
oligonucleotide.
A ~1.4 kb rat RARα cDNA insert, which contained the complete coding
regions, was excised from pCMV-Sport6ccdB (Life Technologies, Carlsbad,
CA) at KpnI and BamHI sites and inserted into the pcDNA3.1(+) vector (Life
Technologies) and pACCMV5 at the same sites to generate rat RARα
expression vector pcDNA3.1-RARα and pACCMV5-RARα, respectively. The
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rat RXRα, RXRγ, and HNF4α cDNA containing the entire coding region were
amplified by PCR from SD rat primary hepatocyte cDNA, using primer pair
oGC90/oGC91, oGC108/oGC109, and oGC1004/oGC1008, respectively. The
amplicons were each ligated into pCR®2.1 vector using TA cloning® Kit (Life
Technologies) according to the manufactureʼs protocol. The respective full
length cDNA was excised from pCR®2.1 at EcoRI site and inserted into
pcDNA3.1(+) or pACCMV5 at the same site to generate expression vector
pcDNA3.1-RXRα, pcDNA3.1-RXRγ, pACCMV5-RXRα, pACCMV5-RXRγ, and
pACCMV5-HNF4α.
See Table 4.1 for primer sequences and mutated nucleotides.

Cell Lines
HL1C rat hepatoma cells, INS-1 833/15 rat insulinoma cells, and 293
human embryonic kidney (HEK) cells were cultured as described previously
[334].
HL1C cells were cultured in DMEM containing 4.5 g/L glucose, 4%
(vol/vol) heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin and
100 μg/ml streptomycin sulfate. They were incubated in 150 mm dishes with
serum free DMEM containing 1 μM retinoic acid for 4 h before being collected
for ChIP assays.
833/15 INS-1 cells were cultured in RPMI 1640 medium containing 2 mM
L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES，and 50 μM betamercaptoethanol, 10% (vol/vol) heat-inactivated FBS, 100 U/ml of penicillin,
and 100 μg/ml streptomycin sulfate.
293 HEK cells were cultured in DMEM containing 4.5 g/L glucose, 8%
(vol/vol) heat-inactivated FBS, 100 U/ml of penicillin and 100 μg/ml
streptomycin sulfate.
All cell lines were cultured at 37°C and 5% CO2.
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Table 4.1 Plasmid constructs and primers with mutated nucleotides indicated
by lower cases
Plasmid

Primer

Sequence (5ʼ-3ʼ)

(oGC-)
839

CCATGGAGATCTCCGACAGGCACCCTATGTAC

838

GAATTCACATGTTGAGAGGACAACCCAGG

840

CCATGGAGATCTGGCCAAACCCAAAGAAAGG

838

GAATTCACATGTTGAGAGGACAACCCAGG

842

CCATGGAGATCTGTCAGGGCAGCCAGAGGACCTG

838

GAATTCACATGTTGAGAGGACAACCCAGG

844

CCATGGAGATCTCAGGTGAAATCCCACGAGGATC

838

GAATTCACATGTTGAGAGGACAACCCAGG

846

CCATGGAGATCTGTGGCCTTTGTCAAACCC

838

GAATTCACATGTTGAGAGGACAACCCAGG

816

AGATCTTCCtccgatgtgcgtTCAAACCCGACC

817

CCATGGTGAGAGGACAACCCAGG

818

AGATCTTCCCTGTGGCCTTgtcacgcaatacCCCCACGTGG

817

CCATGGTGAGAGGACAACCCAGG

819

CTTTGTCAAACCCacggagcgcgctTTCTTTGTCCTGG

820

CCAGGACAAAGAAagcgcgctccgtGGGTTTGACAAAG

821

CCGACCCCACGTctgatgactggtTGGCCCTGGCCC

822

GGGCCAGGGCCAaccagtcatcagACGTGGGGTCGGGT

823

GTGGTTCTTTGTgtgccgcgaccgCCTGGCCCTGAC

824

GTCAGGGCCAGGcggtcgcggcacACAAAGAACCACGTG

825

GTCCTGGCCCTGcgtgcctgggccACCTTGTGACAC

826

GTGTCACAAGGTggcccaggcacgCAGGGCCAGGACAAAG

827

GGCCCTGGCCCcctgacatgtctACTAGGCAGGG

828

CCCTGCCTAGTagacatgtcaggGGGCCAGGGCCAGGG

pGL3-Gck-1K

pGL3-Gck-0.8K

pGL3-Gck-0.6K

pGL3-Gck-0.4K

pGL3-Gck-0.2K

m1

m2

m3

m4

m5

m6

m7
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Table 4.1 Continued.
Plasmid

Primer

Sequence (5ʼ-3ʼ)

(oGC-)
834

CCCTGACCTTGTGctgaggacagacGTATTTCAGGAGCCAC

835

GCTCCTGAAATACgtctgtcctcagCACAAGGTCAGGGCC

836

GTGACACTAGGCAactaggagttatAGCCACCCCTCAGGC

837

CTGAGGGGTGGCTataactcctagtTGCCTAGTGTCACAAG

838

GCAGGGTATTTCAatccggcggagcCAGGCCCGTTAGTGC

m8

m9

m10
839

CACTAACGGGCCTGgctccgccggatTGAAATACCCTGCCT
AG

840

CAGGAGCCACCCgcgtctgatcgcAGTGCGGAAGTCCTTG

841

GGACTTCCGCACTgcgatcagacgcGGGTGGCTCCTGAAA

842

CCCCTCAGGCCCGgcgtaagtctgaTCCTTGGCTGCCTATC

843

GGCAGCCAAGGAtcagacttacgcCGGGCCTGAGGGGTG

951

CCTGGCCCTGcgtgcGGCCCTGACCTTG

952

GGTCAGGGCCgcacgCAGGGCCAGGAC

953

GCCCTGGCCCcctggCTGACCTTGTGAC

954

CACAAGGTCAGccaggGGGCCAGGGCCAG

955

CTGGCCCTGGCggcctCCTTGTGACACTAG

956

GTGTCACAAGGaggccGCCAGGGCCAGGG

957

CCTGGCCCTGtgacaGTGACACTAGGCAT

958

CTAGTGTCACtgtcaCAGGGCCAGGGCC

959

GCCCTGACCTatgtctACTAGGCAGGG

960

CCTGCCTAGTagacatAGGTCAGGGCCAG

970

CCTGGCCCTGtCCTTGTGACAC

971

GTGTCACAAGGaCAGGGCCAGG

972

CTGGCCCTGAgCTTGTGACAC

973

GTGTCACAAGcTCAGGGCCAG

m11

m12

m6/7-1

m6/7-2

m6/7-3

m6/7-4

m6/7-5

m6/7-4-1

m6/7-4-2
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Table 4.1 Continued.
Plasmid

Primer

Sequence (5ʼ-3ʼ)

(oGC-)
974

CTGGCCCTGACaTTGTGACAC

975

GTGTCACAAtGTCAGGGCCAG

976

GGCCCTGACCcTGTGACACTAG

977

CTAGTGTCACAgGGTCAGGGCC

978

GCCCTGACCTaGTGACACTAG

979

CTAGTGTCACtAGGTCAGGGC

90

GGATCCCCGGAATTCATGGACACCAAACATTTCCTGCC

m6/7-4-3

m6/7-4-4

m6/7-4-5

pcDNA3.1-rRXRα
91

AAGCTTGAGCTCGAGCTAGGTGGTTTGATGTGGGGCC
TC

108

GCTAGCCACCATGTATGGAAATTATTCCCACTTC

109

TCTAGATCAGGTGATCTGCAGTGGGGTC

1004

GGATCCGTAGAGGAGAATGCGAC

1008

GAATTCTAGATGGCTTCCTGCTTGGTG

pcDNA3.1-rRXRγ

pACCMV5-HNF4α
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Preparation of Primary Hepatocytes
Rat hepatocytes were isolated as described previously [334]. After
euthanasia of the animal, a catheter was inserted into portal vein and
connected to a peristaltic pump that is connected to liver perfusion medium
and liver digestive buffer. The inferior vena cava was cut open to allow the
outflow of the media at flow rate of 10 ml/min. The liver was perfused for 15
min followed by digestion for 15 min. After completion of the digestion, livers
were excised from the rat and put into a tissue culture plate containing liver
digest buffer for removal of connective tissues and release of hepatocytes.
Medium containing hepatocytes was filtered through a cell strainer (100 μm,
Fisher Scientific, Pittsburgh, PA) and the flow through was spun at 50 g for 3
minutes. The cell pellets were washed twice with 50 ml of DMEM containing
5% FBS, 100 units/ ml sodium penicillin, and 100 μg/ml strepromycin sulfate,
and suspended in the same medium for assessment of cell number and
viability. The isolated hepatocytes were plated onto 60- (~ 2 million cells) and
150-mm (~ 2 × 107 cells) dishes coated with rat-tail collagen type I (Life
Technologies) at ~ 0.1 mg/cm2), and incubated in 4 and 20 ml of the same
medium at 37°C and 5% CO2, respectively. After incubation for 3-4 h, the
attached cells were washed once with 4 ml (for 60-mm plates) and 20 ml (for
100-mm plates) of PBS, and incubated in medium A (medium 199 with 100
nM dexamethasone, 100 nM 3,3ʼ,5-triiodo-L-thyronine (T3), 100 units/ml
penicillin, and 100 μg/ml strepromycin sulfate) containing 1 nM insulin for 1416 hours (18 hours for adenovirus groups) until being used for the indicated
experiments. For the treatments, primary hepatocytes were washed once with
4 ml of PBS and then incubated in 2 ml of medium A containing indicated
reagents for indicated time as shown in the figure legends.

Cell Transfection and Luciferase Assay
All plasmids were isolated using the Qiagen Plasmid Maxi Kits (Qiagen)
and dissolved in 600 μl of water. To extract the plasmids, equal volume of
Phenol: Chloroform: Isoamyl Alcohol (25:24:1, v/v) was added and the mixture
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was vigorously vortexed for 15 s and spun at 14,000 rpm for 5 min at room
temperature (RT). The upper supernatant (~580 μl) was transferred to a new
vial and mixed with equal volume of chloroform. The mixture was vigorously
vortexed for 15 s and spun at 14,000 rpm for 5 min at RT. The resulted upper
supernatant was transferred to a new vial, mixed with 1/10 volume of 3M
sodium acetate (pH 5.2) and 2 volumes of absolute ethanol, frozen overnight
at -20°C, and spun at 14,000 rpm for 30 min at 4°C. The pellet was washed
once with 70% ethanol and dissolved in 500 μl water for assessment of DNA
concentration.
Methods for plasmid transfection with primary hepatocytes and INS-1
cells, and dual luciferase assay have been described previously [12, 168]. For
transfection of primary hepatocytes, one dish (60 mm) of hepatocytes were
washed once with 4 ml of PBS, incubated in 2 ml of serum- and antibiotic-free
RPMI medium 1640 at pH 7.55, and co-transfected with 1.8 μg of the
respective luciferase reporter construct and 0.1 μg rat RARα, RXRα, and/ or
RXRγ expression vectors. Transfection efficiency was monitored by cotransfection

with

0.2

μg

of

Renilla

luciferase

expression

vector

(pRLSV40)(Promega). Appropriate amounts of the empty expression vectors
pGL3-Basic were added to make a total of 2.2 μg of plasmids. Transfections
were performed with 10 μl/ dish of Lipofectin (Life Technologies) according to
manufacturerʼs instructions. 6 h post transfection, the cells were washed twice
with 4 ml of PBS and incubated in 2 ml of medium containing indicated
reagents for 21 h as shown in the figure legends. The cells were then washed
once with 4 ml of PBS and incubated in 0.4 ml of 1 × passive lysis buffer
(Promega, Madison, WI) on a rocking plates for 20 at RT before they were
collected by scraping and stored at -70°C for measurement of luciferase
activities.
For transfection of INS-1 cells, one dish (35 mm) of 833/15 cells grown to
70% confluence were washed once with 2 ml of PBS, incubated in 1 ml of
serum- and antibiotic-free RPMI medium 1640, and co-transfected with 0.9 μg
of the respective luciferase reporter construct and 0.05 μg rat RARα, RXRα,
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and/ or RXRγ expression vectors. Transfection efficiency was monitored by
cotransfection with 0.1 μg of Renilla luciferase expression vector (pRLSV40).
Appropriate amounts of the empty expression vectors pGL3-Basic were
included to make a total of 1.1 μg of plasmids. Transfections were performed
with 10 μl/ dish of Fugene 6 transfection reagent (Roche Applied Science,
Indianapolis, IN) according to manufacturerʼs instructions. 6 h post
transfection, the cells were washed twice with PBS and incubated in 1 ml of
medium containing indicated reagents for 21 h as shown in the figure legends,
and cells were then washed once with 2 ml of PBS and collected by scraping
in 0.17 ml of 1 × passive lysis buffer as described above.
Firefly and Renilla luciferase activities in the cell lysates were measured
with the Dual-Luciferase reporter assay system (Promega) according to the
manufacturerʼs protocol. Photon production was detected as relative light units
by using an Orion L Microplate Luminometer (Berthold System, Pforzheim,
Germany). All values represent the mean of duplicate transfections, each
assayed in triplicate. The amount of firefly luciferase activity in transfected cell
lysates was normalized to the amount of Renilla luciferase activity from the
same test tube. Normalized luciferase activities are shown as the mean ± S.D.
of three independent experiments performed in duplicate and are expressed
as -fold increases relative to the basal activity of the reporters in the absence
of expression plasmids.

Preparation of Recombinant Adenovirus
Methods for recombinant adenovirus generation have been described
previously [334]. HEK293 cells were seeded into 6-well plates at a density of 1
× 106 cells/well in DMEM supplemented with 10% fetal bovine serum, 100
U/ml penicillin, and 100 μg/ml streptomycin sulfate, and allowed to grow to
90% confluence. The cells were co-transfected with 1 μg each of pACCMV5RARα,

pACCMV5-RXRα,

Lipofectamine

2000

(Life

or

pACCMV5-HNF4α

Technologies)

according

and
to

pJM17

with

manufacturerʼs

instructions. Transfected 293 cells were incubated in 2 ml of DMEM
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containing 2% FBS at 37°C and 5% CO2. Samples demonstrating lysis 6-10
days post-transfection were harvested for viral amplification. Crude lysates
were screened for the presence of the specific genes via PCR.
For each recombinant adenovirus, confirmed original crude lysate was
then used to infect HEK 293 cells grown to 80% confluence in 150 mm tissue
culture plates. The ratio of the medium to crude lysate is 10 to 1 (v/v). After
the lysis of the cells at around 48 h post infection, the cell culture medium
(crude lysate) was collected, and stored at -80°C until being used.
For purification of each recombinant adenovirus, NP-40 was first added
into the crude lysate to reach the final concentration at 0.5%. The mixture was
shaken gently at RT for 30 min and subjected to centrifugation at 8,000 rpm
and 4°C for 15 min. The supernatant was transferred to a clean bottle, and 0.5
× volume of 20% PEG8000/ 2.5 NaCl was added. The preparation was
shaken gently at 4°C overnight. The resulting mixture was transferred to
centrifuge bottles and spun at 12,000 rpm at 4°C for 15 min. The precipitated
pellet was resuspended in a small volume of PBS (2-3 ml), and spun at
12,000 rpm and 4°C for 10 min to remove insoluble matters. Solid CsCl was
added to the supernatant until its final density reached 1.34 g/ml. The mixture
was spun at 90,000 rpm at 25°C for 3 h using OptimaTM MAX-XP
Ultracentrifuge (Beckman Coulter Inc., Brea, CA). The corresponding band
containing pure viral particles was collected in a total volume less than 1 ml
for desalting. The PD-10 column SephadexTM G-25 M (Amersham Pharmacia
Biotech AB, Sweden) was equilibrated with 5 ml PBS. The purified virus in
CsCl solution was loaded onto the column and eluted with 5 ml PBS. The flow
through was collected into ten fractions. The optical density (OD) of each of
these fractions at 260-nm was determined after 1 to 50 dilution in water using
Spectronic® GENESYSTM 5 Spectrophotometer (Thermo Scientific Inc.,
Pittsburgh, PA). The fractions containing significant values of OD (usually at
around fractions 7-9) were collected and pooled. Bovine serum albumin (BSA)
and glycerol were added to the pooled solution to make the stock viral solution
with the final concentrations of them at 0.2% and 10%, respectively. After the
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filtration of the stock solution for sterilization, its OD was determined to
estimate the plaque forming units (pfu). We used that 1 OD equals to 1 × 1012
pfu/ml. The final purified virus stock was frozen at -80°C until being used in
the indicated experiments.
Recombinant adenovirus expressing human COUP-TFII (Ad-COUP-TFII)
was provided by Mireille Vasseur-Cognet [207].

RNA Preparation and Quantitative Real-Time RCR (qPCR)
Isolation of total RNA and qPCR were performed as described [334]. Rat
hepatocytes in 60 mm plates were infected with purified recombinant
adenoviruses at 1000 pfu/cell for 18 h. After the indicated treatments, total
RNA was extracted from the treated cells using 1 ml of RNA STAT 60 reagent
(TEL-TEST Inc., Friendswood, TX) according to the manufactureʼs protocol.
The contaminated DNA was removed using the DNA-freeTM kit (Applied
Biosystems) according to the manufactureʼs instruction. First strand cDNA
was synthesized using cDNA synthesis kit (Applied Biosystems). The reaction
was carried out in a total volume of 100 μl, containing 2 μg of DNA-free RNA,
50 mM Tris-HCl, 75 mM KCl, 10 mM DTT, 8.5 mM magnesium chloride, 0.5
mM of each dNTP (dATP, dCTP, dTTP, and dGTP), 2.5 mM random hexamer
primers, 40 units of RNase inhibitor, 125 units of multiscribe reverse
transcriptase. The conditions are 25°C for 10 min, 48°C for 30 min, and 95°C
for 5 min. The qPCR primer sequences are summarized in Table 4.2. Each
SYBR Green based qPCR reaction contains, in a final volume of 14 μl, cDNA
from 14 ng of reverse transcribed total RNA, 2.33 pmol primers, and 7 μl of 2
× SYBR Green PCR Master Mix (Applied Biosystems). Triplicate PCR
reactions were carried out in 96-well plates using 7300 Real-Time PCR
System (Applied Biosystems). The conditions are 50°C for 2 min, 95°C for 10
min, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 min. The
gene expression level was normalized to that of invariable control gene 36B4.
Data are presented as the induction fold for which the control group is
arbitrarily assigned a value of 1 using the ΔΔCT method.
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Western Blotting
Proteins

from

primary

hepatocytes

infected

with

recombinant

adenoviruses were isolated and their concentrations were determined as
described [7]. Rat hepatocytes in 60 mm plates were infected with purified
recombinant adenoviruses as shown in the figure legends at 1000 pfu/cell for
18-24 h, washed once with 4 ml of PBS, and scrapped into 0.4 ml of wholecell lysis buffer (1% Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM
Hepes, 100 mM NaF, 10 mM EDTA, 1 mM sodium molybdate, 1 mM sodium
β-glycerophosphate, 5 mM sodium orthovanadate, 1.9 mg/ml aprotinin, 5
μg/ml leupeptin, 1 mM benzamide, 2.5 mM PMSF, pH 8.0). The lysates were
placed on ice for at least 20 min before being subjected to centrifugation at
13,00 rpm for 20 min. The protein concentration in the supernatant was
determined with PIERCE BCA protein assay kit (Rockford, IL). Proteins (40
μg/lane) in whole cell lysates were separated on a 10% SDS-polyacrylamide
gel, transferred onto BIO-RAD Immuno-Blot PVDF membrane (Hercules, CA),
blocked for 1 h at RT in TBS plus 0.05% TWEEN®20 (TBST), 5% non-fat dry
milk, and incubated overnight at 4°C in primary antibodies against RARα (#
2554), RXRα (#5388), HNF4α (#3113), COUP-TFII (#6434), or β-Actin
(#4970S) diluted 1:1000 in TBST and 1% BSA. Blots were washed with TBST
twice for 5 min, twice for 10 min at RT, and incubated for 1 h at RT in
secondary antibody anti-rabbit IgG horseradish peroxidase (#7074P2) diluted
1:5000 in TBST. Blots were then washed with TBST twice for 5 min and twice
for 10 min at RT. All blots were developed using the ECL Western blotting
system (Thermo Scientific) and exposed to X-ray films (Phenix Research
Products, Candler, NC) for protein band detection. The films were scanned
using an HP Scanjet 3970 (Palo Alto, CA) and stored as Tagged Image File
Format.
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Table 4.2 Primers for qPCR
Gene

Primer

Sequence (5ʼ-3ʼ)

(oGC-)

TTCCCACTGGCTGAAAAGGT
36B4
CGCAGCCGCAAATGC
222

CCTGGGCTTCACCTTCTCCTT

223

GAGGCCTTGAAGCCCTTGGT

Gck

AGTCACCATCACTTCCTGGAAGA
Pck1
GGTGCAGAATCGCGAGTTG
GGAGCCATGGATTGCACATT
Srebp-1c
AGGCCAGGGAAGTCACTGTCT
636

GATCACTGACCTCAAGAAATGGAA

637

GCGGCACGTAATCTCTCTAACA

452

AGTGATGGGCGCGGATAAT

453

TGCACTGACACCAACCGGT

1081

GAACAAGCCTCCAAGACGGT

1082

GGGATTTGAAGCGATTGTCC

580

GTCATCCGGCTACCACTATGG

581

TGGATACTGCGTCGGAAGAAG

582

GGCCTCTGGGACAAATTCAG

583

GCAGACGCTTGGCGAACT

654

GCCCAAATGACCCAGTGACT

655

TCGTCCAGAGGTAGGGAGGAA

658

TGCGGATAAGCAGCTCTTCA

659

TCCAAGGTGAGGTCTGAGAAGTG

998

CAAGAACACATGGGCACCAATG

999

GGTGATGGCTGTGGAGTCT

Igfbp1

Cyp26a1

Apociii

Rara

Rarb

Rxra

Rxrg

Hnf4a
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Table 4.2 Continued.
Gene

Primer

Sequence (5ʼ-3ʼ)

(oGC-)
1057

TGCCTGTGGTCTGTCTGATG

1058

GGAAGGGAGACGAAGCAAAA

Gck

968

GGGTGGCTCCTGAAATACCC

promoter

969

CCTCATGCCTACCTGTTTCG

Coup-tfii
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Preparation of Nuclear Extracts
Nuclear extracts were prepared from rat liver essentially as described
previously [335]. All manipulations were performed in the cold, and all
solutions, tubes, and centrifuges were chilled to 0°C. When included,
phenylmethylsulfonyl fluoride (PMSF), spermidine, and dithiothreitol (DTT)
were added to the buffers just prior to use. Minced rat liver (~10 g) was
brought up to 30 ml with homogenization buffer (10 mM Hepes-KOH [pH 7.8],
10 mM KCl, 0.1 mM EDTA, 1 mM spermidine, 1mM DTT, 0.5 mM PMSF, 0.3
M sucrose) and was homogenized using a 100 ml Wheaton glass
homogenizer until more than 90% of the cells were broken. The homogenate
was diluted with one-third volume (~ 10 ml) of cushion buffer (20 mM HepesKOH [pH 7.8], 25 mM KCl, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM spermidine, 1
mM DTT, 0.5 mM PMSF, 2 M sucrose, 10% glycerol). The resulted mixture
was aliquoted into six 6-ml portions, each of which was then layered onto 2 ml
cushion buffer, and centrifuged at 24,000 rpm for 1 h at 4°C in an Sorvall TH64I rotor (Sorvall Ultra-80). The nuclear pellets were resuspended in 2 ml lysis
buffer (10 mM Hepes-KOH [pH 7.8], 100 mM KCl, 3 mM MgCl2, 1 mM DTT,
10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, 1.9 μg/ml aprotitin, 1 μM
pepstatin A, 5 μg/ml leupeptin, 1 mM sodium beta-glycerol phosphate, 1 mM
sodium molybdate, 1 mM benzamidine, 5 mM sodium metavanadate, and 5
mM sodium fluoride), and centrifuged as described above. The pelleted nuclei
were resuspended in 0.5 ml of lysis buffer and combined. One-tenth volume of
5 M (NH2)SO4 was added dropwise, and the extract was gently shaken for 1 h
at 4°C. The viscous lysate was then centrifuged at 90,000 rpm for 1 h at 4°C
in a TLA 100.3 rotor (OptimaTM Max-XP Ultracentrifuge, Beckman Coulter) to
pellet chromatin. The supernatant was aliquoted and stored at -70°C. Once
thawed, the extracts were not refrozen.
INS-1 833/15 cells grown to 80% confluence in 150 mm plates were
infected with recombinant adenoviruses Ad-RARα, Ad-RXRα, Ad-HNF4α, AdCOUP-TFII or control Ad-β-gal at 1000 pfu/cell for 24 h, washed once with 25
ml of PBS, scrapped into 1 ml of homogenization buffer, and transferred into a
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1 ml Wheaton glass homogenizer. A tight-fit pestle was passed up and down
for 120 times (30 strikes each for 4 times). The lysate was spun at 1000 × g
for 10 m. The pellet was suspended into 0.67 ml of homogenization buffer and
mixed with 1.33 ml of cushion buffer. The resulted 2 ml mixture was overlayered onto 1 ml of cushion buffer in a 14 × 89 mm centrifuge tube
(Beckman), and spun at 24,000 rpm for 1 h. The pellet at the bottom of the
cushion buffer was suspended in 100 μl of nuclear extract lysis buffer and
transferred to a micro centrifuge tube. The suspended nuclei were mixed with
0.1 volume of 5 M NaCl and rotated at 4°C for 30 m. After a 14,000 rpm spin
to pull down the nuclear lysate, it was transferred to a centrifuge tube and
spun at 85,000 rpm for 45 m. The resulted unclear extract was stored at -70°C
before protein content determination and further analysis as indicated in the
figure legends.

Electrophoretic Mobility Shift Assay (EMSA)
All oligonucleotides used for EMSAs were summarized in Table 4.3.
Double-stranded synthetic oligonucleotide probes were prepared by heating
equal molar amounts (100 pmol) of complementary synthetic oligomers in a
volume of 100 μl containing 50 mM NaCl to 100°C for 10 min, then allowing
the hybridization mix to cool to ambient temperature. The resulting doublestranded fragments were labeled by 5ʼ-end labeling with [γ-32P] ATP (3000
mCi/mmol, Perkin Elmer, Waltham, MA) and T4 polynucleotide kinase (PNK,
New England Biolabs, Ipswich, MA) in a total volume of 20 μl, containing 2
pmol probes, 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 5 mM DTT, 10 units of
PNK, and 5 μl [γ-32P] ATP. After incubation at 37°C for 15 min, the reaction
was terminated by addition of EDTA to a final concentration of 10 mM.
Labeled fragments were purified with Illustra MicroSpin G-50 columns (GE
healthcare, Pittsburgh, PA).
Binding reactions were carried out in a total volume of 20 μl, containing
10 mM Hepes-KOH (pH 7.9), 100 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 2 mM
dithioerythritol, 100 ng/μl poly d(I-C), 5% (v/v) glycerol, 100 ng/μl bovine
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serum albumin and 6 μg nuclear extract. After preincubation for 10 min at RT,
105 c.p.m. labeled probe was added and the incubation was continued for an
additional 20 min at RT.
In Figure 4.11 and 4.12, 1 μg of each of the specific antibodies or a
combination of them, together with appropriate amounts of IgG control were
added to preincubated DNA-protein complexes for 20 m at RT before addition
of probe. The electrophoresis was then performed with a 12% (w/v) nondenaturing polyacrylamide gel (acrylamide/ bis-acrylamide ratio 37.5:1) in 0.5
× TBE beffer (44.5 mM Tris/ 44.5 mM boric acid/ 1 mM EDTA) at constant
current 10 mA for 5 h at 4°C. After electrophoresis the gels were dried using
Slab Gel Dryer (Model SE 540, Hoefer Scientific Instruments, San Francisco,
CA) that is connected to a Savant Refrigerated Condensation Trap (Thermo
Scientific). Gels were then exposed to X-ray films (Phenix Research Products)
at RT for the time indicated in figure legends. The films were scanned using
an HP Scanjet 3970 and stored as Tagged Image File Format.

Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assay was performed based on a previously described method
with some modifications [336]. Following the treatment as indicated in the
figure legends, hepatocytes or HL1C cells in 150 mm plates were washed
twice with 25 ml of PBS and cross-linked in 10 ml of PBS by adding
formaldehyde to a final concentration of 1% and incubating for 15 min at 37°C.
The cross-linking reaction was quenched by adding one-ninth volume of 1.25
M glycine and continued the incubation for 5 min at RT. Cross-linked cells
then were washed with 25 ml of ice-cold PBS twice, scrapped into 1 ml of icecold PBS, and centrifuged for 5 min at 2000 × g. Cells were then resuspended
in 600 μl of lysis buffer (1% SDS, 10 mM Tris-HCl [pH 8], 10 mM EDTA, 0.5
mM phenylmethylsulfonyl fluoride, 1.9 μg/ml aprotitin, 1 μM pepstatin A, 5
μg/ml leupeptin, 1 mM sodium beta-glycerol phosphate, 1 mM sodium
molybdate, 1 mM benzamidine, 5 mM sodium metavanadate, and 5 mM
sodium fluoride), incubated for 30 min at 4°C, and sonicated with 45 pulses of
92

Table 4.3 Oligonucleotides for EMSA
Oligonucleotides

Primer

Sequence (5ʼ-3ʼ)

(oGC-)
1010

GGCCCTGGCCCTGACCTTGTGACACTAG

1011

CCTGCCTAGTGTCACAAGGTCAGGGCCA

1012

GGCCCTGGCCCTGAatTcGTGACACTAG

1013

CCTGCCTAGTGTCACgAatTCAGGGCCA

1020

GGCCCTGGCCCTGtCCTTGTGACACTAG

1021

CCTGCCTAGTGTCACAAGGaCAGGGCCA

1022

GGCCCTGGCCCTGAgCTTGTGACACTAG

1023

CCTGCCTAGTGTCACAAGcTCAGGGCCA

1024

GGCCCTGGCCCTGACaTTGTGACACTAG

1025

CCTGCCTAGTGTCACAAtGTCAGGGCCA

EMSA-Gck-m6/7-WT

EMSA-Gck-m6/7-mut

EMSA-Gck-m6/7-4-1

EMSA-Gck-m6/7-4-2

EMSA-Gck-m6/7-4-3
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10 s each at power setting 60% with the Misonix Sonicator 4000 Ultrasonic
Liquid Processor (Qsonica, Newtown, CT) to fragment 300 bp to 500 bp. The
resulted mixture was centrifuged for 10 min at 12,000 rpm. Supernatants were
collected and diluted with ten volumes of dilution buffer (0.01% SDS, 1%
Triton X-100, 1 mM EDTA, 10 mM Tris-HCl [pH 8], 150 mM NaCl). One-tenth
volume was saved as ʻtotal inputʼ in the subsequent DNA extraction and PCR
analysis. The rest was divided into 2 portions (hepatocytes) or 4 portions
(HL1C cells) and each was incubated with 2 μg IgG control (sc-2027), or
antibody against RAR (sc-773X), RXR (sc-774X), HNF4α (sc-8987X), or
COUP-TFII (PP-H7147-00). After the overnight incubation at 4°C with gentle
rotation, 20 μl Dynabeads® protein A (Life Technologies, Norway) and 100
μg/ml sheared salmon sperm (Invitrogen) DNA were added and the incubation
continued for 2 h at 4°C. The tube was then placed on a magnetic separation
stand to collect the Dynabeads protein A-Ig complex at the tube wall. The
immune complexes were washed sequentially for 10 min each in TSE I (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8], 150 mM NaCl),
TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8], 500
mM NaCl), and buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, 10 mM Tris-HCl [pH 8]). The immune complexes were then extracted
twice with 150 μl freshly prepared elution buffer (1% SDS, 0.1 M NaHCO3) for
20 min at 4°C with gentle rotation. To reverse the crosslinking, 1 μl RNase A
(10 mg/ml) was added to the eluates and incubated at 65°C for at least 5 h.
To precipitate the DNA, 1/10 volume of 3M sodium acetate (pH5.2), 2.5
volumes of cold 100% ethanol, and 10 mg of glycogen were added, incubated
overnight at -20°C, and centrifuged for 20 min at 12,000 rpm. To remove
protein, 100 μl Tris-HCl/EDTA (TE, pH 8.0) and 2 μl proteinase K (10 mg/ml)
were added and incubated for 1.5 h at 55°C. DNA was extracted once with
Phenol: Chloroform: Isoamyl Alcohol (25: 24: 1, v/v) and resuspended in 50 μl
TE. 2 μl of DNA were amplified by PCR for a 251 bp hepatic Gck promoter
region between nucleotide -390 and nucleotide -140 (relative to the translation
initiation site +1), using primer pair oGC968/969, under 35 cycles of 94°C for
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30 s, 59°C for 45 s, and 72°C for 1 min. The PCR products were resolved on
2% agarose gels containing ethidium bromide.

Statistical Analysis
Quantitative results are expressed as means ± standard edeviation (SD).
Leveneʼs test was used to determine homogeneity of variance among groups
using SPSS 21 statistical software (IBM, Armonk, NY) and where necessary
natural log transformation was performed before analysis. We performed the
statistical analyses using one-way analysis of variance (ANOVA) when more
than two groups of data were compared, and Studentʼs t test when only two
groups of data were concerned. We considered the difference to be
statistically significant at p < 0.05.

4.3 Results
Progressive Deletion of 5ʼ Flanking Region of Rat Hepatic Gck Promoter
Transient transfection studies of rat hepatocytes revealed that a reporter
plasmid with 3.4 kb of genomic DNA flanking the liver Gck promoter elicits the
maximal luciferase activity. In addition, the gene fragment from -1003 to -707
(with respect to the start of transcription) was shown to be a bona fide
hepatocyte-specific enhancer [92]. In our preliminary observations, luciferase
reporter gene construct containing about 1 kb (with respect to the start of
translation) of rat Gck promoter is sufficient to mediate RA response.
Therefore, a series of luciferase gene reporter constructs containing deletions
of this 1 kb promoter fragment were constructed. As shown in Fig. 4.1,
plasmids A, B, C, D, and E contain about 1, 0.8, 0.6, 0.4, and 0.2 kb of 5ʼ
flanking region of liver Gck promoter, respectively. Primary hepatocytes were
transfected with reporter plasmids, followed by exposure to RA (5 μM), insulin
(INS, 10 nM), or both for 21 hours, and luciferase activity was subsequently
analyzed. RA and RA + INS stimulated the luciferase activity of plasmid A by
1.9- and 2.3-fold, respectively. Progressive deletion of promoter did not result
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Figure 4.1 Deletion analysis of rat hepatic Gck promoter in rat primary
hepatocytes
Primary rat hepatocytes were transfected with 2 μg of indicated constructs
together with 0.2 μg phRL4-TK as transfection efficiency control using
Lipofectin as described in Materials and Methods. Six hours after transfection,
the medium was switch to medium without or with 10 nM insulin in the
absence or presence of 5 μM RA and incubated for 21 h, after which the cells
were harvested and assayed for dual luciferase activities as described in
Materials and Methods. Each value represents the mean ± SD of three
independent transfection experiments in duplicate. The luciferase activity of
each promoter in the presence of control (ethanol) was arbitrarily assigned a
value of 1.
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in decrease in luciferase expression, as demonstrated by similar fold induction
of plasmids B-E under the same conditions. Insulin had little effect on any of
the plasmids and there was no significant difference between RA and RA +
INS group. These results suggest that the RAREs may be located in the
promoter fragment in plasmid E.

Over-expression of RARα Augments RA Response of Reporter Gene
Constructs
Given the moderate induction in luciferase activity of plasmids A-E by RA,
we next tried to test whether we can enhance the RA induction further in case
that multiple RAREs exist in Gck promoter. This prompted us to test whether
over-expression of RARs and/or RXRs is able to augment RA-induced
luciferase activity and re-introduce insulin response of reporter plasmids. As
shown in Fig. 4.2, transient co-transfection of plasmid A and pGL3 empty
vector into rat primary hepatocytes resulted in 1.8- and 2.2-fold induction of
luciferase activity by RA and RA + INS, respectively. Surprisingly, overexpression of RARα, but not RXRα or RXRγ, substantially augmented the RAand RA + INS-mediated increase in luciferase activity to 4.1- and 5.5-fold,
respectively. Co-expression of RARα and RXRα or RXRγ did not further
increase the fold induction. Over-expression of these retinoid receptors had
little effect on basal levels of transcription. These data together with those
described above suggest that RA response of proximal Gck promoter can be
observed in the absence of insulin stimulation and that primary hepatocytes
are not fungible in the identification of RARE in Gck promoter.

Reconstitution of RA Response of Gck Reporter Constructs in INS-1 Cells
Due to the persistent RA-induced Srebp-1c expression in INS-1 cells,
they were used successfully to identify RARE in Srebp-1c promoter [12]. To
evaluate if INS-1 833/15 cell line would be an appropriate tool for identification
of RARE in Gck promoter, we repeated the transient transfection experiments
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Figure 4.2 Activation of plasmid A in rat primary hepatocytes
Primary rat hepatocytes were transfected with 2 μg of plasmid A together with
0.2 μg phRL4-TK as transfection efficiency control and 0.2 μg expression
vectors as indicated using Lipofectin. 6 hours after transfection, the medium
was switch to medium without or with 10 nM insulin in the absence or
presence of 5 μM RA and incubated for 21 h, after which the cells were
harvested and assayed for dual luciferase activities as described in Materials
and Methods. Each value represents the mean ± SD of three independent
transfection experiments in duplicate. The luciferase activity of promoter in the
presence of control (ethanol) was arbitrarily assigned a value of 1.
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in 833/15 cells. Similar observations were obtained from INS-1 833/15 cells.
Thus, 833/15 cells were transiently co-transfected with plasmids A, C, D, E, or
pGL3 empty vector, together with pcDNA3.1 empty vector, pcDNA3.1-RARα,
pcDNA3.1-RXRγ,

or

pcDNA3.1-RARα

+

pcDNA3.1-RXRγ

(Fig.

4.3).

Luciferase activities were measured after incubation of the cells for 21 h in the
presence or absence of 5 μM RA. For plasmid A, over-expression of RARα
slightly but significantly increased the level of basal transcription. Overexpression of RXRγ alone did not change the basal transcription. However,
co-expression of RARα and RXRγ resulted in 2.3-fold induction of basal
transcription. Plasmid C, D, and E showed the same level of basal
transcription under all conditions. With the expression of RARα, but not RXRγ,
RA induced 7.3-, 6.7-, and 6,5-fold activation of deletion constructs A, C, and
D, respectively. The combination of RARα and RXRγ resulted in more robust
induction of RA-dependent promoter activity, which are 12.2-, 10.6-, and 11.5fold, respectively. Luciferase activity of plasmid E was still substantially
activated by RA both with RARα and RARα + RXRγ (4.3- and 6.7-fold,
respectively). However, the folds were significantly less than other reporter
constructs, suggesting that there might be more than one RARE in the hepatic
Gck promoter, one located within the 0.2 kb region (plasmid E) for sure and
possibly the other between 0.4 kb and 0.2 kb (plasmid D).

Linker-scan Analysis of 0.2 kb Hepatic Gck Promoter Region in Plasmid E
To identify the possible RARE in the 0.2 kb region of plasmid E, we
introduced a series of overlapping 12-bp scramble mutations covering the
nucleotide sequence from -237 to -118 into the 0.2 kb deletion promoter
construct to generate plasmids m1 to m12 (Fig. 4.4), which were then cotransfected into primary rat hepatocytes together with pcDNA3.1-RARα and
pcDNA3.1-RXRγ. Promoter activity of the WT 0.2 kb (plasmid E) and mutant
constructs m1 to m12 in the absence or presence of 5 μM RA was analyzed.
The mutations in mutant plasmids m3, m4, m5, and m8 significantly reduced
the RA-induced promoter activity. The scramble mutations in m6 and m7
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Figure 4.3 Effects of RA on activation of Gck reporter gene constructs in
INS-1 833/15 cells
INS-1 Cells were transefected with 2 μg of indicated constructs together with
0.2 μg phRL4-TK and 0.2 μg expression vectors using Fugene 6 as described
in Materials and Methods. Four hours after transfection, the medium was
switched to serum free medium without or with 5 uM RA and incubated for 21
hours, after which the cells were harvested and assayed for dual luciferase
activities as described in Materials and Methods. Each value represents the
mean ± SD of three independent transfection experiments in duplicate. The
luciferase activity of each promoter co-transfected with pcDNA3.1 in the
absence of RA was arbitrarily assigned a value of 1.
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Figure 4.4 Nucleotide sequences of wild type (WT) and mutant rat
hepatic Gck promoters
The sequence of a portion of the normal Gck promoter (-237/-118, with
respect to the translation initiation start site) is shown at the top. Below the
sequence of the WT promoter are shown 12 bp overlapping scramble
mutations that are separately introduced into the DNA by site-directed
oligonucleotide mutagenesis as described in Materials and Methods. The
names of the mutant plasmids, m1-m12, are denoted on the left. The mutant
scrambled sequence that was introduced is shown below the normal promoter
sequence.
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completely abolished the RA-activated transcription (Fig. 4.5). Same results
were obtained from transfection studies performed with 833/15 cells. The
mutants m5 and m8 reduced, while mutants m6 and m7 abolished the RAinduced promoter activity (Fig. 4.6).

Introduction of Scramble Mutations of m6 and m7 into Plasmid A Destroys its
RA Response
We next investigated whether there is another RARE located between the
0.4 kb and 0.2 kb regions. To test this, we introduced the scramble mutations
in m6 and m7 into plasmid A by replacing the WT nucleotide sequence from 237 to -4 of the 1 kb fragment in plasmid A with corresponding mutant
nucleotide sequence in m6 and m7 to get plasmid pGL3-GK-1k-m6 and pGL3GK-1k-m7, respectively. If the hypothesis that another RARE is present
between 0.4 kb and 0.2 kb region is true, these two plasmids should be able
to respond to RA. However, introduction of the mutation either in m6 or in m7
destroyed hepatic Gck transcription activated by RA, RAR agonist TTNPB, or
RXR agonist LG268, or the combination of both (Fig. 4.7), indicating the
uniqueness of the RARE located within the 0.2 kb region (plasmid E).

Linker-scan Analysis of Gck Promoter Region in Plasmid E Covered by
Scramble Mutations of m6 and m7
To map the RARE more precisely in plasmid E, we introduced 5
overlapping 5- to 6- bp scramble mutations covered by scramble mutations in
m6 and m7 (-189/-168) into WT plasmid E to generate plasmids m6/7-1, -2, 3, -4, and -5, respectively. Fig. 4.8 shows that mutations in m6/7-4 (-177/-173)
resulted in a 54% decrease in RA-dependent activation, suggesting the
important role of this ACCTT sequence. Further, point mutations at -177 (A to
t), -176 (C to g), and -175 (C to a) impaired the RA-dependent activation of
luciferase activities by 39%, 47%, and 39%, respectively, whereas point
mutations at -174 (T to C) and -173 (T to A) had little effect on RA
responsiveness of reporter constructs (Fig. 4.9). These data suggested that
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Figure 4.5 Effects of RA on activation of WT and mutant Gck reporter
gene constructs in primary rat hepatocytes
Primary rat hepatocytes were transfected with 2 μg of indicated plasmids
together with 0.2 μg phRL4-TK as transfection efficiency control, 0.1 μg
expression vector containing RARα, and 0.1 μg expression vector containing
RXRγ using Lipofectin. Six hours after transfection, the medium was switch to
medium without or with 5 μM RA and incubated for 21 h, after which the cells
were harvested and assayed for dual luciferase activities as described in
Materials and Methods. Each value represents the mean ± SD of three
independent transfection experiments in duplicate. The luciferase activity of
WT promoter in the absence of RA was arbitrarily assigned a value of 1 (** p
< 0.01 and # p < 0.001 for comparing control and RA groups).
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Figure 4.6 Effects of RA on activation of WT and mutant Gck reporter
gene constructs in INS-1 833/15 cells
Cells were transfected with 2 μg of indicated constructs together with 0.2 μg
phRL4-TK, 0.1 μg expression vector containing RARα, and 0.1 μg expression
vector containing RXRγ using Fugene 6 as described in Materials and
Methods. Four hours after transfection, the medium was switched to serum
free medium without or with 5 uM RA and incubated for 21 hours, after which
the cells were harvested and assayed for dual luciferase activities as
described in Materials and Methods. Each value represents the mean ± SD of
three independent transfection experiments in duplicate. The luciferase
activity of each promoter in the absence of RA was arbitrarily assigned a
value of 1 (a > b > c for comparing RA groups using one way ANOVA; all p <
0.05).
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Figure 4.7 Effects of ligands on activation of WT and mutant plasmid A
in INS-1 833/15 cells
Plasmid A was digested with KpnI and PmlI to yield an approximately 770 bp
fragment, which was inserted in the sense orientation of plasmids m6 and m7
cut with KpnI and PmlI to obtain pGL3-Gck-1k-m6 and pGL3-Gck-1k-m7,
respectively, as described in Materials and Methods. Cells were transfected
with 2 μg of indicated constructs together with 0.2 μg phRL4-TK, 0.1 μg
expression vector containing RARα, and 0.1 μg expression vector containing
RXRγ using Fugene 6 as described in Materials and Methods. Four hours
after transfection, the medium was switched to serum free medium without or
with 5 uM RA and incubated for 21 hours, after which the cells were harvested
and assayed for dual luciferase activities as described in Materials and
Methods. Each value represents the mean ± SD of three independent
transfection experiments in duplicate. The luciferase activity of each promoter
in the presence of C (control, ethanol) was arbitrarily assigned a value of 1.
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Figure 4.8 Linker-scan analysis of Gck promoter region in plasmid E
covered by scramble mutations of m6 and m7
(Left) The sequence of WT Gck promoter covered by m6 and m7 is shown at
the top and numbered as previously described. Five overlapping scramble
mutations were separately introduced into the DNA by site-directed
oligonucleotide mutagenesis to generate m6/7-1, -2, -3, -4, and -5,
respectively, as described in Materials and Methods. (Right) Fold induction of
WT and mutant m6/7 constructs in 833/15 cells. Cells were transfected with 2
μg of indicated constructs together with 0.2 μg phRL4-TK, 0.1 μg expression
vector containing RARα, and 0.1 μg expression vector containing RXRγ using
Fugene 6 as described in Materials and Methods. Four hours after
transfection, the medium was switched to serum free medium without or with
5 uM RA and incubated for 21 hours, after which the cells were harvested and
assayed for dual luciferase activities as described in Materials and Methods.
Each value represents the mean ± SD of three independent transfection
experiments in duplicate. The luciferase activity of each promoter in the
absence of RA was arbitrarily assigned a value of 1 (a > b > c > d for
comparing RA groups using one way ANOVA; all p < 0.05).
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Figure 4.9 Effect of RA on activation of WT and mutant m6/7-4
constructs
(Left) The sequence of WT Gck promoter covered by scramble mutation of
m6/7-1 is shown at the top and numbered as previously described. Five point
mutations were separately introduced into the DNA by site-directed
oligonucleotide mutagenesis to generate m6/7-4-1, -2, -3, -4, and -5,
respectively, as described in Materials and Methods. (Right) Fold induction of
WT and mutant m6/7 constructs in 833/15 cells. Cells were transfected with 2
μg of indicated constructs together with 0.2 μg phRL4-TK, 0.1 μg expression
vector containing RARα, and 0.1 μg expression vector containing RXRγ using
Fugene 6 as described in Materials and Methods. Four hours after
transfection, the medium was switched to serum free medium without or with
5 uM RA and incubated for 21 hours, after which the cells were harvested and
assayed for dual luciferase activities as described in Materials and Methods.
Each value represents the mean ± SD of three independent transfection
experiments in duplicate. The luciferase activity of each promoter in the
absence of RA was arbitrarily assigned a value of 1 (a > b for comparing RA
groups using one way ANOVA; all p < 0.05).
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RA activated hepatic Gck transcription through transcriptional factors bound to
the -177/-175 region of its promoter.

Promiscuous Binding of RAR, RXR, HNF4, and COUP-TFII to RARE in Rat
Hepatic Gck Promoter
Fig. 4.10 shows the alignment of human, rat, and mouse downstream
Gck promoter DNA sequence (-237/+1) and the regions with high
conservation across these three mammalian species. The RARE identified in
this study is also a potential HNF4 binding site reported previously [130]. To
corroborate the interaction of RAR/RXR with RARE, the binding of proteins in
the rat liver nuclear extracts (NEs) to this region of the downstream Gck
promoter was examined by electrophoretic mobility shift assay (EMSA). An
oligonucleotide probe corresponding to the rat Gck -190/-163 region (EMSAGck-m6/7-WT) was able to form five complexes (Fig. 4.11, lane 1, arrows A to
E). Mutations of CCTT in the putative RARE/HNF4α binding site to ATTC
(EMSA-Gck-m6/7-mut) resulted in complete loss of the formation of these
binding complexes (Fig. 4.11, lanes 2, 7,12). Single nucleotide mutation in
plasmids pGck-1k-m6/7-4-1 (C to A at -177) and pGck-1k-m6/7-4-2 (T to C at
-176) had little effect on the formation of the binding complexes. However,
point mutation in plasmid pGck-1k-m6/7-4-3 (T to C at -175) enhanced the
formation of complexes. To determine the presence of RARs, RXRs, HNF4α,
and COUP-TFII in these complexes, individual antibodies against each of
them, or in combinations, were included in the binding reaction. Addition of the
HNF4α antibody in the binding reaction increased the formation of complex C
but decreased the formation of complexes B, D, and E, with EMSA-Gck-m6/7WT probe (Fig. 4.11 and Fig. 4.12). COUP-TFII antibody strongly reduced the
formation of complex A (Fi.g 4.11 and Fig. 4.12, lanes 3, 6, 9,10, 12, 13, 15,
and 16). The formation of binding complexes seemed not to be affected by
addition of RAR or RXR antibody alone (Fig. 4.12, lanes 4 and 5,
respectively).
To further confirm these observations, NEs were prepared from INS-1
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Figure 4.10 Alignment of the human, rat, and mouse downstream
promoter DNAs
Bases are numbered with respect to the rat gene. The translation initiation site
and putative HNF4 binding site are underlined. Conserved nucleotides are in
boldface.
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Figure 4.11 Changes in gel shift pattern resulting from mutations in the
sequence of hepatic Gck -190/-163 oligonucleotide
A, diagram of oligonucleotide probes. Mutated bases are shown in lower-case
letters. B, 6 μg of nuclear extracts of rat liver were pre-incubated with 1 μg
antibodies for 20 m at room temperature as indicated, followed by incubation
for 20 m at room temperature with 105 cpm of one of the following 32P-labelled
probes: lanes 1, 6, and 11, EMSA-Gck-m6/7-WT; lanes 2, 7, and 12, EMSAGck-m6/7-mut; lanes 3, 8, and 13, EMSA-Gck-m6/7-4-1; lanes 4, 9, and 14,
EMSA-Gck-m6/7-4-2; lanes 5, 10, and 15, EMSA-Gck-m6/7-4-3. The DNA
protein binding was analyzed by electrophoresis on 12% (acrylamide/bisacrylamide ratio: 29:1) native polyacrylamide gels. The gel was exposed to Xray film for 10 h at room temperature with intensifying screen. A, COUP-TFII,
C, HNF4α.
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Figure 4.12 Electrophoretic mobility shift assay (EMSA) of binding of
HNF4α, COUP-TFII, RAR, and RXR from rat liver nuclear protein extracts
to the hepatic Gck -190/-163 oligonucleotide
6 μg of nuclear extracts of rat liver were pre-incubated with 4 μg antibodies for
20 m at room temperature as indicated, followed by incubation with 105 cpm
32

P-labelled EMSA-Gck-m6/7-WT oligonucleotides (-190/-163) for 20 minutes

at room temperature. The DNA protein binding was analyzed by
electrophoresis on 12% (acrylamide/bis-acrylamide ratio: 37.5:1) native
polyacrylamide gels. The gel was exposed to X-ray film for 17 h at room
temperature with intensifying screen. A, COUP-TFII. B, HNF4α.
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833/15 cells over-expressing β-gal, RARα, RXRα, HNF4α, or COUP-TFII, and
their binding to EMSA-Gck-m6/7-WT was examined by EMSA. INS-1 cells
were used here because of the lack of transcription of the downstream Gck
gene. As shown in Fig. 4.13, recombinant adenovirus-mediated overexpression of these transcriptional factors resulted in increased formation of
the indicated complexes, which are not observed in the NEs derived from cells
infected by Ad-β-gal.
To determine whether RA affects the formation of the binding complexes
or not, the EMSA assay was performed in the absence or presence of
increasing concentrations of RA. As shown in Fig. 4.14, the presence of RA at
10 μM increased the formation of all the binding complexes.
We next determined whether the Gck promoter in the context of
chromatin is bound by these transcriptional factors using chromatin
immunoprecipitation (ChIP) assays. Primary rat hepatocytes were infected
with Ad-β-gal, Ad-RARα, RXRα, Ad-HNF4α, or Ad-COUP-TFII for 18 h and
chromatin was prepared. As shown in Fig. 4.15, these transcription factors
were successfully over-expressed. Recombinant adenovirus-mediated overexpression of RARα, RXRα, or COUP-TFII significantly increased their
occupancy in Gck promoter as compared with Ad-β-gal. However, overexpression of RXRα did not affect the precipitation of Gck promoter by RXRα
antibody (Fig. 4.16). Despite HL1C hepatoma cells are known not to express
Gck, RA was able to induce the binding of RARα and HNF4α to the promoter
of Gck (Fig. 4.17).
Taken together, these data demonstrate that RARE in the hepatic Gck
promoter is a promiscuous binding site for RAR, RXR, HNF4α, and COUPTFII and that RA may modulate the binding of nuclear proteins to this site.

Effects of Over-expression of RARα, RXRα, HNF4α, and COUP-TFII on Gck
and Other Metabolic Genes in Primary Rat Hepatocytes
Given the fact that these transcription factors bind to the RARE, it
becomes essential to determine whether any change or shift of the occupancy
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Figure 4.13 Effect of over-expression of RARα, RXRα, HNF4, and COUPTFII on the EMSA pattern of hepatic Gck -190/-163 oligonucleotide in
INS-1 cells
2 μg of nuclear extracts prepared from INS-1 833/15 cells infected with
adenoviruses Ad-β-gal, Ad-RARα, Ad-RXRα, Ad-HNF4, or Ad-COUP-TFII
were

incubated

with

105

cpm

32

P-labelled

EMSA-Gck-m6/7-WT

oligonucleotides (-190/-163) for 20 m at room temperature. The DNA protein
binding was analyzed by electrophoresis on 12% (acrylamide/bis-acrylamide
ratio: 29:1) native polyacrylamide gels. The gel was exposed to X-ray film for
16 h at room temperature with intensifying screen. A, COUP-TFII, B, HNF4α,
C, RARα/RXRα.
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Figure 4.14 Effect of retinoic acid on the EMSA pattern of hepatic Gck 190/-163 oligonucleotide
6 μg of nuclear extracts of rat liver were incubated with 105 cpm

32

P-labelled

EMSA-Gck-m6/7-WT oligonucleotides (-190/-163) in the presence of the
indicated amount of all-trans retinoic acid (ATRA) for 20 m at room
temperature. The DNA protein binding was analyzed by electrophoresis on
12% (acrylamide/bis-acrylamide ratio: 37.5:1) native polyacrylamide gels. The
gel was exposed to X-ray film for 12 h at room temperature with intensifying
screen.
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Figure 4.15 The adenovirus-mediated over-expression of nuclear
receptors in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα (A), Ad-RXRα (B),
Ad-HNF4α (C), or Ad-COUP-TFII (D) at 1,000 PFU/cell for 24 h. Shown are
representative Western blots of 20 μg/lane of whole cell lysates showing
nuclear receptors (top) and β-actin (bottom) as the loading control.
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Figure 4.16 Effect of recombinant adenoviruses on immunoprecipitation
of the Gck promoter-containing chromatin from primary hepatocytes
with RARα, RXRα, HNF4α, and COUP-TFII antibodies
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h and crosslinked with
formaldehyde and immunoprecipitated with the antibody against RARα,
RXRα, HNF4, and COUP-TFII or with control IgG. Sonicated genomic DNA
from the nuclei treated with antibody or IgG and the nuclei not treated with
antibody (input) were isolated and amplified by PCR for a 250 bp Gck
promoter region using Gck-specific primers. PCR products were resolved on
agarose gels containing ethidium bromide. * P < 0.05, ** P < 0.01, and *** P <
0.001 for comparing indicated adenovirus with β-gal.
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Figure 4.17 Immunoprecipitation of the Gck promoter-containing
chromatin from HL1C hepatoma cells with RARα, RXRα, and HNF4α
antibodies
HL1C cells treated without or with 1 μM RA for 6 h were crosslinked with
formaldehyde and immunoprecipitated with the antibody against RARα,
RXRα, and HNF4α, or with control IgG. Sonicated genomic DNA from the
nuclei treated with antibody or IgG and the nuclei not treated with antibody
(input) were isolated and amplified by PCR for a 250 bp Gck promoter region
using Gck-specific primers. PCR products were resolved on agarose gels
containing ethidium bromide. *** p < 0.001 for comparing with control.
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of one of these transcription factors will influence Gck expression in the
presence or absence of RA an insulin. As shown in Fig. 4.18, in β-gal
adenovirus control group, RA and insulin increased Gck mRNA expression
level by 5.6- and 53.7-fold, respectively. RA + insulin synergistically induced
its mRNA level by 397-fold. Recombinant adenovirus-mediated overexpression of RARα, RXRα, or HNF4α had little effect on the basal
transcription of Gck. However, over-expression of COUP-TFII significantly
reduced basal transcription of Gck by 56%. Over-expression of RARα
potentiated RA-induced Gck transcription by 44.6-fold, an effect not observed
in RXRα over-expression group. In contrast, over-expression of HNF4α
attenuated RA-induced Gck transcription by 71.0% and over-expression of
COUP-TFII completely abolished the induction. Whereas over-expression of
RXRα did not affect insulin-induced Gck transcription, over-expression of
RARα, HNF4α, and COUP-TFII suppressed insulin-induced Gck transcription
by 85.9%, 96.0%, and 90.0%, respectively. Synergistic induction of Gck
transcription by RA and insulin was not affected by over-expression of RXRα,
increased by 5.2-fold by over-expression of RARα, and almost completely
abolished by over-expression of HNF4α and COUP-TFII (99.3% and 96.8%,
respectively).
To confirm that insulin and RA treatment worked, we measured the
expression of Pck1, which is regulated by both RA and insulin. As shown in
Fig. 4.19, over-expression of RXRα had little effect on basal expression level
of Pck1 mRNA. However, over-expression of RARα and COUP-TFII
suppressed the basal expression of Pck1 mRNA by 85% and 81%,
respectively. RA induced the mRNA level of Pck1 in β-galactosidase
adenovirus control group by 2.7-fold, which, without being affected by overexpression of RARα or RXRα, was attenuated by 83.5% in the presence of
over-expressed COUP-TFII. As expected, insulin dramatically suppressed the
expression level of Pck1 mRNA in control group and none of the adenoviruses
had any further effect. RA and insulin together restored the transcription of
Pck1 to basal level in control group. However, this effect was antagonized by
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Figure 4.18 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on Gck mRNA expression in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Gck in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (a < b < c < d, e < g < f < h, i < j < k < l, q < r < s < t, a
> q, r < n < b < j < f, o < g/s < c/k, p < t < d/l < h for comparing C, RA, INS, and
RA + INS in the presence of indicated adenoviruses, and for comparing each
treatment in the presence of different adenoviruses using one way ANOVA; all
p < 0.05).
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Figure 4.19 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on Pck1 mRNA expression in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Pck1 in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (c < a/d < b, e/g < f/h, k < i < l < j, m < n, m/o < p, s <
r, m < e < a/i, m < q < a, n < r < b/f/j, p/t < d/h/l for comparing C, RA, INS, and
RA + INS in the presence of indicated adenoviruses, and for comparing each
treatment in the presence of different adenoviruses using one way ANOVA; all
p < 0.05).
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over-expression of COUP-TFII. The mRNA expression of Pck1 was eliminated
in cells over-expressing of HNF4α under all conditions.
To determine the responses of an insulin-suppressed gene that is not
affected by RA, the expression levels of Igfbp1 mRNA were measured in the
same samples. As shown in Fig. 4.20 in β-galactosidase adenovirus control
group, RA had no effect on Igfbp1 transcription, whereas insulin suppressed
its mRNA expression by about 60% independent of the presence of RA.
Neither over-expression of RARα nor RXRα had any effect on the basal
transcription of Igfbp1. However, over-expression of COUP-TFII reduced the
basal mRNA level of Igfbp1 by 58%. In the presence of RA, over-expression
of RARα, RXRα, and COUP-TFII reduced the transcription of Igfbp1 by 50%,
39%, and 55%, respectively. Only over-expression of HNF4α resulted in
change of insulin-suppressed Igfbp1 expression. In the presence of both RA
and insulin, over-expression of RXRα and COUP-TFII did not affect Igfbp1
transcription, which was almost eliminated by over-expression of RARα. The
transcription of Igfbp1 was eliminated by over-expression of HNF4α under all
conditions.
To determine the effects of over-experssion of these NRs on another
gene which is induced by both RA and insulin, we measured the expression
levels of Srebp-1c in the same cells. As shown in Fig. 4.21, in β-galactosidase
adenovirus control group, RA and insulin alone induced Srebp-1c mRNA
expression by 2- and 4-fold, respectively. RA and insulin synergistically
increased Srebp-1c mRNA level up to 32.6-fold. Basal mRNA level of Srebp1c, without being affected by over-expression of RARα and RXRα, was
increased by 2.8-fold and decreased by 60% by over-expression of HNF4α
and COUP-TFII, respectively. Over-expression of RARα, RXRα, and HNF4α
augmented RA-induced Srebp-1c transcription by 1.4-, 2.2-, and 0.8-fold,
respectively. Insulin-induced Srebp-1c transcription was abolished by overexpression of RARα and COUP-TFII, without being affected by overexpression of RXRα and HNF4α. Synergistic inducion of Srebp-1c
transcription was not affected by over-expression of RARα, potentiated by
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Figure 4.20 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on Igfbp1 mRNA expression in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα,
Ad-HNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by
treatment without or with 5 μM RA in the absence or presence of 1 nM insulin
for 6 h, after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Igfbp1 in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (c/d < a/b, h < f/g < e, k/l < i/j, m < q < a/e/i, n < f/j/r <
b, o < c/g/k/s, h/p < d/l/t for comparing C, RA, INS, and RA + INS in the
presence of indicated adenoviruses, and for comparing each treatment in the
presence of different adenoviruses using one way ANOVA; all p < 0.05).
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Figure 4.21 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on Srebp-1c mRNA expression in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Srebp-1c in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (a < b/c < d, e < g < f < h, i < j/k < l, m/n < p, q/r/s < t,
q < a < m, e/q < i < m, r < b < f, r < b < n < j, g/s < c, g/s < o < k, p/t < d/h < l
for comparing C, RA, INS, and RA + INS in the presence of indicated
adenoviruses, and for comparing each treatment in the presence of different
adenoviruses using one way ANOVA; all p < 0.05).
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2.3-fold with over-expression of RXRα, abolished by over-expression of
HNF4α and COUP-TFII.

4.4 Discussion
As an energy source, glucose homeostasis is delicately regulated. The
expression of two GK isoforms in different cells serves the purpose to control
the transcription initiation by distinct sets of cis-acting regulatory elements in
different cellular environment in response to the same nutrient and hormonal
stimuli. The regulation of the hepatic (downstream) Gck promoter is more
complex and less understood than that of the β cell promoter. It has been
shown that the β cell Gck promoter contains a putative RARE (-196/-154).
However, no classical RARE consensus appears to be present on the hepatic
Gck promoter [337]. In the present study, we identify a RARE in the hepatic
Gck promoter and demonstrate that this RARE is a convergent site for NRs
RARα, RXRα, HNF4α, and COUP-TFII to regulate hepatic Gck expression.
Hepatic GK is regulated by nutritional and hormonal stimuli, of which
insulin is the most potent. During rat development, GK expresssion first
appears in the liver 2 weeks after birth and its activity rapidly increases after
weaning in response to feeding of a high-carbohydrate diet due to the
increase of plasma insulin and the decrease of plasma glucagon
concentrations [338, 339]. In contrast, GK mRNA and protein disappear in the
liver of insulin-deficient rats and are restored after insulin treatment [340]. It
was reported that insulin-induced GK activity was mainly resulted from
alterations in the mRNA level [341]. In a previous study [12], we demonstrated
that insulin was able to synergize with RA to induce hepatic Gck mRNA
expression in 3 h, which is consistent with a recent report showing that insulin
triggered a 15- to 30-fold increase in hepatic Gck mRNA in 3 h independent of
the presence of glucose [87]. The rapid effect of insulin on hepatic Gck mRNA
expression indicates that insulin directly stimulates hepatic Gck transcription,
supporting the previous observations [340]. However, the reporter gene
constructs used in this study is unable to mediate insulin-stimulated Gck
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transcription (Fig. 4.1). This phenomenon supported by another groupʼs work
which could not identify the insulin responsive element (IRE) in primary
hepatocytes using a reporter gene construct with a 5.5 kb hepatic Gck
promoter fragment [341].
Introduction of expression plasmids containing RARα and RXRγ
improved the fold induction of promoter activity by RA, but not insulin, allowing
us to determine the RARE in hepatic Gck promoter. A scan of the Gck locus
for DNase-I hypersensitive sites revealed that two hypersensitive proximal
sites, both of which were located within the 1 kb of promoter, might be
involved in the regulation of Gck by insulin [342]. However, the insulinresponse sequence like that is located near the hypersensitive sites was not
able to confer a positive effect of insulin in transfection experiments [342].
These observations suggest that transient transfection may not be an ideal
technique to identify the IRE on hepatic Gck promoter and new strategies are
necessary in order to gain an insight into the hormonal regulation of the
transcription of hepatic Gck.
Recently, Kim et al. [121] reported that LXRα can increase hepatic Gck
expression by directly binding to a functional LXR response element (LXRE)
on the Gck promtor, which overlaps the RARE identified in the present study.
In the former study, the authors performed transient transfection in Alexander
human hepatoma cells and did not observe any induction of the Gck promoter
(~ 1.5 kb) activity by T1317 and/ or 9-cis RA in the absence of expression
plasmids containing LXRα and/ or RXRα. Similarly, our Gck promoter
construct (~ 1kb) did not respond to treatment of all-trans RA in HL1C
hepatoma cells (data not shown) or in INS-1 833/15 cells (Fig. 4.3) in the
absence of expression plasmids containing RARα and/ or RXRγ. However,
all-trans RA was able to significantly induce the 1k Gck promoter acitivity in
primary rat hepatocytes as shown in Fig. 4.1 and Fig. 4.2. This induction was
further augmented by co-transfection of RARα, RXRα, and/ or RXRγ
expression vectors. The differential response of hepatic Gck promoter to the
abovementioned ligands in different cells may be attributed to the different
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expression levels of NRs that mediating the promoter activation. In addition,
Kim et al. could not rule out the possibility that heterodimer RAR/RXR might
also play a role in mediating the induction of Gck promoter activity in the
presence of 9-cis, which is also capable of activating RAR.
It has been suggested that whether TTNPB (a specific agonist of RAR)
mediated-RAR activation in primary hepatocytes attenuates or potentiates
insulin-regulated gene expression depends on the promoter context, since
TTNPB differentially regulates insulin-induce mRNA expression of Gck and
Srebp-1c [12]. However, the induction patterns of mRNA expression of Gck
and Srebp-1c by over-expression of RARα were similar in the present study.
We found that over-expression of RARα attenuated the insulin-induced Gck
and Srebp-1c mRNA expression in the absence of RA. On the other hand, the
synergistic effect between RA and insulin on hepatic Gck and Srebp-1c
mRNA expression was further boosted by RARα over-expression (Fig. 4.18
and Fig. 4.21). It is possible that activated RARα by RA or by TTNPB function
differentially in the same promoter context (Srebp-1c promoter). Another
possibility is that high levels of unliganded RARα can interfere with insulin
signaling pathway. The presence of RA results in a repartition of liganded
RARα from signaling cascade to the RARE on target gene promoters. Further
studies will be necessary to reveal the mechanism.
In the liver, GK expression shows a slight predominance in the less
aerobic, perivenous zone [343]. It has been shown that HNF4α may play a
role in the O2-mediated zonated Gck expression in rat liver [130]. The
expression of HNF4α in rat hepatocytes cultured under perivenous pO2 (8%
O2) is significantly higher than that under periportal pO2 (16% O2).
Transfection of the HNF4α expression vector into hepatocytes increases GK
mRNA, protein, and enzyme activity under both culturing conditions [130]. In
the

present

study,

however,

recombinant

adenovirus-mediated

over-

expression of HNF4α did not result in significant increase in Gck mRNA
expression in rat hepatocytes cultured in a more aerobic atmosphere (~20%
O2) (Fig. 4.18). Whether the discrepancy is due to different culturing
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conditions merits further investigation. Althought it is well established that GK
is regulated by nutritional (e.g. RA) and hormonal (e.g. insulin) stimuli, the role
of HNF4α in this process has not been well addressed. We demonstrate that
RA- and insulin-induced Gck mRNA expression is markedly suppressed by
over-expression of HNF4α, indicating that HNF4α may function as a negative
regulator for the hepatic Gck expression. The inhibition may be caused by the
direct binding of HNF4α to the RARE as ChIP assay results shown in Fig.
4.16

demonstrated

the

increased

occupancy

at

RARE

after

its

overexpression.
COUP-TFII plays an important role in regulating metabolism. It has been
suggested that COUP-TFII can modulate RA signaling pathway in
embryogenesis (see Chapter 2), but little information is available about the
effect of COUP-TFII on RA-induced expression of genes involved in glucose
and lipid metabolism. We show here that recombinant adenovirus-mediated
over-expression of COUP-TFII suppresses expression of RARs and RXRs in
hepatocytes (Fig. 4.22-4.25), which is accompanied by markedly suppression
of basal and activated mRNA expression of Gck, Srebp-1c, Pck1, and
G6pase. The COUP-TFII effects on these genesʼ expression can be attributed
to several reasons. First, COUP-TFII might modulate the expression of RARs
and RXRs and in turn, affects their expression. Second, COUP-TFII occupied
the RARE upon over-expression and functioned as a suppressor of these
genesʼ expression in hepatocytes. Last, COUP-TFII could affect these geneʼs
expression indirectly via the control of HNF4α expression. Further studies are
needed to determine which one is relevant.
The interplay between NRs RARα, RXRα, HNF4α, and COUP-TFII has
been observed in different cell types and promoter contexts. For example,
RXR, HNF4, and COUP-TFII interact to modulate transcription of the
cholesterol 7α-hydroxylase gene [344, 345]. A common binding site for RAR,
RXR, HNF4, and COUP-TFII was also identified on the mouse cellular retinolbinding protein II gene promoter [197]. In the present study, we demonstrate
that RARα, RXRα, HNF4α, and COUP-TFII bind to the RARE on the proximal
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Figure 4.22 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on mRNA expression of Rara in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Rara in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (f/h < e/g, m< p, a/i/q < m < e, b/j/r < n < f, c/k/s < o <
g, d/l/t < p < h for comparing C, RA, INS, and RA + INS in the presence of
indicated adenoviruses, and for comparing each treatment in the presence of
different adenoviruses using one way ANOVA; all p < 0.05)
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Figure 4.23 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on mRNA expression of Rarb in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Rarb in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (a/c < b/d, f/h < e, f/h < g, i/k < j < l, q/s < t, r < t,
a/i/m/q < e, n/r < b < j < f, c/k/o/s < g, p < t < d < l < h for comparing C, RA,
INS, and RA + INS in the presence of indicated adenoviruses, and for
comparing each treatment in the presence of different adenoviruses using one
way ANOVA; all p < 0.05).
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Figure 4.24 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on mRNA expression of Rxra in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Rxra in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (j/l < k < i, a/e/m/q < i, b/f/n/r < j, c/g/o/s < k, d/h/p/t < l
for comparing C, RA, INS, and RA + INS in the presence of indicated
adenoviruses, and for comparing each treatment in the presence of different
adenoviruses using one way ANOVA; all p < 0.05).
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Figure 4.25 Effect of over-expression of RARα, RXRα, HNF4α, and
COUP-TFII on mRNA expression of Rxrg in primary hepatocytes
Primary hepatocytes were infected with Ad-β-gal, Ad-RARα, Ad-RXRα, AdHNF4α, or Ad-COUP-TFII at 1,000 PFU/cell for 18 h, followed by treatment
without or with 5 μM RA in the absence or presence of 1 nM insulin for 6 h,
after which the cells were harvested and total RNA was extracted and
subjected to real-time PCR analysis. The mRNA level of Rarg in control
hepatocytes infected with Ad-β-gal and treated with vehicle control was
arbitrarily assigned a value of 1. Each value represents the mean ± SD of four
independent treatments (a < b/c < d, e/g < f < h, i < k < j < l, a/e/i/q < m, r < b/f
< j/n, g/s < c/k < o, t < d/h/p < l for comparing C, RA, INS, and RA + INS in the
presence of indicated adenoviruses, and for comparing each treatment in the
presence of different adenoviruses using one way ANOVA; all p < 0.05).
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hepatic Gck promoter and regulate the transcription of Gck, with the former
two functioning as positive regulators and the latter two functioning as
negative regulators. RAR and RXR isoforms exhibit different expression
patterns. Rarα, Rxrα, and Rxrb are widely expressed, which resembles the
pattern of expression of Coup-tfii, whereas Rarb, Rarg, and Rxr are highlyrestricted [346], which resembles the pattern of expression of Hnf4a (see
Chapter 2). The co-existence of RARα/RXRα, HNF4α, and COUP-TFII in the
liver and their capacity to bind to Gck promoter confer the change of
expression of Gck under different nutritional and hormonal stimuli, as
evidenced by the fact that RA can induce a dynamic change in the binding of
these nuclear receptors to the Gck promoter (Fig. 4.17). The occupancy of the
specific NRs at this RARE under specific conditions may be a direct reflection
of the nutritional and hormonal states of the liver, an organ constantly
integrating the internal and environmental signals for achieving glucose and
lipid homeostasis.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTION
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Conclusions
In this dissertation, we have shown that retinoids, metabolites of vitamin
A (VA), can synergize with insulin to induce the expression of Srebp-1c and
Gck in primary rat hepatocytes. Retinoid-induced expression of Srebp-1c, due
to the activation of RXR, results in increased expression of SREBP-1c target
gene, fatty acid synthase. We demonstrate that retinoic acid responsive
elements (RAREs) in the Srebp-1c promoter overlap previously identified two
liver X receptor elements that mediate insulin action. Moreover, we have
characterized the promoter of hepatic Gck and identified a RARE using serial
deletion reporter gene assays and linker-scan analyses. This RARE overlaps
a putative binding site for HNF4α. We show that nuclear receptors RARα,
RXRα, HNF4α, and COUP-TFII are capable of binding to the RARE and their
binding activities can be modulated by RA, the physiological active form of
VA. In addition, the expression of retinoids- and insulin-responsive genes is
profoundly modulated by recombinant adenovirus-mediated over-expression
of these nuclear receptors. We conclude that VA can control hepatic glucose
and lipid metabolism via regulation of the expression of genes involved.

Future Direction
Since the discovery of RARs by P. Chambon and R. M. Evans and their
respective co-workers in 1987, we have witnessed a new era of VA research.
Currently, there is general agreement that not only the VA status, but also the
metabolism of VA, plays critical roles in regulating metabolic homeostasis by
activating specific genes to stimulate the cells to produce specific proteins or
to inhibit the expression of other genes.
In this dissertation, we tried to answer the question how retinoids regulate
nutrient metabolism using Srebp-1c and Gck as model genes. The analyses
of Srebp-1c promoter reveal that insulin and RA converge at the same site of
Srebp-1c promoter and result in a synergistic induction of mRNA expression
of Srebp-1c. However, we could not identify an insulin responsive element
(IRE) at the hepatic Gck promoter, which prevents us from further
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understanding the mechanism of the synergistic effect between RA and
insulin on the induction of hepatic Gck transcription. Is there any interaction
between the transcriptional factors binding to the RARE and those binding to
the IRE, if such an IRE does exist? A possible solution is to integrate serial
deletions of hepatic Gck promoter into the genome of a cell line that is
responsive to insulin and to characterize the promoter activity upon insulin
stimulation. Ideally, deletions of promoter containing the IRE can drive the
expression of a specific marker. This will allow a direct comparison of
constructs within the same genomic context and a systematic and quantitative
assessment of the promoter. Alternatively, transgenic mice bearing these
promoters can be produced and compared in terms of their response to
fasting and re-feeding cycle. However, a potential problem is that sites of
integration of the transgenic constructs in the genome, which may affect the
regulation of the gene. Another limitation is that unequal number of copies
being integrated into different locations in the genome may cause problems in
the interpretation of the data obtained.
Although RARα, RXRα, HNF4α, and COUP-TFII can bind to the RARE
and regulate Gck transcription, the quantitative contribution of each NR is not
known. In addition, how is the expression of hepatic Gck controlled by these
NRs in vivo? Since RA can induce a dynamic change in the binding of these
NRs to the promoter, it evokes the question that what the effects of other
nutritional and hormonal stimuli are on the promoter context. For example,
whether insulin alone or insulin together with RA can induce a dynamic
change in the binding of these NRs to the Gck promoter in primary
hepatocytes is under investigation in our lab. Additionally, is there any change
in the binding of these NRs to the promoter during the transition from healthy
status to metabolic disorder? Other than nutritional and hormonal stimuli, what
else can regulate the dynamic change in the binding of these NRs to the
hepatic Gck promoter? Does circadian clock play a role? Answers to these
questions will help further our understanding of the physiological functions of
these NRs in the integrated regulation of hepatic Gck transcription.
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The human physiology is so complex that disruption of one gene or
pathway will result in systemic changes to compensate for unbalanced
homeostasis. In addition, unregulated overexpression of transgenic gene
products may have unwanted physiological or toxic effects. Therefore,
transgenic mice bearing the Tet-Off or Tet-On expression systems may be
appropriate tools to study the physiological functions of these NRs in
regulating hepatic Gck transcription. Expression of the NRs in these mice can
be regulated both reversibly and quantitatively by exposing them to varying
concentrations of tetracycline, or its derivatives such as doxycycline. Ideally,
mice with different expression levels of these NRs will respond differentially to
fasting and re-feeding cycles or dietary signals (e.g. VAD and VAS) in terms
of hepatic Gck expression. Alternatively, the relative contribution of each of
these NRs to the Gck transcription can be quantitatively assessed by cotransfection experiments, in which a combination of varying amounts of
expression plasmids containing each of the NRs, together with hepatic Gck
promoter, are co-transfected into primary hepatocytes. A comparison of Gck
promoter activities upon stimulation will reflect the relative contribution of each
of these NRs.
The general pathways involved in Gck expression are beginning to be
understood. However, a lot more needs to be done to decipher the molecular
mechanisms of this transcriptional regulation.
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